beta-alanine has been researched along with Atrial Fibrillation in 543 studies
Atrial Fibrillation: Abnormal cardiac rhythm that is characterized by rapid, uncoordinated firing of electrical impulses in the upper chambers of the heart (HEART ATRIA). In such case, blood cannot be effectively pumped into the lower chambers of the heart (HEART VENTRICLES). It is caused by abnormal impulse generation.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Warfarin and aspirin are used to prevent stroke in patients with atrial fibrillation (AF)." | 10.27 | Mixed treatment comparison meta-analysis of aspirin, warfarin, and new anticoagulants for stroke prevention in patients with nonvalvular atrial fibrillation. ( Al-Majzoub, O; Assiri, A; Donovan, JL; Kanaan, AO; Silva, M, 2013) |
| "The aim of this study was to compare the management and prognosis of major bleeding in patients treated with dabigatran or warfarin." | 10.27 | Management and outcomes of major bleeding during treatment with dabigatran or warfarin. ( Brueckmann, M; Connolly, SJ; Eikelboom, JW; Ezekowitz, MD; Fraessdorf, M; Hwang, HG; Majeed, A; Schulman, S; Wallentin, L; Yusuf, S, 2013) |
| " In the Randomized Evaluation of Long-Term Anticoagulant Therapy (RELY) trial, dabigatran, with ≈80% renal elimination, displayed superiority over warfarin for prevention of stroke and systemic embolism in the 150-mg dose and significantly less major bleeding in the 110-mg dose in 18 113 patients with nonvalvular atrial fibrillation." | 9.19 | Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation: a RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) trial analysis. ( Andersson, U; Connolly, SJ; Eikelboom, JW; Ezekowitz, MD; Hijazi, Z; Hohnloser, SH; Oldgren, J; Reilly, PA; Siegbahn, A; Wallentin, L; Yusuf, S, 2014) |
| "We observed a rate of major bleeding similar to that reported in randomized clinical trials among patients with AF prescribed dabigatran or rivaroxaban." | 9.19 | Major bleeding with dabigatran and rivaroxaban in patients with atrial fibrillation: a real-world setting. ( Evans, RS; Fontaine, GV; Lloyd, JF; Mathews, KD; Stevens, SM; Woller, SC, 2014) |
| " Here we present a first comparison of complications after cardiac rhythm device (CRD) implantations in patients with atrial fibrillation (AF) treated with dabigatran or uninterrupted warfarin." | 9.19 | Comparison of dabigatran and uninterrupted warfarin in patients with atrial fibrillation undergoing cardiac rhythm device implantations. Case-control study. ( Bollmann, A; Breithardt, OA; Darma, A; Dinov, B; Doering, M; Hindricks, G; Kosiuk, J; Koutalas, E; Nedios, S; Richter, S; Rolf, S; Sommer, P, 2014) |
| "A total of 202 patients received dabigatran as part of their periprocedural anticoagulation regimen at the time of initial or redo catheter ablation for symptomatic atrial fibrillation." | 9.17 | Dabigatran versus warfarin anticoagulation before and after catheter ablation for the treatment of atrial fibrillation. ( Amnueypol, M; Calkins, H; Haines, DE; Marchlinski, FE; Mead-Salley, M; Nademanee, K; Saklani, P; Salazar, M; Skanes, AC; Yarmohammadi, H; Zado, E, 2013) |
| "In 18,113 AF patients in the RE-LY (Randomized Evaluation of Long Term Anticoagulant Therapy) trial, we used a previously developed method for integrating ischemic and bleeding events as "ischemic stroke equivalents" in order to compare a weighted benefit of 2 doses of dabigatran with each other, and with that of warfarin." | 9.17 | Balancing the benefits and risks of 2 doses of dabigatran compared with warfarin in atrial fibrillation. ( Connolly, SJ; Eikelboom, JW; Hart, RG; Oldgren, J; Reilly, P; Wallentin, L; Yang, S; Yusuf, S, 2013) |
| "3 years of continued treatment with dabigatran after RE-LY, there was a higher rate of major bleeding with dabigatran 150 mg twice daily in comparison with 110 mg, and similar rates of stroke and death." | 9.17 | The Long-Term Multicenter Observational Study of Dabigatran Treatment in Patients With Atrial Fibrillation (RELY-ABLE) Study. ( Alings, M; Amerena, JV; Avezum, A; Baumgartner, I; Brueckmann, M; Budaj, AJ; Chen, JH; Connolly, SJ; Dans, AL; Darius, H; Di Pasquale, G; Duffy, CO; Eikelboom, J; Ezekowitz, MD; Ferreira, J; Flaker, GC; Flather, MD; Franzosi, MG; Golitsyn, SP; Halon, DA; Heidbuchel, H; Hohnloser, SH; Huber, K; Jansky, P; Kamensky, G; Keltai, M; Kim, SS; Lau, CP; Le Heuzey, JY; Lewis, BS; Liu, L; Nanas, J; Oldgren, J; Omar, R; Pais, P; Pedersen, KE; Piegas, LS; Pogue, J; Raev, D; Reilly, PA; Smith, PJ; Talajic, M; Tan, RS; Tanomsup, S; Themeles, E; Toivonen, L; Vinereanu, D; Wallentin, L; Wang, SQ; Xavier, D; Yusuf, S; Zhu, J, 2013) |
| "We evaluated the effects of dabigatran compared with warfarin in the subgroup of patients with previous symptomatic heart failure (HF) in the RE-LY trial." | 9.17 | Dabigatran compared with warfarin in patients with atrial fibrillation and symptomatic heart failure: a subgroup analysis of the RE-LY trial. ( Brueckmann, M; Connolly, SJ; Ezekowitz, MD; Ferreira, J; Fraessdorf, M; Reilly, PA; Wallentin, L; Yusuf, S, 2013) |
| "Two new oral anticoagulants, rivaroxaban and dabigatran, with no need for anticoagulation monitoring, are available for patients with atrial fibrillation (AF)." | 9.17 | A head-to-head comparison of periprocedural coagulability under anticoagulation with rivaroxaban versus dabigatran in patients undergoing ablation of atrial fibrillation. ( Ando, M; Hirayama, H; Kihara, Y; Nakano, Y; Sairaku, A; Yoshida, Y, 2013) |
| "To validate a patient decision aid (DA) for warfarin versus dabigatran, the first NOAC approved for atrial fibrillation (AF)." | 9.17 | Validation of a patient decision aid for choosing between dabigatran and warfarin for atrial fibrillation. ( Curnew, G; Holbrook, A; Hong, C; Kim, S; Pullenayegum, E; Schulman, S, 2013) |
| "We aimed to evaluate the feasibility of an oral direct thrombin inhibitor, dabigatran, as a periprocedural anticoagulant for use with ablation of atrial fibrillation (AF)." | 9.17 | A randomized controlled trial of dabigatran versus warfarin for periablation anticoagulation in patients undergoing ablation of atrial fibrillation. ( Hirayama, H; Inden, Y; Kamiya, H; Murohara, T; Nanasato, M; Nin, T; Sairaku, A; Tatematsu, Y; Yoshida, Y, 2013) |
| "The distribution of activated partial thromboplastin time (APTT) in nonvalvular atrial fibrillation (NVAF) patients under dabigatran therapy remains to be clarified." | 9.16 | Dabigatran in clinical practice for atrial fibrillation with special reference to activated partial thromboplastin time. ( Aizawa, T; Funada, R; Kirigaya, H; Koike, A; Matsuno, S; Nagashima, K; Oikawa, Y; Otsuka, T; Sagara, K; Sawada, H; Suzuki, S; Uejima, T; Yajima, J; Yamashita, T, 2012) |
| "Analysis of 18 113 participants with atrial fibrillation in the Randomized Evaluation of Long-term anticoagulant therapY (RE-LY) trial assigned to adjusted-dose warfarin (target international normalized ratio, 2-3) or dabigatran (150 mg or 110 mg, both twice daily)." | 9.16 | Intracranial hemorrhage in atrial fibrillation patients during anticoagulation with warfarin or dabigatran: the RE-LY trial. ( Connolly, SJ; Diener, HC; Ezekowitz, MD; Hart, RG; Reilly, PA; Wallentin, L; Yang, S; Yusuf, S, 2012) |
| "Periprocedural anticoagulation using uninterrupted warfarin could reduce the risk of thromboembolic complications of atrial fibrillation (AF) ablation." | 9.16 | Efficacy and safety of periprocedural dabigatran in patients undergoing catheter ablation of atrial fibrillation. ( Fuke, E; Hayano, M; Kaseno, K; Kumagai, K; Miki, Y; Naito, S; Nakamura, K; Nishiuchi, S; Oshima, S; Sakamoto, T; Sasaki, T; Tada, H; Tsukada, N; Yamashita, E, 2012) |
| " The frequencies of stroke and major bleeding within 30 days of cardioversion on the 2 doses of dabigatran were low and comparable to those on warfarin with or without transesophageal echocardiography guidance." | 9.15 | Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion. ( Aikens, TH; Brugada, J; Chernick, M; Connolly, SJ; Ezekowitz, MD; Flaker, G; Kamensky, G; Nagarakanti, R; Oldgren, J; Parekh, A; Reilly, PA; Yang, S; Yusuf, S, 2011) |
| "RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) is an international multicenter study (18,113 patients from 967 centers in 44 countries) that demonstrated the ability of dabigatran to reduce the occurrence of both stroke and hemorrhage in patients who had atrial fibrillation (AF) with high risks of stroke compared with patients who received warfarin." | 9.15 | Efficacy and safety of dabigatran vs. warfarin in patients with atrial fibrillation--sub-analysis in Japanese population in RE-LY trial. ( Connolly, SJ; Ezekowitz, MD; Hori, M; Reilly, PA; Wallentin, L; Yusuf, S, 2011) |
| "In patients with atrial fibrillation at risk for stroke, both doses of dabigatran compared with warfarin have lower risks of both intracranial and extracranial bleeding in patients aged <75 years." | 9.15 | Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. ( Alings, M; Connolly, SJ; Diener, HC; Eikelboom, JW; Ezekowitz, M; Franzosi, MG; Healey, JS; Hohnloser, SH; Huber, K; Kaatz, S; Oldgren, J; Reilly, P; Varrone, J; Wallentin, L; Yang, S; Yusuf, S, 2011) |
| "To evaluate the prognostic importance of CHADS(2) risk score in patients with atrial fibrillation receiving oral anticoagulants, including the vitamin K antagonist warfarin and the direct thrombin inhibitor dabigatran." | 9.15 | Risks for stroke, bleeding, and death in patients with atrial fibrillation receiving dabigatran or warfarin in relation to the CHADS2 score: a subgroup analysis of the RE-LY trial. ( Alings, M; Connolly, SJ; Darius, H; Diener, HC; Eikelboom, J; Ezekowitz, MD; Kamensky, G; Oldgren, J; Reilly, PA; Wallentin, L; Yang, S; Yusuf, S, 2011) |
| "Dabigatran etexilate, a new thrombin inhibitor, has been shown to be comparable to warfarin in patients with atrial fibrillation (AF)." | 8.90 | Safety and efficacy of dabigatran versus warfarin in patients undergoing catheter ablation of atrial fibrillation: a systematic review and meta-analysis. ( Albenque, JP; Bouzeman, A; Boveda, S; Casteigt, B; Combes, N; Combes, S; Marijon, E; Narayanan, K; Providência, R, 2014) |
| "Pharmacogenetics-guided warfarin dosing is an alternative to standard clinical algorithms and new oral anticoagulants for patients with nonvalvular atrial fibrillation." | 8.90 | Cost-effectiveness of pharmacogenetics-guided warfarin therapy vs. alternative anticoagulation in atrial fibrillation. ( Hughes, DA; Lane, S; Pink, J; Pirmohamed, M, 2014) |
| "In October 2011, DTB reviewed the use of dabigatran, the first new oral anticoagulant licensed for the prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (AF) and one or more defined risk factors." | 8.90 | {blacktriangledown} Apixaban and {blacktriangledown} rivaroxaban for stroke prevention in AF. ( , 2014) |
| "Dabigatran is a direct, competitive inhibitor of thrombin recently approved for the prophylaxis of stroke and systemic embolism in patients with nonvalvular atrial fibrillation." | 8.90 | Increased risk of myocardial infarction with dabigatran: fact or fiction? ( Basile, E; Di Biase, L; Giglio, AF; Natale, A; Santangeli, P; Trotta, F, 2014) |
| "Dabigatran is a novel oral anticoagulant and may be useful during atrial fibrillation (AF) ablation for prevention of thromboembolic events." | 8.90 | Meta-analysis of risk of stroke or transient ischemic attack with dabigatran for atrial fibrillation ablation. ( Aronow, WS; Chatterjee, S; Ghosh, J; Nairooz, R; Sardar, P; Wetterslev, J, 2014) |
| "Since the approval of dabigatran etexilate, numerous case reports have suggested the potential dangers of bleeding complications, especially given that there is no known antidote." | 8.90 | Dabigatran for stroke prevention in nonvalvular atrial fibrillation: focus in the geriatric population. ( Brunetti, L; Chen, C; White, J, 2014) |
| " Treatment with dabigatran (220 mg per day) was initiated because of atrial fibrillation." | 8.90 | [Successful thrombolysis without hemorrhage in a patient with cardioembolic stroke under dabigatran treatment-a case report and review of literature]. ( Inaishi, J; Mano, Y; Nogawa, S; Okada, S; Yoshizaki, T, 2014) |
| "Several studies have been conducted to study the efficacy and safety of rivaroxaban in the atrial fibrillation periprocedural ablation period with similar rates of thromboembolism and major bleeding risks compared with warfarin or dabigatran." | 8.90 | Meta-analysis of efficacy and safety of rivaroxaban compared with warfarin or dabigatran in patients undergoing catheter ablation for atrial fibrillation. ( Aryal, MR; Bhandari, Y; Donato, A; Jalota, L; Karmacharya, P; Mainali, NR; Pandit, A; Pathak, R; Pradhan, R; Ukaigwe, A, 2014) |
| "Warfarin has remained the mainstay of stroke prevention in atrial fibrillation for the past 60 years." | 8.90 | Novel anticoagulants vs warfarin for stroke prevention in atrial fibrillation. ( Bongu, NR; Kocheril, AG; Turagam, MK; Velagapudi, P, 2014) |
| "The objective of this review was to compare the safety and efficacy of dabigatran, rivaroxaban and apixaban to warfarin for the management of atrial fibrillation (AF) in older adults." | 8.89 | Risk versus benefit of non-vitamin K dependent anticoagulants compared to warfarin for the management of atrial fibrillation in the elderly. ( Jeffery, SM; Ogbonna, KC, 2013) |
| "The National Institute for Health and Clinical Excellence (NICE) invited the manufacturer of dabigatran etexilate (Boehringer Ingelheim Ltd, UK) to submit evidence for the clinical and cost-effectiveness of this drug for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation (AF) as part of the NICE single technology appraisal process." | 8.89 | Dabigatran for the prevention of stroke and systemic embolism in atrial fibrillation: A NICE single technology appraisal. ( Burch, J; Corbacho, B; Faria, R; Palmer, S; Pepper, C; Spackman, E; Todd, D; Woolacott, N, 2013) |
| "The primary objective was to assess the cost-effectiveness of new oral anticoagulants compared with warfarin in patients with nonvalvular atrial fibrillation." | 8.89 | Cost-effectiveness of new oral anticoagulants compared with warfarin in preventing stroke and other cardiovascular events in patients with atrial fibrillation. ( Cameron, C; Coyle, D; Coyle, K; Kelly, S; Lee, K; Steiner, S; Wells, GA, 2013) |
| "Dabigatran is approved for prevention of stroke or systemic embolism in patients with nonvalvular atrial fibrillation (AF)." | 8.89 | Dabigatran for periprocedural anticoagulation following radiofrequency ablation for atrial fibrillation: a meta-analysis of observational studies. ( Alexander, JH; Atwater, BD; Bahnson, TD; Daubert, JP; Hasselblad, V; Piccini, JP; Steinberg, BA; Washam, JB, 2013) |
| "The safety and efficacy of dabigatran in the periprocedural period for patients undergoing atrial fibrillation ablation is not well established." | 8.89 | Safety and efficacy of dabigatran compared with warfarin for patients undergoing radiofrequency catheter ablation of atrial fibrillation: a meta-analysis. ( Crystal, E; Danon, A; Healey, JS; Kansal, N; Lashevsky, I; Morillo, CA; Newman, D; Schulman, S; Shurrab, M, 2013) |
| "Dabigatran is a direct inhibitor of thrombin that has recently been approved for primary and secondary stroke prevention and prevention of systemic embolism in patients with atrial fibrillation." | 8.88 | Preventing cardioembolic stroke in atrial fibrillation with dabigatran. ( Diener, HC; Eikelboom, JW; Hohnloser, SH; Weimar, C, 2012) |
| "Oral anticoagulation with vitamin K antagonists (warfarin, phenprocoumon) is successful in both primary and secondary stroke prevention in patients with atrial fibrillation, yielding a 60-70% relative reduction in stroke risk compared with placebo, as well as a mortality reduction of 26%." | 8.88 | Stroke prevention in atrial fibrillation: do we still need warfarin? ( Diener, HC; Hohnloser, SH; Lip, GY; Weber, R, 2012) |
| "To critically assess current evidence regarding the cost effectiveness of dabigatran for preventing stroke in patients with NVAF compared with warfarin." | 8.88 | Is dabigatran cost effective compared with warfarin for stroke prevention in atrial fibrillation? A critically appraised topic. ( Adcock, AK; Aguilar, MI; Demaerschalk, BM; Hoffman-Snyder, CR; Lee-Iannotti, JK; Wellik, KE; Wingerchuk, DM, 2012) |
| "For patients with atrial fibrillation and a high risk of thrombosis, the standard prophylaxis is warfarin, an anticoagulant, at a dose adjusted to the INR." | 8.88 | Dabigatran and atrial fibrillation: the alternative to warfarin for selected patients. ( , 2012) |
| "In the Randomized Evaluation of Long-term Anticoagulant Therapy (RE-LY) trial, dabigatran 150 mg was shown to be superior to warfarin for the prevention of stroke or systemic embolism." | 8.88 | Dabigatran or warfarin for the prevention of stroke in atrial fibrillation? A closer look at the RE-LY trial. ( DiNicolantonio, JJ, 2012) |
| "New oral anticoagulants, including apixaban, dabigatran, and rivaroxaban, have been developed as alternatives to warfarin, the standard oral anticoagulation therapy for patients with atrial fibrillation (AF)." | 8.88 | Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation. ( Eisenberg, MJ; Filion, KB; Grandi, SM; Miller, CS; Shimony, A, 2012) |
| "New oral anticoagulant drugs are emerging as alternatives to warfarin for the prevention of stroke in patients with non-valvular atrial fibrillation." | 8.88 | An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation. ( Ansell, J; Mantha, S, 2012) |
| "A network meta-analysis of the three new oral anticoagulants was performed from the three trials comparing dabigatran, rivaroxaban and apixaban with warfarin in patients with atrial fibrillation." | 8.88 | Comparison of efficacy and safety of dabigatran, rivaroxaban and apixaban in patients with atrial fibrillation using network meta-analysis. ( Diener, HC; Harenberg, J; Lip, GY; Marder, VJ; Marx, S; Wehling, M; Weiss, C, 2012) |
| "In patients with NVAF at risk of stroke, the randomized evaluation of long-term anticoagulation therapy (RE-LY) trial demonstrated that, compared with warfarin, dabigatran 150 mg b." | 8.88 | New evidences for old concerns with oral anticoagulation in atrial fibrillation: focus on dabigatran. ( Barrios, V; Escobar, C, 2012) |
| "Dabigatran and other new oral anticoagulants (OAC) represent a step forward in stroke prevention in patients with atrial fibrillation (AF)." | 8.87 | Questions and answers on the use of dabigatran and perspectives on the use of other new oral anticoagulants in patients with atrial fibrillation. A consensus document of the Italian Federation of Thrombosis Centers (FCSA). ( Crippa, L; Falanga, A; Finazzi, G; Manotti, C; Marongiu, F; Palareti, G; Pengo, V; Poli, D; Testa, S; Tiraferri, E; Tosetto, A; Tripodi, A, 2011) |
| " The recently introduced oral direct thrombin antagonist, dabigatran, has been shown in phase III clinical trials to be noninferior in efficacy to warfarin for the prevention of thromboembolic events in patients with atrial fibrillation, as well as in treatment of acute venous thromboembolism." | 8.87 | Dabigatran: a new option for anticoagulation in atrial fibrillation and venous thromboembolism. ( Acharjee, S; Cannon, CP, 2011) |
| "The objective of this review is to summarize data from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) and Apixaban Versus Acetylsalicylic Acid to Prevent Stroke in Atrial Fibrillation Patients Who Have Failed or Are Unsuitable for Vitamin K Antagonist Treatment (AVERROES) trials of apixaban for stroke prevention in patients with atrial fibrillation (AF)." | 8.87 | Apixaban for stroke prevention in atrial fibrillation: a review of the clinical trial evidence. ( Yates, SW, 2011) |
| "A Markov decision analysis model was developed to compare dabigatran (110 or 150 mg twice a day) to warfarin titrated to target prothrombin time in patients with NVAF at high risk of stroke." | 8.12 | Cost-Utility Analysis of Dabigatran and Warfarin for Stroke Prevention Among Patients With Nonvalvular Atrial Fibrillation in India. ( Aggarwal, R; Aghoram, R; Kar, SS; Kumar, SM; Rajasulochana, SR, 2022) |
| "The comparative safety of dabigatran versus warfarin for treatment of nonvalvular atrial fibrillation in general practice settings has not been established." | 7.81 | Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation. ( Goulding, MR; Graham, DJ; Houstoun, M; Kelman, JA; Levenson, M; MaCurdy, TE; Mott, K; Reichman, ME; Sheu, TC; Southworth, MR; Wernecke, M; Worrall, C; Zhang, R, 2015) |
| "It remains unclear whether dabigatran etexilate mesylate is associated with higher risk of bleeding than warfarin sodium in real-world clinical practice." | 7.81 | Risk of bleeding with dabigatran in atrial fibrillation. ( Baik, SH; Hernandez, I; Piñera, A; Zhang, Y, 2015) |
| " We investigated the risks of ischemic stroke and intracranial hemorrhage (ICH) in relation to warfarin at various TTRs in a real-world cohort of Chinese patients with atrial fibrillation receiving warfarin and compared with those on dabigatran, aspirin, and no therapy." | 7.81 | Ischemic stroke and intracranial hemorrhage with aspirin, dabigatran, and warfarin: impact of quality of anticoagulation control. ( Chan, KH; Chan, PH; Cheung, E; Hai, JJ; Ho, CW; Ho, MH; Lau, CP; Lau, KK; Leung, GK; Lip, GY; Siu, CW; Tse, HF; Yeung, CY, 2015) |
| "Compared with warfarin, periprocedural anticoagulation with dabigatran resulted in fewer minor hemorrhages and total adverse events after AF ablation." | 7.81 | Safety of novel oral anticoagulants compared with uninterrupted warfarin for catheter ablation of atrial fibrillation. ( Armbruster, HL; Berger, RD; Calkins, H; Habibi, M; Khurram, IM; Lindsley, JP; Marine, JE; Moranville, MP; Spragg, DD, 2015) |
| "Prevalence plots were used to describe the point prevalence (monthly) of dabigatran and rivaroxaban use among 29977 hemodialysis patients with atrial fibrillation." | 7.81 | Dabigatran and rivaroxaban use in atrial fibrillation patients on hemodialysis. ( Chan, KE; Edelman, ER; Maddux, FW; Thadhani, RI; Wenger, JB, 2015) |
| " She had been on dabigatran for 13 months due to atrial fibrillation and arterial hypertension." | 7.81 | [Exfoliative esophagitis while taking dabigatran]. ( Meesmann, M; Scheppach, W, 2015) |
| "Dabigatran is a direct thrombin inhibitor that has been approved for preventing stroke in patients with atrial fibrillation." | 7.81 | Relation between dabigatran concentration, as assessed using the direct thrombin inhibitor assay, and activated clotting time/activated partial thromboplastin time in patients with atrial fibrillation. ( Fujino, T; Kuwahara, T; Nakajima, J; Nakashima, E; Okubo, K; Takagi, K; Takahashi, A; Takigawa, M; Tsutsui, H; Watari, Y; Yamao, K, 2015) |
| "Bleeding and thromboembolic events during the periprocedural period were evaluated in 363 consecutive patients who underwent CA for AF at Nagoya University Hospital, and received uninterrupted dabigatran (n=173) or uninterrupted warfarin (n=190) for periprocedural anticoagulation." | 7.81 | Feasibility and safety of uninterrupted dabigatran therapy in patients undergoing ablation for atrial fibrillation. ( Fujita, M; Hirai, M; Inden, Y; Ishikawa, S; Kato, H; Miyoshi, A; Murohara, T; Nagao, T; Ohguchi, S; Okumura, S; Shimano, M; Yamamoto, T; Yanagisawa, S; Yoshida, N, 2015) |
| "Dabigatran is an oral thrombin inhibitor which has been approved for prevention of stroke or embolism in atrial fibrillation patients as an alternative to vitamin K antagonists." | 7.80 | Life-threatening epistaxis and red blood cell polyagglutination under dabigatran. ( Finsterer, J; Krutisch, G; Stöllberger, C, 2014) |
| "Dabigatran may provide less protection against myocardial infarction than vitamin K antagonists (VKAs) in patients with atrial fibrillation." | 7.80 | Myocardial ischemic events in 'real world' patients with atrial fibrillation treated with dabigatran or warfarin. ( Gorst-Rasmussen, A; Lane, DA; Larsen, TB; Lip, GY; Rasmussen, LH; Rosenzweig, M; Skjøth, F, 2014) |
| "Acute ischemic stroke thrombolysis in patients taking dabigatran is controversial because of a presumed increased risk of symptomatic hemorrhagic transformation." | 7.80 | Proposed approach to thrombolysis in dabigatran-treated patients presenting with ischemic stroke. ( Butcher, K; Kate, M; Shuaib, A; Szkotak, A; Witt, A, 2014) |
| "Apixaban (5 mg BID), dabigatran (available as 150 mg and 110 mg BID in Europe), and rivaroxaban (20 mg once daily) are 3 novel oral anticoagulants (NOACs) currently approved for stroke prevention in patients with atrial fibrillation (AF)." | 7.80 | Cost-effectiveness of apixaban versus other new oral anticoagulants for stroke prevention in atrial fibrillation. ( Dorian, P; Hernandez, L; Iloeje, U; Kongnakorn, T; Kuznik, A; Lanitis, T; Lip, GY; Liu, LZ; Phatak, H, 2014) |
| "Advantages of dabigatran, a thrombin inhibitor, for stroke prevention in patients with atrial fibrillation are numerous." | 7.80 | Impaired renal function and bleeding in elderly treated with dabigatran. ( Assayag, P; Berthelot, E; Desconclois, C; Lavenu-Bombled, C; Orostegui-Giron, L, 2014) |
| "By using nationwide Danish prescription and patient registries, we identified 11,315 first-time dabigatran users with atrial fibrillation." | 7.80 | Bleeding events among new starters and switchers to dabigatran compared with warfarin in atrial fibrillation. ( Gorst-Rasmussen, A; Larsen, TB; Lip, GY; Rasmussen, LH; Rosenzweig, M; Skjøth, F, 2014) |
| "We report a case of life-threatening haemoptysis after administration of dabigatran in a patient with bronchiectasis." | 7.80 | Massive haemoptysis following dabigatran administration in a patient with bronchiectasis. ( Hayama, M; Inoue, H; Mio, T; Wada, H, 2014) |
| "Large Phase 3 clinical trials for stroke prevention in atrial fibrillation (AF) have compared non-vitamin K antagonist oral anticoagulants (NOACs) against warfarin, with the edoxaban trial only recently reported." | 7.80 | Efficacy and safety of edoxaban in comparison with dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation. An indirect comparison analysis. ( Larsen, TB; Lip, GY; Rasmussen, LH; Skjøth, F, 2014) |
| "Dabigatran is an oral anticoagulant from the class of the direct thrombin inhibitors, indicated for prevention of thromboembolic events in patients with non valvular atrial fibrillation." | 7.80 | [Hemodialysis to remove anticoagulant dabigatran during emergencies]. ( Campbell, S; Carrizo, A, 2014) |
| "To conduct an economic evaluation of the currently prescribed treatments for stroke prevention in patients with non-valvular atrial fibrillation (NVAF) including warfarin, aspirin, and novel oral anticoagulants (NOACs) from a French payer perspective." | 7.80 | Stroke prevention in patients with atrial fibrillation in France: comparative cost-effectiveness of new oral anticoagulants (apixaban, dabigatran, and rivaroxaban), warfarin, and aspirin. ( Cotté, FE; Durand-Zaleski, I; Gaudin, AF; Kachaner, I; Kongnakorn, T; Lanitis, T, 2014) |
| "In randomized trials, patients with atrial fibrillation (AF) receiving dabigatran, a direct oral anticoagulant, had lower risk of intracranial bleeding (ICB) than those on warfarin." | 7.80 | Intracranial hemorrhage mortality in atrial fibrillation patients treated with dabigatran or warfarin. ( Alonso, A; Bengtson, LG; Chen, LY; Lakshminarayan, K; Lutsey, PL; MacLehose, RF, 2014) |
| "This study aims to estimate the cost-effectiveness of dabigatran 150 mg twice daily versus warfarin for stroke and systemic embolism risk reduction in patients with nonvalvular atrial fibrillation initiating treatment before age 75 (<75), at or after age 75 (≥ 75), and the overall population (All) from a US Medicare payer perspective." | 7.80 | Efficacy and cost-effectiveness of dabigatran etexilate versus warfarin in atrial fibrillation in different age subgroups. ( Brand, S; Brueckmann, M; Clemens, A; Kansal, A; Lim, J; Noack, H; Peng, S; Sander, S; Sorensen, S, 2014) |
| "Clinical trial data suggest that dabigatran and warfarin have similar rates of major bleeding but higher rates of gastrointestinal bleeding." | 7.80 | Bleeding rates in Veterans Affairs patients with atrial fibrillation who switch from warfarin to dabigatran. ( Chrischilles, E; Cram, P; Jones, M; Mazur, A; Vaughan Sarrazin, MS, 2014) |
| " The purpose of this study was to estimate the change in medical costs related to stroke and major bleeding for each NOAC (apixaban, dabigatran, and rivoraxaban) relative to warfarin in a RW NVAF population." | 7.80 | Estimated medical cost reductions associated with use of novel oral anticoagulants vs warfarin in a real-world non-valvular atrial fibrillation patient population. ( Amin, A; Lawrence, JH; Makenbaeva, D; Stokes, M; Wiederkehr, D; Wu, N, 2014) |
| "The oral direct thrombin inhibitor dabigatran is increasingly used to prevent thromboembolic stroke in patients with atrial fibrillation (AF)." | 7.80 | On the monitoring of dabigatran treatment in "real life" patients with atrial fibrillation. ( Antovic, JP; Beck, O; Eintrei, J; Hjemdahl, P; Malmström, RE; Muhrbeck, J; Pohanka, A; Rönquist-Nii, Y; Skeppholm, M, 2014) |
| " New oral anticoagulants (apixaban, rivaroxaban and dabigatran) are recommended for antithrombotic therapy in patients with non-valvular atrial fibrillation (NVAF) with moderate and high risk of stroke." | 7.80 | [Cost-effectiveness of apixaban compared to other new oral anticoagulants in patients with non-valvular atrial fibrillation]. ( Rudakova, AV; Tatarskiĭ, BA, 2014) |
| "This register-based observational study compares dabigatran to warfarin for secondary stroke prevention in atrial fibrillation patients among both "new starters" on dabigatran and "switchers" to dabigatran from warfarin." | 7.80 | Dabigatran and warfarin for secondary prevention of stroke in atrial fibrillation patients: a nationwide cohort study. ( Gorst-Rasmussen, A; Lane, DA; Larsen, TB; Lip, GY; Rasmussen, LH; Skjøth, F, 2014) |
| "This study aimed to evaluate the cost-effectiveness of dabigatran and rivaroxaban compared with warfarin for the prevention of stroke in patients with atrial fibrillation (AF) in Singapore." | 7.80 | Cost-effectiveness of dabigatran and rivaroxaban compared with warfarin for stroke prevention in patients with atrial fibrillation. ( Ko, Y; Kong, MC; Lee, LH; Ng, HJ; Wang, Y; Xie, F, 2014) |
| "Bleeding complications post-ablation were similar for warfarin, dabigatran, and rivaroxaban in patients undergoing cryoballoon ablation." | 7.80 | A comparison of bleeding complications between warfarin, dabigatran, and rivaroxaban in patients undergoing cryoballoon ablation. ( Duart, M; Kauffman, C; Kusumoto, F; Ray, JC; Snipelisky, D; Ung, R, 2014) |
| "We report a case of a patient receiving dabigatran who developed a life-threatening bleeding complication during cardiac ablation that rapidly resolved after administration of Factor Eight Inhibitor Bypassing Activity (FEIBA)." | 7.79 | Reversing dabigatran in life-threatening bleeding occurring during cardiac ablation with factor eight inhibitor bypassing activity. ( Dager, WE; Gosselin, RC; Roberts, AJ, 2013) |
| "To compare the management cost and cost-effectiveness of dabigatran with warfarin in patients with nonvalvular atrial fibrillation (AF) from the hospital's and patients' perspectives." | 7.79 | Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in patients with atrial fibrillation--a real patient data analysis in a Hong Kong teaching hospital. ( Chang, AM; Ho, JC; Lam, YY; Lee, VW; Yan, BP; Yu, CM, 2013) |
| "Dabigatran is an oral anticoagulant direct thrombin inhibitor recently registered in South Africa (SA) to reduce the risk of stroke and systemic embolism in patients with atrial fibrillation (AF)." | 7.79 | Economic appraisal of dabigatran as first-line therapy for stroke prevention in atrial fibrillation. ( Bergh, M; Marais, CA; Miller-Jansön, H; Salie, F; Stander, MP, 2013) |
| "It is a case report of bleeding when using dabigatran in patient with renal failure caused by the concurrent use of spironolactone and angiotensin-converting enzyme (ACE) inhibitors." | 7.79 | [Bleeding in the appointment of dabigatran in the patients with renal insufficiency caused by coadministration of spironolactone and ACE inhibitors]. ( Andreev, DA; Gappoeva, ZK; Giliarov, MIu; Sychev, DA, 2013) |
| "To estimate the cost-effectiveness of stroke prevention in patients with nonvalvular atrial fibrillation by using novel oral anticoagulants apixaban 5 mg, dabigatran 150 mg, and rivaroxaban 20 mg compared with warfarin." | 7.79 | Cost-effectiveness of apixaban, dabigatran, rivaroxaban, and warfarin for stroke prevention in atrial fibrillation. ( Armstrong, EP; Harrington, AR; Malone, DC; Nolan, PE, 2013) |
| "Uninterrupted oral anticoagulant (OA) therapy with warfarin has become the standard of care at many centers performing catheter ablation of atrial fibrillation (AF)." | 7.79 | Dabigatran versus warfarin therapy for uninterrupted oral anticoagulation during atrial fibrillation ablation. ( Doppalapudi, H; Gunter, A; Kay, GN; Maddox, W; McElderry, HT; Osorio, J; Plumb, VJ; Yamada, T, 2013) |
| "Dabigatran is effective for both the prevention of stroke and bleeding in patients with atrial fibrillation (AF)." | 7.79 | Dabigatran in the peri-procedural period for radiofrequency ablation of atrial fibrillation: efficacy, safety, and impact on duration of hospital stay. ( Fujiwara, R; Fukuzawa, K; Hirata, K; Imamura, K; Itoh, M; Kiuchi, K; Matsumoto, A; Nakanishi, T; Suzuki, A; Takami, K; Takami, M; Takei, A; Yamashita, S; Yoshida, A, 2013) |
| "The use of dabigatran would lead to a significant reduction of strokes and deaths attributable to AF in France." | 7.79 | Modeling of the impact on health outcomes of the use of dabigatran in patients with atrial fibrillation. ( Chevalier, J; de Pouvourville, G; Giroud, M, 2013) |
| "A number of models exploring the cost-effectiveness of dabigatran versus warfarin for stroke prevention in atrial fibrillation have been published." | 7.79 | A comparative analysis of models used to evaluate the cost-effectiveness of dabigatran versus warfarin for the prevention of stroke in atrial fibrillation. ( Bradley-Kennedy, C; Kansal, AR; Monz, BU; Peng, S; Sorensen, SV, 2013) |
| "Alternative anticoagulants to warfarin (dabigatran, rivaroxaban, and apixaban) are becoming available for the prevention of thromboembolic stroke in atrial fibrillation (AF), but there is a lack of information on their comparative effectiveness." | 7.79 | Comparative effectiveness of dabigatran, rivaroxaban, apixaban, and warfarin in the management of patients with nonvalvular atrial fibrillation. ( Hughes, DA; Pink, J; Pirmohamed, M, 2013) |
| "In patients undergoing left atrial catheter ablation for AF or left atrial flutter, use of periprocedural dabigatran etexilate provides a safe and effective anticoagulation strategy compared to warfarin." | 7.79 | Continuous warfarin versus periprocedural dabigatran to reduce stroke and systemic embolism in patients undergoing catheter ablation for atrial fibrillation or left atrial flutter. ( Ellis, CR; Kaiser, DW; Nagarakanti, R; Streur, MM; Whalen, SP, 2013) |
| " We evaluated the influence of the putative etiological variables and the bleeding score, HAS-BLED score, on APTT values: age greater than 70 years, renal function, gender, dose of dabigatran, and the concomitant prescription of a P-glycoprotein inhibitor." | 7.79 | Bleeding events and activated partial thromboplastin time with dabigatran in clinical practice. ( Hachiya, H; Hirao, K; Isobe, M; Kawabata, M; Nakamura, T; Sasano, T; Sugiyama, K; Suzuki, M; Tanaka, Y; Yagishita, A; Yokoyama, Y, 2013) |
| "Percutaneous left atrial appendage (LAA) occlusion and novel pharmacological therapies are now available to manage stroke risk in patients with nonvalvular atrial fibrillation; however, the cost-effectiveness of LAA occlusion compared with dabigatran and warfarin in patients with nonvalvular atrial fibrillation is unknown." | 7.79 | Economic evaluation of percutaneous left atrial appendage occlusion, dabigatran, and warfarin for stroke prevention in patients with nonvalvular atrial fibrillation. ( Micieli, A; Singh, SM; Wijeysundera, HC, 2013) |
| "The role of concomitant aspirin (ASA) therapy in patients with atrial fibrillation (AF) receiving oral anticoagulation (OAC) is unclear." | 7.79 | Use and associated risks of concomitant aspirin therapy with oral anticoagulation in patients with atrial fibrillation: insights from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Registry. ( Ansell, J; Chang, P; Ezekowitz, MD; Fonarow, GC; Gersh, B; Go, AS; Hylek, E; Kim, S; Kowey, P; Lopes, RD; Mahaffey, KW; Peterson, ED; Piccini, JP; Singer, DE; Steinberg, BA; Thomas, L, 2013) |
| "Based on clinical trials the oral anticoagulants (OACs) apixaban, dabigatran, and rivaroxaban are efficacious for reducing stroke risk for non-valvular atrial fibrillation (NVAF) patients." | 7.79 | Medical costs in the US of clinical events associated with oral anticoagulant (OAC) use compared to warfarin among non-valvular atrial fibrillation patients ≥75 and <75 years of age, based on the ARISTOTLE, RE-LY, and ROCKET-AF trials. ( Amin, A; Deitelzweig, S; Graham, J; Jing, Y; Lin, J; Makenbaeva, D; Wiederkehr, D, 2013) |
| "Cerebral microthromboembolism after atrial fibrillation (AF) ablation has been reported in 4-20% with perioperative warfarin." | 7.79 | The incidence of asymptomatic cerebral microthromboembolism after atrial fibrillation ablation: comparison of warfarin and dabigatran. ( Hamasaki, S; Ichiki, H; Iriki, Y; Ishida, S; Maenosono, R; Miyata, M; Namino, F; Ninomiya, Y; Oketani, N; Okui, H; Tei, C, 2013) |
| "Patients receiving dabigatran were younger and at a lower risk of stroke and bleeding." | 7.79 | Early adoption of dabigatran and its dosing in US patients with atrial fibrillation: results from the outcomes registry for better informed treatment of atrial fibrillation. ( Ansell, J; Chang, P; Ezekowitz, MD; Fonarow, GC; Gersh, B; Holmes, DN; Hylek, EM; Kowey, PR; Mahaffey, KW; Peterson, ED; Piccini, JP; Singer, DE; Steinberg, BA; Thomas, L, 2013) |
| "In an 89-year-old female with atrial fibrillation dabigatran had been started 11 days before admission, following a transitory ischemic attack." | 7.79 | Ischemic stroke and intestinal bleeding under dabigatran in metabolic myopathy. ( Bastovansky, A; Finsterer, J; Paul, G; Stöllberger, C, 2013) |
| " Six months before presentation, the patient was placed on Dabigatran etexilate (Dabigatran) (110 mg BID) for atrial fibrillation." | 7.79 | The untold story of Dabigatran etexilate: alveolar hemorrhage in an elderly patient with interstitial pulmonary fibrosis. ( Beydoun, A; Husari, A; Maakaron, JE; Sheik Ammar, A; Taher, A, 2013) |
| "Dabigatran is a recently introduced direct thrombin inhibitor licensed for use as an oral anticoagulant for stroke prevention in non-valvular atrial fibrillation." | 7.79 | Dabigatran for anticoagulation in atrial fibrillation - early clinical experience in a hospital population and comparison to trial data. ( Boga, T; Michel, J; Mundell, D; Sasse, A, 2013) |
| "It is not clear whether dabigatran is as safe and effective as uninterrupted anticoagulation with warfarin during radiofrequency catheter ablation (RFA) of atrial fibrillation (AF)." | 7.79 | Dabigatran vs warfarin for radiofrequency catheter ablation of atrial fibrillation. ( Bogun, F; Carrigan, T; Chugh, A; Crawford, T; Ghanbari, H; Good, E; Jongnarangsin, K; Kennedy, R; Kim, JS; Latchamsetty, R; Morady, F; Oral, H; Pelosi, F; Saint-Phard, W; She, F; Sinno, M; Suwanagool, A; Yokokawa, M, 2013) |
| "Dabigatran, administered orally as the prodrug dabigatran etexilate (DE), is a direct thrombin inhibitor shown to be effective in the prevention of stroke and systemic embolism in patients with atrial fibrillation (AF)." | 7.78 | Dabigatran etexilate in atrial fibrillation patients with severe renal impairment: dose identification using pharmacokinetic modeling and simulation. ( Clemens, A; Friedman, J; Haertter, S; Lehr, T; Liesenfeld, KH; Reilly, PA; Staab, A, 2012) |
| "The concept of net clinical benefit has been used to quantify the balance between risk of ischaemic stroke (IS) and risk of intracranial haemorrhage (ICH) with the use oral anticoagulant therapy (OAC) in the setting of non-valvular atrial fibrillation (AF), and has shown that patients at highest risk of stroke and thromboembolism gain the greatest benefit from OAC with warfarin." | 7.78 | Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a 'real world' atrial fibrillation population: a modelling analysis based on a nationwide cohort study. ( Banerjee, A; Lane, DA; Lip, GY; Torp-Pedersen, C, 2012) |
| "To present a case of dabigatran use for nonvalvular atrial fibrillation in a patient from a population for whom it has not been studied." | 7.78 | Dabigatran use in a postoperative coronary artery bypass surgery patient with nonvalvular atrial fibrillation and heparin-PF4 antibodies. ( Fieland, D; Taylor, M, 2012) |
| "Dabigatran is a new oral anticoagulant recently approved for the prevention of stroke or systemic embolism in patients with atrial fibrillation (AF)." | 7.78 | Twice daily dosing of dabigatran for stroke prevention in atrial fibrillation: a pharmacokinetic justification. ( Brueckmann, M; Clemens, A; Friedman, J; Haertter, S; Lehr, T; Stangier, J; van Ryn, J, 2012) |
| "In patients undergoing AF ablation, periprocedural dabigatran use significantly increases the risk of bleeding or thromboembolic complications compared with uninterrupted warfarin therapy." | 7.78 | Feasibility and safety of dabigatran versus warfarin for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation: results from a multicenter prospective registry. ( Burkhardt, JD; Chalhoub, F; Coffey, J; D'Avila, A; Di Biase, L; Lakkireddy, D; Mansour, MC; Mohanty, P; Monir, G; Natale, A; Pimentel, R; Reddy, VY; Reddy, YM; Ruskin, J; Sanchez, JE; Santangeli, P; Shaik, N; Swarup, V; Vanga, SR, 2012) |
| "The cost-effectiveness of dabigatran for stroke prevention in patients with atrial fibrillation and prior stroke or transient ischemic attack has not been directly assessed." | 7.78 | Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in patients with atrial fibrillation and prior stroke or transient ischemic attack. ( Easton, JD; Johnston, SC; Kamel, H; Kim, AS, 2012) |
| " Based on various everyday situations in clinical routine, the purpose of the present expert recommendations is to provide appropriate perioperative and periinterventional management for patients with atrial fibrillation undergoing long-term treatment with the thrombin inhibitor dabigatran." | 7.78 | Dabigatran in patients with atrial fibrillation: perioperative and periinterventional management. ( Brodmann, M; Domanovits, H; Eber, B; Gottsauner-Wolf, M; Halbmayer, WM; Hiesmayr, JM; Kyrle, PA; Längle, F; Roithinger, FX; Watzke, H; Weltermann, A; Windhager, R; Wolf, C; Zweiker, R, 2012) |
| "Dabigatran is a novel direct thrombin inhibitor that has recently been approved for primary and secondary stroke prevention and prevention of systemic embolism in patients with atrial fibrillation." | 7.78 | Dabigatran for stroke prevention in atrial fibrillation. ( Diener, HC; Hohnloser, SH, 2012) |
| "Dabigatran is associated with lower rate of stroke comparing to warfarin when anticoagulation control is sub-optimal." | 7.78 | Cost-effectiveness of dabigatran versus genotype-guided management of warfarin therapy for stroke prevention in patients with atrial fibrillation. ( Cheng, G; Tsui, KK; Wong, RS; You, JH, 2012) |
| "This case report describes agranulocytosis immediately after oral administration of cibenzoline and dabigatran in a 70-year-old woman with paroxysmal atrial fibrillation (AF)." | 7.78 | Agranulocytosis immediately after oral administration of cibenzoline and dabigatran in a patient with paroxysmal atrial fibrillation. ( Hayashi, H; Horie, M; Kitoh, K; Mitsunami, K, 2012) |
| "In our cohort, bleeding-related complications 48 h and 1 week post-ablation were similar for warfarin and dabigatran." | 7.78 | A comparison of bleeding complications post-ablation between warfarin and dabigatran. ( Johns, G; Kauffman, C; Kusumoto, F; Prussak, K; Snipelisky, D; Venkatachalam, K, 2012) |
| "Canadian patients with atrial fibrillation (AF) in whom anticoagulation is appropriate have two new choices for anticoagulation for prevention of stroke and systemic embolism--dabigatran etexilate (dabigatran) and rivaroxaban." | 7.78 | Dabigatran versus rivaroxaban for the prevention of stroke and systemic embolism in atrial fibrillation in Canada. Comparative efficacy and cost-effectiveness. ( Bradley-Kennedy, C; Clemens, A; Kansal, AR; Monz, BU; Peng, S; Roskell, N; Sharma, M; Sorensen, SV, 2012) |
| "Assessment of the cost-effectiveness of dabigatran for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation in Spain, from the perspective of the National Health System." | 7.78 | Cost-effectiveness of dabigatran for stroke prevention in non-valvular atrial fibrillation in Spain. ( Álvarez-Sabin, J; Becerra, V; González-Juanatey, JR; González-Rojas, N; Lobos, JM; Martínez-Rubio, A; Oyagüez, I; Reverter, JC, 2012) |
| "Dabigatran is an oral direct thrombin inhibitor recently approved for stroke prevention in atrial fibrillation (AF) as an alternative to warfarin." | 7.78 | Dabigatran compared with warfarin for stroke prevention with atrial fibrillation: experience in Hong Kong. ( Chang, AM; Ho, JC; Lam, YY; Lee, VW; Yan, BP; Yu, CM, 2012) |
| "Warfarin, at a dose adjusted according to the INR, is the standard prophylactic anticoagulant for patients with atrial fibrillation and a major risk of thrombosis." | 7.78 | Rivaroxaban and atrial fibrillation: continue to use warfarin or in some cases, dabigatran. ( , 2012) |
| "To estimate the quality-adjusted survival, costs, and cost-effectiveness of dabigatran compared with adjusted-dose warfarin for preventing ischemic stroke in patients 65 years or older with nonvalvular AF." | 7.77 | Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation. ( Freeman, JV; Garber, AM; Go, AS; Hutton, DW; Owens, DK; Turakhia, MP; Wang, PJ; Zhu, RP, 2011) |
| "Dabigatran 150 mg (twice daily) was cost-effective in AF populations at high risk of hemorrhage or high risk of stroke unless international normalized ratio control with warfarin was excellent." | 7.77 | Cost-effectiveness of dabigatran for stroke prophylaxis in atrial fibrillation. ( Gage, BF; Shah, SV, 2011) |
| "The central pharmacologic approach to stroke prevention in atrial fibrillation has recently changed with the approval of dabigatran by the US Food and Drug Administration (FDA)." | 7.77 | Dabigatran in atrial fibrillation: pharmacology and clinical trials. ( Ezekowitz, MD; Nagarakanti, R, 2011) |
| "To report an incident of a drug-induced exanthem during treatment with dabigatran in a patient without prior exposure to the drug." | 7.77 | Drug-induced exanthem following dabigatran. ( Blais, DM; Boyd, JM; Hummel, J; Whitehead, H, 2011) |
| "Clinical results of the European Action on Anticoagulation (EAA) computer-assisted dosage study and the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial have been compared." | 6.79 | Warfarin or dabigatran for treatment of atrial fibrillation. ( Ibrahim, S; Jespersen, J; Poller, L, 2014) |
| " Rywaroxaban more frequently causes minor bleeding, whereas treatment with dabigatran is associated with more frequent gastrointestinal adverse symptoms." | 6.79 | [Comparison of the safety of rivaroxaban versus dabigatran therapy in patients with persistent atrial fibrillation]. ( Broncel, M; Ciastkowska, A; Duraj, I; Gorzelak-Pabiś, P; Szlagowska, L, 2014) |
| "Dabigatran is a cost-effective treatment in Sweden, as its incremental cost-effectiveness ratio is below the normally accepted willingness to pay limit." | 6.78 | Cost-effectiveness of dabigatran compared with warfarin for patients with atrial fibrillation in Sweden. ( Davidson, T; Husberg, M; Janzon, M; Levin, LÅ; Oldgren, J, 2013) |
| "Dabigatran is a univalent low-molecular-weight direct thrombin inhibitor that has been developed as an alternative to vitamin K antagonists (VKAs)." | 6.50 | Meta-analysis of randomized controlled trials on the risk of bleeding with dabigatran. ( Atallah, R; Bloom, BJ; Eisenberg, MJ; Filion, KB, 2014) |
| " However, in elderly patients with impaired renal function or considerable bleeding risks, label advice regarding dosing needs strict observation." | 6.50 | Benefit-risk assessment of dabigatran in the treatment of stroke prevention in non-valvular atrial fibrillation. ( Harder, S; Meyer Dos Santos, S, 2014) |
| "Ischemic stroke is a severe complication of AF often resulting in disability or death." | 6.50 | [The use of dabigatran for prevention of ischemic stroke in patiets with atrial fibrillation: special features of treatment in different clinical situations]. ( Shchendrygina, AA, 2014) |
| "Stroke is the most feared complication among patients with atrial fibrillation." | 6.49 | Alternatives to warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a look back at the state of the field in 2012. ( Lopes, RD; Newby, LK; Truffa, AA, 2013) |
| "Dabigatran was the first of the agents to be widely available, and in the RE-LY study, dabigatran (150 mg dose) showed superiority to warfarin in preventing ischemic stroke and a significant reduction in intracranial bleeding." | 6.49 | New alternative anticoagulants in atrial fibrillation: the move beyond warfarin. ( Bhimani, AA; Hong, M, 2013) |
| "NOACs have shown a large reduction in intracranial hemorrhage compared with warfarin." | 6.49 | [Effective, safe stroke prevention with novel oral anticoagulants in patients with atrial fibrillation. Focus on dabigatran]. ( Bosnyák, E; Csécsei, P; Deli, G; Fehér, G; Szapary, L, 2013) |
| "Dabigatran is a direct thrombin (factor IIa) inhibitor that overcomes many of the limitations associated with warfarin." | 6.48 | Dabigatran and factor Xa inhibitors for stroke prevention in patients with nonvalvular atrial fibrillation. ( Ibayashi, S; Matsumoto, M; Nagao, T; Nagata, K; Nakagawara, J; Tanahashi, N; Tanaka, K; Toyoda, K; Uchiyama, S; Yasaka, M, 2012) |
| "Dabigatran is an oral direct thrombin inhibitor." | 6.48 | [Clinical studies, the interests and limits of using dabigatran in atrial fibrillation]. ( Chatelain, B; Chatelain, C; Dogné, JM; Douxfils, J; Mullier, F; Spinewine, A; Sternotte, A, 2012) |
| " The vitamin K antagonist warfarin has traditionally been used in these patients but presents challenges in dosing and monitoring in these patients." | 6.47 | Dabigatran: an oral direct thrombin inhibitor for use in atrial fibrillation. ( Baker, WL; Bendel, SD; Bona, R, 2011) |
| "Warfarin and aspirin are used to prevent stroke in patients with atrial fibrillation (AF)." | 6.27 | Mixed treatment comparison meta-analysis of aspirin, warfarin, and new anticoagulants for stroke prevention in patients with nonvalvular atrial fibrillation. ( Al-Majzoub, O; Assiri, A; Donovan, JL; Kanaan, AO; Silva, M, 2013) |
| "The aim of this study was to compare the management and prognosis of major bleeding in patients treated with dabigatran or warfarin." | 6.27 | Management and outcomes of major bleeding during treatment with dabigatran or warfarin. ( Brueckmann, M; Connolly, SJ; Eikelboom, JW; Ezekowitz, MD; Fraessdorf, M; Hwang, HG; Majeed, A; Schulman, S; Wallentin, L; Yusuf, S, 2013) |
| "Dabigatran was administrated twice daily in a two dose regimens: 150 mg (5 patients) and 110 mg (14 patients)." | 5.42 | Monitoring of dabigatran therapy using Hemoclot(®) Thrombin Inhibitor assay in patients with atrial fibrillation. ( Dobrotová, M; Galajda, P; Ivanková, J; Kovář, F; Kubisz, P; Mokáň, M; Samoš, M; Stančiaková, L; Staško, J, 2015) |
| "Warfarin-related intracerebral hemorrhage carries a particularly high risk of neurologic deterioration and death because of a high rate of hematoma expansion of about 50%." | 5.40 | Dabigatran-related intracerebral hemorrhage resulting in hematoma expansion. ( Damgaard, D; Simonsen, CZ; Steiner, T; Tietze, A, 2014) |
| " The rate of occurrences of adverse effects and bleeding were lower than those seen in the RE-LY trial." | 5.40 | A single centre experience of the efficacy and safety of dabigatran etexilate used for stroke prevention in atrial fibrillation. ( Hussin, A; Kaur, S; Muhammad, Z; Omar, R; Rusani, BI; Umadevan, D; Yap, LB, 2014) |
| "Direct-current cardioversion (DCCV) for persistent atrial fibrillation or atrial flutter (AF) carries a risk of thromboembolic events (TEs)." | 5.40 | Safety of short-term use of dabigatran or rivaroxaban for direct-current cardioversion in patients with atrial fibrillation and atrial flutter. ( Groh, C; Passman, R; Yadlapati, A, 2014) |
| "Dabigatran is a new oral anticoagulant that does not require INR monitoring." | 5.39 | Cost-effectiveness of dabigatran for stroke prevention in atrial fibrillation in Switzerland. ( Eichler, K; Plessow, R; Pletscher, M; Wieser, S, 2013) |
| "Dabigatran is a new anticoagulant and may be useful after AF ablation to prevent thromboembolic events." | 5.38 | The use of dabigatran immediately after atrial fibrillation ablation. ( Engel, G; Kong, MH; Mead, RH; Patrawala, RA; Winkle, RA, 2012) |
| "Dabigatran is a direct thrombin inhibitor, acting like other members in its class (bivalirudin, argatroban) to impede the clotting process through selective and reversible binding with both free and clot-bound thrombin." | 5.38 | Spontaneous splenic hemorrhage after initiation of dabigatran (Pradaxa) for atrial fibrillation. ( Boniface, K; Moore, CH; Scott, J; Snashall, J, 2012) |
| " In the Randomized Evaluation of Long-Term Anticoagulant Therapy (RELY) trial, dabigatran, with ≈80% renal elimination, displayed superiority over warfarin for prevention of stroke and systemic embolism in the 150-mg dose and significantly less major bleeding in the 110-mg dose in 18 113 patients with nonvalvular atrial fibrillation." | 5.19 | Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation: a RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) trial analysis. ( Andersson, U; Connolly, SJ; Eikelboom, JW; Ezekowitz, MD; Hijazi, Z; Hohnloser, SH; Oldgren, J; Reilly, PA; Siegbahn, A; Wallentin, L; Yusuf, S, 2014) |
| "We observed a rate of major bleeding similar to that reported in randomized clinical trials among patients with AF prescribed dabigatran or rivaroxaban." | 5.19 | Major bleeding with dabigatran and rivaroxaban in patients with atrial fibrillation: a real-world setting. ( Evans, RS; Fontaine, GV; Lloyd, JF; Mathews, KD; Stevens, SM; Woller, SC, 2014) |
| " Here we present a first comparison of complications after cardiac rhythm device (CRD) implantations in patients with atrial fibrillation (AF) treated with dabigatran or uninterrupted warfarin." | 5.19 | Comparison of dabigatran and uninterrupted warfarin in patients with atrial fibrillation undergoing cardiac rhythm device implantations. Case-control study. ( Bollmann, A; Breithardt, OA; Darma, A; Dinov, B; Doering, M; Hindricks, G; Kosiuk, J; Koutalas, E; Nedios, S; Richter, S; Rolf, S; Sommer, P, 2014) |
| "A total of 202 patients received dabigatran as part of their periprocedural anticoagulation regimen at the time of initial or redo catheter ablation for symptomatic atrial fibrillation." | 5.17 | Dabigatran versus warfarin anticoagulation before and after catheter ablation for the treatment of atrial fibrillation. ( Amnueypol, M; Calkins, H; Haines, DE; Marchlinski, FE; Mead-Salley, M; Nademanee, K; Saklani, P; Salazar, M; Skanes, AC; Yarmohammadi, H; Zado, E, 2013) |
| "In 18,113 AF patients in the RE-LY (Randomized Evaluation of Long Term Anticoagulant Therapy) trial, we used a previously developed method for integrating ischemic and bleeding events as "ischemic stroke equivalents" in order to compare a weighted benefit of 2 doses of dabigatran with each other, and with that of warfarin." | 5.17 | Balancing the benefits and risks of 2 doses of dabigatran compared with warfarin in atrial fibrillation. ( Connolly, SJ; Eikelboom, JW; Hart, RG; Oldgren, J; Reilly, P; Wallentin, L; Yang, S; Yusuf, S, 2013) |
| "3 years of continued treatment with dabigatran after RE-LY, there was a higher rate of major bleeding with dabigatran 150 mg twice daily in comparison with 110 mg, and similar rates of stroke and death." | 5.17 | The Long-Term Multicenter Observational Study of Dabigatran Treatment in Patients With Atrial Fibrillation (RELY-ABLE) Study. ( Alings, M; Amerena, JV; Avezum, A; Baumgartner, I; Brueckmann, M; Budaj, AJ; Chen, JH; Connolly, SJ; Dans, AL; Darius, H; Di Pasquale, G; Duffy, CO; Eikelboom, J; Ezekowitz, MD; Ferreira, J; Flaker, GC; Flather, MD; Franzosi, MG; Golitsyn, SP; Halon, DA; Heidbuchel, H; Hohnloser, SH; Huber, K; Jansky, P; Kamensky, G; Keltai, M; Kim, SS; Lau, CP; Le Heuzey, JY; Lewis, BS; Liu, L; Nanas, J; Oldgren, J; Omar, R; Pais, P; Pedersen, KE; Piegas, LS; Pogue, J; Raev, D; Reilly, PA; Smith, PJ; Talajic, M; Tan, RS; Tanomsup, S; Themeles, E; Toivonen, L; Vinereanu, D; Wallentin, L; Wang, SQ; Xavier, D; Yusuf, S; Zhu, J, 2013) |
| "We evaluated the effects of dabigatran compared with warfarin in the subgroup of patients with previous symptomatic heart failure (HF) in the RE-LY trial." | 5.17 | Dabigatran compared with warfarin in patients with atrial fibrillation and symptomatic heart failure: a subgroup analysis of the RE-LY trial. ( Brueckmann, M; Connolly, SJ; Ezekowitz, MD; Ferreira, J; Fraessdorf, M; Reilly, PA; Wallentin, L; Yusuf, S, 2013) |
| "The trial was terminated prematurely after the enrollment of 252 patients because of an excess of thromboembolic and bleeding events among patients in the dabigatran group." | 5.17 | Dabigatran versus warfarin in patients with mechanical heart valves. ( Blatchford, J; Brueckmann, M; Connolly, SJ; Devenny, K; Eikelboom, JW; Friedman, J; Granger, CB; Guiver, K; Harper, R; Kappetein, AP; Khder, Y; Lobmeyer, MT; Maas, H; Mack, MJ; Simoons, ML; Van de Werf, F; Voigt, JU, 2013) |
| "Two new oral anticoagulants, rivaroxaban and dabigatran, with no need for anticoagulation monitoring, are available for patients with atrial fibrillation (AF)." | 5.17 | A head-to-head comparison of periprocedural coagulability under anticoagulation with rivaroxaban versus dabigatran in patients undergoing ablation of atrial fibrillation. ( Ando, M; Hirayama, H; Kihara, Y; Nakano, Y; Sairaku, A; Yoshida, Y, 2013) |
| "To validate a patient decision aid (DA) for warfarin versus dabigatran, the first NOAC approved for atrial fibrillation (AF)." | 5.17 | Validation of a patient decision aid for choosing between dabigatran and warfarin for atrial fibrillation. ( Curnew, G; Holbrook, A; Hong, C; Kim, S; Pullenayegum, E; Schulman, S, 2013) |
| "Among patients given dabigatran for atrial fibrillation, NB-UGI AEs are generally mild or moderate; 4% stopped taking the drug over a median of 21." | 5.17 | Analysis of upper gastrointestinal adverse events among patients given dabigatran in the RE-LY trial. ( Aisenberg, J; Bytzer, P; Connolly, SJ; Ezekowitz, M; Formella, S; Reilly, PA; Yang, S, 2013) |
| "We aimed to evaluate the feasibility of an oral direct thrombin inhibitor, dabigatran, as a periprocedural anticoagulant for use with ablation of atrial fibrillation (AF)." | 5.17 | A randomized controlled trial of dabigatran versus warfarin for periablation anticoagulation in patients undergoing ablation of atrial fibrillation. ( Hirayama, H; Inden, Y; Kamiya, H; Murohara, T; Nanasato, M; Nin, T; Sairaku, A; Tatematsu, Y; Yoshida, Y, 2013) |
| "The distribution of activated partial thromboplastin time (APTT) in nonvalvular atrial fibrillation (NVAF) patients under dabigatran therapy remains to be clarified." | 5.16 | Dabigatran in clinical practice for atrial fibrillation with special reference to activated partial thromboplastin time. ( Aizawa, T; Funada, R; Kirigaya, H; Koike, A; Matsuno, S; Nagashima, K; Oikawa, Y; Otsuka, T; Sagara, K; Sawada, H; Suzuki, S; Uejima, T; Yajima, J; Yamashita, T, 2012) |
| "Analysis of 18 113 participants with atrial fibrillation in the Randomized Evaluation of Long-term anticoagulant therapY (RE-LY) trial assigned to adjusted-dose warfarin (target international normalized ratio, 2-3) or dabigatran (150 mg or 110 mg, both twice daily)." | 5.16 | Intracranial hemorrhage in atrial fibrillation patients during anticoagulation with warfarin or dabigatran: the RE-LY trial. ( Connolly, SJ; Diener, HC; Ezekowitz, MD; Hart, RG; Reilly, PA; Wallentin, L; Yang, S; Yusuf, S, 2012) |
| "Periprocedural anticoagulation using uninterrupted warfarin could reduce the risk of thromboembolic complications of atrial fibrillation (AF) ablation." | 5.16 | Efficacy and safety of periprocedural dabigatran in patients undergoing catheter ablation of atrial fibrillation. ( Fuke, E; Hayano, M; Kaseno, K; Kumagai, K; Miki, Y; Naito, S; Nakamura, K; Nishiuchi, S; Oshima, S; Sakamoto, T; Sasaki, T; Tada, H; Tsukada, N; Yamashita, E, 2012) |
| " The frequencies of stroke and major bleeding within 30 days of cardioversion on the 2 doses of dabigatran were low and comparable to those on warfarin with or without transesophageal echocardiography guidance." | 5.15 | Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion. ( Aikens, TH; Brugada, J; Chernick, M; Connolly, SJ; Ezekowitz, MD; Flaker, G; Kamensky, G; Nagarakanti, R; Oldgren, J; Parekh, A; Reilly, PA; Yang, S; Yusuf, S, 2011) |
| "RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) is an international multicenter study (18,113 patients from 967 centers in 44 countries) that demonstrated the ability of dabigatran to reduce the occurrence of both stroke and hemorrhage in patients who had atrial fibrillation (AF) with high risks of stroke compared with patients who received warfarin." | 5.15 | Efficacy and safety of dabigatran vs. warfarin in patients with atrial fibrillation--sub-analysis in Japanese population in RE-LY trial. ( Connolly, SJ; Ezekowitz, MD; Hori, M; Reilly, PA; Wallentin, L; Yusuf, S, 2011) |
| "In patients with atrial fibrillation at risk for stroke, both doses of dabigatran compared with warfarin have lower risks of both intracranial and extracranial bleeding in patients aged <75 years." | 5.15 | Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. ( Alings, M; Connolly, SJ; Diener, HC; Eikelboom, JW; Ezekowitz, M; Franzosi, MG; Healey, JS; Hohnloser, SH; Huber, K; Kaatz, S; Oldgren, J; Reilly, P; Varrone, J; Wallentin, L; Yang, S; Yusuf, S, 2011) |
| "To evaluate the prognostic importance of CHADS(2) risk score in patients with atrial fibrillation receiving oral anticoagulants, including the vitamin K antagonist warfarin and the direct thrombin inhibitor dabigatran." | 5.15 | Risks for stroke, bleeding, and death in patients with atrial fibrillation receiving dabigatran or warfarin in relation to the CHADS2 score: a subgroup analysis of the RE-LY trial. ( Alings, M; Connolly, SJ; Darius, H; Diener, HC; Eikelboom, J; Ezekowitz, MD; Kamensky, G; Oldgren, J; Reilly, PA; Wallentin, L; Yang, S; Yusuf, S, 2011) |
| "The objective of this analysis was to test the equivalence of three NOACs (dabigatran, rivaroxaban, apixaban) in orthopedic surgery and four NOACs (dabigatran, rivaroxaban, apixaban, and edoxaban) in non-valvular atrial fibrillation." | 4.91 | Testing the therapeutic equivalence of novel oral anticoagulants for thromboprophylaxis in orthopedic surgery and for prevention of stroke in atrial fibrillation. ( Fadda, V; Maratea, D; Marinai, C; Messori, A; Trippoli, S, 2015) |
| " They are effective and safe compared to warfarin for the prevention of stroke and systemic embolism in patients with atrial fibrillation and for the treatment of venous thromboembolism, and they are comparable to low-molecular-weight heparin for thromboprophylaxis after hip or knee arthroplasty." | 4.91 | Changing practice of anticoagulation: will target-specific anticoagulants replace warfarin? ( Arepally, GM; Ortel, TL, 2015) |
| "Dabigatran etexilate, a new thrombin inhibitor, has been shown to be comparable to warfarin in patients with atrial fibrillation (AF)." | 4.90 | Safety and efficacy of dabigatran versus warfarin in patients undergoing catheter ablation of atrial fibrillation: a systematic review and meta-analysis. ( Albenque, JP; Bouzeman, A; Boveda, S; Casteigt, B; Combes, N; Combes, S; Marijon, E; Narayanan, K; Providência, R, 2014) |
| "Pharmacogenetics-guided warfarin dosing is an alternative to standard clinical algorithms and new oral anticoagulants for patients with nonvalvular atrial fibrillation." | 4.90 | Cost-effectiveness of pharmacogenetics-guided warfarin therapy vs. alternative anticoagulation in atrial fibrillation. ( Hughes, DA; Lane, S; Pink, J; Pirmohamed, M, 2014) |
| " Three non-VKA oral anticoagulants (OACs), dabigatran, rivaroxaban and apixaban, are available for the prevention of stroke in patients with atrial fibrillation (AF) and may change clinical practice." | 4.90 | Non-vitamin K antagonist oral anticoagulants in cardiovascular disease management: evidence and unanswered questions. ( Barillari, G; Cheng, JW, 2014) |
| "In October 2011, DTB reviewed the use of dabigatran, the first new oral anticoagulant licensed for the prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (AF) and one or more defined risk factors." | 4.90 | {blacktriangledown} Apixaban and {blacktriangledown} rivaroxaban for stroke prevention in AF. ( , 2014) |
| "Dabigatran is a direct, competitive inhibitor of thrombin recently approved for the prophylaxis of stroke and systemic embolism in patients with nonvalvular atrial fibrillation." | 4.90 | Increased risk of myocardial infarction with dabigatran: fact or fiction? ( Basile, E; Di Biase, L; Giglio, AF; Natale, A; Santangeli, P; Trotta, F, 2014) |
| "Dabigatran is a novel oral anticoagulant and may be useful during atrial fibrillation (AF) ablation for prevention of thromboembolic events." | 4.90 | Meta-analysis of risk of stroke or transient ischemic attack with dabigatran for atrial fibrillation ablation. ( Aronow, WS; Chatterjee, S; Ghosh, J; Nairooz, R; Sardar, P; Wetterslev, J, 2014) |
| "Four recently introduced new oral anticoagulants (dabigatran, rivaroxaban, apixaban and edoxaban) have been shown to be at least as efficacious and safe as warfarin for stroke prevention in patients with atrial fibrillation in their respective trials." | 4.90 | New oral anticoagulants for stroke prevention in atrial fibrillation: impact of study design, double counting and unexpected findings on interpretation of study results and conclusions. ( Chan, NC; Eikelboom, JW; Ginsberg, JS; Hirsh, J; Lauw, MN; Paikin, JS, 2014) |
| "Dabigatran, a direct thrombin inhibitor and 2 factor Xa inhibitors, rivaroxaban and apixaban, are target-specific oral anticoagulants (TSOACs) approved for prevention of stroke or systemic embolism in patients with nonvalvular atrial fibrillation (AF)." | 4.90 | Practical aspects of new oral anticoagulant use in atrial fibrillation. ( Crowther, M; Pasierski, T; Undas, A; Windyga, J, 2014) |
| "Since the approval of dabigatran etexilate, numerous case reports have suggested the potential dangers of bleeding complications, especially given that there is no known antidote." | 4.90 | Dabigatran for stroke prevention in nonvalvular atrial fibrillation: focus in the geriatric population. ( Brunetti, L; Chen, C; White, J, 2014) |
| " Treatment with dabigatran (220 mg per day) was initiated because of atrial fibrillation." | 4.90 | [Successful thrombolysis without hemorrhage in a patient with cardioembolic stroke under dabigatran treatment-a case report and review of literature]. ( Inaishi, J; Mano, Y; Nogawa, S; Okada, S; Yoshizaki, T, 2014) |
| "Several studies have been conducted to study the efficacy and safety of rivaroxaban in the atrial fibrillation periprocedural ablation period with similar rates of thromboembolism and major bleeding risks compared with warfarin or dabigatran." | 4.90 | Meta-analysis of efficacy and safety of rivaroxaban compared with warfarin or dabigatran in patients undergoing catheter ablation for atrial fibrillation. ( Aryal, MR; Bhandari, Y; Donato, A; Jalota, L; Karmacharya, P; Mainali, NR; Pandit, A; Pathak, R; Pradhan, R; Ukaigwe, A, 2014) |
| "Warfarin has remained the mainstay of stroke prevention in atrial fibrillation for the past 60 years." | 4.90 | Novel anticoagulants vs warfarin for stroke prevention in atrial fibrillation. ( Bongu, NR; Kocheril, AG; Turagam, MK; Velagapudi, P, 2014) |
| "The availability of 4 non-vitamin K oral anticoagulants (NOACs), that is, dabigatran, rivaroxaban, apixaban, and edoxaban, has changed the landscape of stroke prevention in patients with atrial fibrillation." | 4.90 | Oral anticoagulants for stroke prevention in atrial fibrillation. ( Lane, DA; Lip, GY; Senoo, K, 2014) |
| " Dabigatran, rivaroxaban, apixaban, and edoxaban have been shown to be as effective as warfarin in the treatment and prevention of venous thromboembolism and prevention of stroke in nonvalvular atrial fibrillation." | 4.90 | Target-specific oral anticoagulants: practice issues for the clinician. ( Giugliano, RP; Plitt, A, 2014) |
| "All NOACs are at least as effective as warfarin for stroke prevention in patients with nonvalvular AF, and are at least as safe in terms of bleeding risk according to 3 large trials." | 4.90 | Approach to the new oral anticoagulants in family practice: part 1: comparing the options. ( Bell, AD; Douketis, J; Eikelboom, J; Liew, A, 2014) |
| "The objective of this review was to compare the safety and efficacy of dabigatran, rivaroxaban and apixaban to warfarin for the management of atrial fibrillation (AF) in older adults." | 4.89 | Risk versus benefit of non-vitamin K dependent anticoagulants compared to warfarin for the management of atrial fibrillation in the elderly. ( Jeffery, SM; Ogbonna, KC, 2013) |
| "The National Institute for Health and Clinical Excellence (NICE) invited the manufacturer of dabigatran etexilate (Boehringer Ingelheim Ltd, UK) to submit evidence for the clinical and cost-effectiveness of this drug for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation (AF) as part of the NICE single technology appraisal process." | 4.89 | Dabigatran for the prevention of stroke and systemic embolism in atrial fibrillation: A NICE single technology appraisal. ( Burch, J; Corbacho, B; Faria, R; Palmer, S; Pepper, C; Spackman, E; Todd, D; Woolacott, N, 2013) |
| "Dabigatran was the first of a new generation of anticoagulation drugs for the indication of non-valvular atrial fibrillation (AF) to be approved." | 4.89 | Is dabigatran considered a cost-effective alternative to warfarin treatment: a review of current economic evaluations worldwide. ( Asmussen, MB; Hesselbjerg, LJ; Pedersen, HS; Petersen, KD, 2013) |
| "Dabigatran is an oral, direct, and competitive inhibitor of thrombin, which is administered to patients with non-valvular atrial fibrillation for prevention of stroke at a dose of 110 mg twice daily or 150 mg twice daily." | 4.89 | [Direct oral thrombin inhibitor, "dabigatran"]. ( Yasaka, M, 2013) |
| "Dabigatran is a direct thrombin inhibitor gaining popularity as a stroke prevention agent in patients with atrial fibrillation." | 4.89 | Traumatic intracranial hemorrhage in patients taking dabigatran: report of 3 cases and review of the literature. ( Abel, TJ; Greenlee, JD; Grossbach, A; Howard, MA; Jackson, AW; Viljoen, SV; Wassef, SN, 2013) |
| "Warfarin has been the mainstay oral anticoagulant (OAC) medication prescribed for stroke prevention in atrial fibrillation (AF) patients." | 4.89 | Importance of pharmacokinetic profile and variability as determinants of dose and response to dabigatran, rivaroxaban, and apixaban. ( Gong, IY; Kim, RB, 2013) |
| "The primary objective was to assess the cost-effectiveness of new oral anticoagulants compared with warfarin in patients with nonvalvular atrial fibrillation." | 4.89 | Cost-effectiveness of new oral anticoagulants compared with warfarin in preventing stroke and other cardiovascular events in patients with atrial fibrillation. ( Cameron, C; Coyle, D; Coyle, K; Kelly, S; Lee, K; Steiner, S; Wells, GA, 2013) |
| "Dabigatran is approved for prevention of stroke or systemic embolism in patients with nonvalvular atrial fibrillation (AF)." | 4.89 | Dabigatran for periprocedural anticoagulation following radiofrequency ablation for atrial fibrillation: a meta-analysis of observational studies. ( Alexander, JH; Atwater, BD; Bahnson, TD; Daubert, JP; Hasselblad, V; Piccini, JP; Steinberg, BA; Washam, JB, 2013) |
| " The US Food and Drug Administration recently approved 2 new oral anticoagulants, dabigatran and rivaroxaban, for stroke prevention in patients with atrial fibrillation, and is currently reviewing a drug application for a third new oral anticoagulant, apixaban." | 4.89 | Novel oral anticoagulants: a review of new agents. ( Wanat, MA, 2013) |
| "In patients with atrial fibrillation (AF) oral anticoagulation with vitamin-K antagonists (warfarin, phenprocoumon) is effective both for primary and secondary stroke prevention yielding a 60-70% relative reduction in stroke risk compared with placebo, as well as a mortality reduction of 26 percent." | 4.89 | Novel oral anticoagulants in secondary prevention of stroke. ( Diener, HC; Easton, JD; Hankey, GJ; Hart, RG, 2013) |
| "The safety and efficacy of dabigatran in the periprocedural period for patients undergoing atrial fibrillation ablation is not well established." | 4.89 | Safety and efficacy of dabigatran compared with warfarin for patients undergoing radiofrequency catheter ablation of atrial fibrillation: a meta-analysis. ( Crystal, E; Danon, A; Healey, JS; Kansal, N; Lashevsky, I; Morillo, CA; Newman, D; Schulman, S; Shurrab, M, 2013) |
| "Dabigatran has been associated with greater risk of myocardial infarction (MI) than warfarin." | 4.89 | Meta-analysis of randomized controlled trials on risk of myocardial infarction from the use of oral direct thrombin inhibitors. ( Artang, R; Nielsen, JD; Rome, E; Vidaillet, HJ, 2013) |
| "Indications for use of the new anticoagulants include thromboprophylaxis after total hip and knee replacement surgery (all three), prevention of stroke and systemic embolism in non-valvular atrial fibrillation (all three), treatment of acute venous thrombosis and secondary prophylaxis after venous thrombosis (currently only rivaroxaban)." | 4.89 | New oral anticoagulants--a review. ( Atar, D; Ghanima, W; Sandset, PM, 2013) |
| "Oral anticoagulant therapy, either with vitamin K antagonists (VKAs) or with novel oral anticoagulants such as dabigatran, rivaroxaban, and apixaban, is the mainstay for thromboprophylaxis in patients with atrial fibrillation (AF)." | 4.89 | Anticoagulation management in nonvalvular atrial fibrillation: current and future directions. ( Kornej, J; Lip, GY; Potpara, T, 2013) |
| "Novel oral anticoagulants (NOAC) such as the direct thrombin inhibitor, dabigatran, and oral factor Xa inhibitors, rivaroxaban and apixaban, have recently approved for prevention of stroke in nonvalvular atrial fibrillation (NVAF)." | 4.89 | [Evidence of novel oral anticoagulants (NOAC)]. ( Kitazono, T, 2013) |
| "The novel oral anticoagulant drugs, comprising dabigatran, rivaroxaban, and apixaban, have emerged as compelling alternatives to vitamin K antagonists for stroke prevention in atrial fibrillation, and low‑molecular‑weight heparin for thromboprophylaxis following hip and knee arthroplasty." | 4.89 | Is there a role for novel oral anticoagulants in patients with an acute coronary syndrome? A review of the clinical trials. ( Darvish-Kazem, S; Douketis, JD; Liew, A, 2013) |
| " We review new anticoagulants that have been introduced recently to the market or that are undergoing investigations for treatment of nonvalvular atrial fibrillation and venous thromboembolism prophylaxis: Dabigatran, rivaroxaban, apixiban, and edoxaban." | 4.89 | The novel anticoagulants: the surgeons' prospective. ( Martin, EN; Money, SR; Shamoun, FE, 2013) |
| "Dabigatran and rivaroxaban are novel anticoagulants that have been approved for the prevention of thromboembolic events in atrial fibrillation." | 4.89 | Review of recently approved alternatives to anticoagulation with warfarin for emergency clinicians. ( Brem, E; Foran, M; Koyfman, A, 2013) |
| "Dabigatran is a direct inhibitor of thrombin that has recently been approved for primary and secondary stroke prevention and prevention of systemic embolism in patients with atrial fibrillation." | 4.88 | Preventing cardioembolic stroke in atrial fibrillation with dabigatran. ( Diener, HC; Eikelboom, JW; Hohnloser, SH; Weimar, C, 2012) |
| "Randomized clinical trials have conclusively demonstrated that warfarin prevents stroke in patients with atrial fibrillation." | 4.88 | Promise of factor Xa inhibition in atrial fibrillation. ( Al-Khatib, SM; Alexander, JH; Granger, CB; Lopes, RD; Mahaffey, KW; Patel, MR, 2012) |
| "Oral anticoagulation with vitamin K antagonists (warfarin, phenprocoumon) is successful in both primary and secondary stroke prevention in patients with atrial fibrillation, yielding a 60-70% relative reduction in stroke risk compared with placebo, as well as a mortality reduction of 26%." | 4.88 | Stroke prevention in atrial fibrillation: do we still need warfarin? ( Diener, HC; Hohnloser, SH; Lip, GY; Weber, R, 2012) |
| " This paper reviews the role of the novel anticoagulants, dabigatran, rivaroxaban and apixaban, in stroke prevention among patients with nonvalvular atrial fibrillation." | 4.88 | Direct thrombin inhibitors and factor Xa inhibitors in patients with cerebrovascular disease. ( Biller, J; Flaster, M; Morales-Vidal, S; Schneck, MJ, 2012) |
| "Warfarin has long been considered the gold standard for stroke prevention in patients with atrial fibrillation (AF)." | 4.88 | ARISTOTLE RE-LYs on the ROCKET. What's new in stroke prevention in patients with atrial fibrillation? ( Parma, Z; Syzdół, M; Tendera, M, 2012) |
| "To critically assess current evidence regarding the cost effectiveness of dabigatran for preventing stroke in patients with NVAF compared with warfarin." | 4.88 | Is dabigatran cost effective compared with warfarin for stroke prevention in atrial fibrillation? A critically appraised topic. ( Adcock, AK; Aguilar, MI; Demaerschalk, BM; Hoffman-Snyder, CR; Lee-Iannotti, JK; Wellik, KE; Wingerchuk, DM, 2012) |
| "For patients with atrial fibrillation and a high risk of thrombosis, the standard prophylaxis is warfarin, an anticoagulant, at a dose adjusted to the INR." | 4.88 | Dabigatran and atrial fibrillation: the alternative to warfarin for selected patients. ( , 2012) |
| "In the Randomized Evaluation of Long-term Anticoagulant Therapy (RE-LY) trial, dabigatran 150 mg was shown to be superior to warfarin for the prevention of stroke or systemic embolism." | 4.88 | Dabigatran or warfarin for the prevention of stroke in atrial fibrillation? A closer look at the RE-LY trial. ( DiNicolantonio, JJ, 2012) |
| "New oral anticoagulants, including apixaban, dabigatran, and rivaroxaban, have been developed as alternatives to warfarin, the standard oral anticoagulation therapy for patients with atrial fibrillation (AF)." | 4.88 | Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation. ( Eisenberg, MJ; Filion, KB; Grandi, SM; Miller, CS; Shimony, A, 2012) |
| "New oral anticoagulant drugs are emerging as alternatives to warfarin for the prevention of stroke in patients with non-valvular atrial fibrillation." | 4.88 | An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation. ( Ansell, J; Mantha, S, 2012) |
| "A network meta-analysis of the three new oral anticoagulants was performed from the three trials comparing dabigatran, rivaroxaban and apixaban with warfarin in patients with atrial fibrillation." | 4.88 | Comparison of efficacy and safety of dabigatran, rivaroxaban and apixaban in patients with atrial fibrillation using network meta-analysis. ( Diener, HC; Harenberg, J; Lip, GY; Marder, VJ; Marx, S; Wehling, M; Weiss, C, 2012) |
| "In this overview we address the three phase III studies that compared new oral anticoagulants (dabigatran, rivaroxaban and apixaban) with warfarin in the setting of stroke prevention in atrial fibrillation." | 4.88 | Phase III studies on novel oral anticoagulants for stroke prevention in atrial fibrillation: a look beyond the excellent results. ( Crippa, L; Falanga, A; Finazzi, G; Manotti, C; Marongiu, F; Moia, M; Palareti, G; Pengo, V; Poli, D; Siragusa, S; Testa, S; Tiraferri, E; Tosetto, A; Tripodi, A, 2012) |
| "In patients with atrial fibrillation (AF) warfarin has been the mainstay therapy for stroke prevention." | 4.88 | Emerging oral anticoagulants for stroke prevention in patients with non-valvular atrial fibrillation. ( Destephan, C; Dhruvakumar, S; Gerula, C; Kaluski, E; Maher, J; Mazza, V; Patel, RJ; Waller, AH, 2012) |
| " Dabigatran, does not require dose-adjustment and appears to be more effective at reducing the risk of stroke with similar risks of bleeding in patients with atrial fibrillation (AF)." | 4.88 | Home-monitoring of oral anticoagulation vs. dabigatran. An indirect comparison. ( Alonso-Coello, P; Guyatt, G; Zhou, Q, 2012) |
| " The factor Xa inhibitor, rivaroxaban, has shown promising results in the treatment of acute coronary syndrome but is not yet approved for that indication." | 4.88 | What did we learn from new oral anticoagulant treatment? ( Esmon, CT, 2012) |
| "We present data on possibility of anticoagulant therapy in conjunction with electrical cardioversion in patients with atrial fibrillation using novel anticoagulant - dabigatran - and a case of successful lysis of thrombus in the left ventricular cavity at the background of its administration." | 4.88 | [Anticoagulant therapy in connection with cardioversion in patients with atrial fibrillation]. ( Dovgalevskiĭ, IaP; Furman, NV; Kuvshinova, LE, 2012) |
| "In patients with NVAF at risk of stroke, the randomized evaluation of long-term anticoagulation therapy (RE-LY) trial demonstrated that, compared with warfarin, dabigatran 150 mg b." | 4.88 | New evidences for old concerns with oral anticoagulation in atrial fibrillation: focus on dabigatran. ( Barrios, V; Escobar, C, 2012) |
| "Warfarin has been the effective treatment in the prophylaxis of cardioembolism, in particular in patients with atrial fibrillation, for more than 50 years." | 4.87 | [Thromboembolic prophylaxis 2011: is warfarin on the wane?]. ( Di Pasquale, G; Riva, L, 2011) |
| "Dabigatran and other new oral anticoagulants (OAC) represent a step forward in stroke prevention in patients with atrial fibrillation (AF)." | 4.87 | Questions and answers on the use of dabigatran and perspectives on the use of other new oral anticoagulants in patients with atrial fibrillation. A consensus document of the Italian Federation of Thrombosis Centers (FCSA). ( Crippa, L; Falanga, A; Finazzi, G; Manotti, C; Marongiu, F; Palareti, G; Pengo, V; Poli, D; Testa, S; Tiraferri, E; Tosetto, A; Tripodi, A, 2011) |
| " The recently introduced oral direct thrombin antagonist, dabigatran, has been shown in phase III clinical trials to be noninferior in efficacy to warfarin for the prevention of thromboembolic events in patients with atrial fibrillation, as well as in treatment of acute venous thromboembolism." | 4.87 | Dabigatran: a new option for anticoagulation in atrial fibrillation and venous thromboembolism. ( Acharjee, S; Cannon, CP, 2011) |
| "The objective of this review is to summarize data from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) and Apixaban Versus Acetylsalicylic Acid to Prevent Stroke in Atrial Fibrillation Patients Who Have Failed or Are Unsuitable for Vitamin K Antagonist Treatment (AVERROES) trials of apixaban for stroke prevention in patients with atrial fibrillation (AF)." | 4.87 | Apixaban for stroke prevention in atrial fibrillation: a review of the clinical trial evidence. ( Yates, SW, 2011) |
| "Long-term anticoagulation with a vitamin K antagonist (VKA) or the new agent dabigatran is recommended to decrease stroke risk in patients with atrial fibrillation." | 4.87 | Striking a balance between the risks and benefits of anticoagulation bridge therapy in patients with atrial fibrillation: clinical updates and remaining controversies. ( Garwood, CL; Hwang, JM; Moser, LR, 2011) |
| "Randomized trials have demonstrated that warfarin is effective for stroke prevention in patients with atrial fibrillation (AF), yielding relative risk reductions for ischemic stroke of nearly 70%." | 4.86 | New options for stroke prevention in atrial fibrillation. ( Cannon, CP; Stecker, EC, 2010) |
| "A Markov decision analysis model was developed to compare dabigatran (110 or 150 mg twice a day) to warfarin titrated to target prothrombin time in patients with NVAF at high risk of stroke." | 4.12 | Cost-Utility Analysis of Dabigatran and Warfarin for Stroke Prevention Among Patients With Nonvalvular Atrial Fibrillation in India. ( Aggarwal, R; Aghoram, R; Kar, SS; Kumar, SM; Rajasulochana, SR, 2022) |
| "The comparative safety of dabigatran versus warfarin for treatment of nonvalvular atrial fibrillation in general practice settings has not been established." | 3.81 | Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation. ( Goulding, MR; Graham, DJ; Houstoun, M; Kelman, JA; Levenson, M; MaCurdy, TE; Mott, K; Reichman, ME; Sheu, TC; Southworth, MR; Wernecke, M; Worrall, C; Zhang, R, 2015) |
| "It remains unclear whether dabigatran etexilate mesylate is associated with higher risk of bleeding than warfarin sodium in real-world clinical practice." | 3.81 | Risk of bleeding with dabigatran in atrial fibrillation. ( Baik, SH; Hernandez, I; Piñera, A; Zhang, Y, 2015) |
| " We investigated the risks of ischemic stroke and intracranial hemorrhage (ICH) in relation to warfarin at various TTRs in a real-world cohort of Chinese patients with atrial fibrillation receiving warfarin and compared with those on dabigatran, aspirin, and no therapy." | 3.81 | Ischemic stroke and intracranial hemorrhage with aspirin, dabigatran, and warfarin: impact of quality of anticoagulation control. ( Chan, KH; Chan, PH; Cheung, E; Hai, JJ; Ho, CW; Ho, MH; Lau, CP; Lau, KK; Leung, GK; Lip, GY; Siu, CW; Tse, HF; Yeung, CY, 2015) |
| "Although dabigatran, an oral direct thrombin inhibitor, does not require routine monitoring, high plasma concentration of dabigatran (PDC) at trough level is shown to be a high risk for bleeding in patients with nonvalvular atrial fibrillation (NVAF)." | 3.81 | CHA2DS2-VASc and HAS-BLED scores and activated partial thromboplastin time for prediction of high plasma concentration of dabigatran at trough. ( Horiuchi, D; Ishida, Y; Itoh, T; Kimura, M; Kinjo, T; Okumura, K; Owada, S; Sasaki, K; Sasaki, S; Tomita, H, 2015) |
| "Compared with warfarin, periprocedural anticoagulation with dabigatran resulted in fewer minor hemorrhages and total adverse events after AF ablation." | 3.81 | Safety of novel oral anticoagulants compared with uninterrupted warfarin for catheter ablation of atrial fibrillation. ( Armbruster, HL; Berger, RD; Calkins, H; Habibi, M; Khurram, IM; Lindsley, JP; Marine, JE; Moranville, MP; Spragg, DD, 2015) |
| "Prevalence plots were used to describe the point prevalence (monthly) of dabigatran and rivaroxaban use among 29977 hemodialysis patients with atrial fibrillation." | 3.81 | Dabigatran and rivaroxaban use in atrial fibrillation patients on hemodialysis. ( Chan, KE; Edelman, ER; Maddux, FW; Thadhani, RI; Wenger, JB, 2015) |
| "A report has demonstrated that in patients with atrial fibrillation the novel oral anticoagulant, dabigatran, increases the risk of gastrointestinal bleeding by nearly twofold compared with warfarin." | 3.81 | Gastrointestinal bleeding. Gastrointestinal bleeding risk is increased by novel anticoagulants. ( Rockey, DC, 2015) |
| "Novel oral anticoagulants are available for the management of atrial fibrillation and are considered more convenient to use than warfarin." | 3.81 | Patterns of oral anticoagulants use in atrial fibrillation. ( Beauchesne, M; Blais, L; Brais, C; Farand, P; Larochelle, J; Letemplier, G; Perreault, S; Tousignant, A; Turgeon, M, 2015) |
| "The objectives of this national chart audit (January to June 2013) of 6,346 patients with atrial fibrillation (AF; ≥18 years without a significant heart valve disorder) from 647 primary care physicians were to (1) describe the frequency of stroke and bleed risk assessments in patients with nonvalvular AF by primary care physicians, including the accuracy of these assessments relative to established predictive indexes; (2) outline contemporary methods of anticoagulation used; and (3) report the time in the therapeutic range among patients prescribed warfarin." | 3.81 | Risk stratification and stroke prevention therapy care gaps in Canadian atrial fibrillation patients (from the Co-ordinated National Network to Engage Physicians in the Care and Treatment of Patients With Atrial Fibrillation chart audit). ( Angaran, P; Bell, AD; Berall, M; Bucci, C; Demchuk, AM; Essebag, V; Goldin, L; Goodman, SG; Green, MS; Gregoire, JC; Gross, PL; Heilbron, B; Lin, PJ; Patel, AD; Ramanathan, K; Skanes, A; Tan, MK; Wheeler, BH, 2015) |
| " She had been on dabigatran for 13 months due to atrial fibrillation and arterial hypertension." | 3.81 | [Exfoliative esophagitis while taking dabigatran]. ( Meesmann, M; Scheppach, W, 2015) |
| " A total of 67 Veterans Health Administration sites with 20 or more patients filling dabigatran prescriptions between 2010 and 2012 for nonvalvular atrial fibrillation were sampled (4863 total patients; median, 51 patients per site)." | 3.81 | Site-level variation in and practices associated with dabigatran adherence. ( Carey, EP; Cunningham, F; Glorioso, TJ; Ho, PM; Jackevicius, C; Lambert-Kerzner, A; Longo, L; Rose, A; Shore, S; Turakhia, MP, 2015) |
| "Incidence rates (events/100 patient years) and propensity score matched Cox proportional hazards models were used to estimate rates of total gastrointestinal bleeds, upper gastrointestinal bleeds, and lower gastrointestinal bleeds for the novel oral anticoagulants compared with warfarin in patients with and without atrial fibrillation." | 3.81 | Comparative risk of gastrointestinal bleeding with dabigatran, rivaroxaban, and warfarin: population based cohort study. ( Abraham, NS; Alexander, GC; Crown, W; Haas, LR; Heien, H; Shah, ND; Singh, S, 2015) |
| "Dabigatran is a direct thrombin inhibitor that has been approved for preventing stroke in patients with atrial fibrillation." | 3.81 | Relation between dabigatran concentration, as assessed using the direct thrombin inhibitor assay, and activated clotting time/activated partial thromboplastin time in patients with atrial fibrillation. ( Fujino, T; Kuwahara, T; Nakajima, J; Nakashima, E; Okubo, K; Takagi, K; Takahashi, A; Takigawa, M; Tsutsui, H; Watari, Y; Yamao, K, 2015) |
| "Bleeding and thromboembolic events during the periprocedural period were evaluated in 363 consecutive patients who underwent CA for AF at Nagoya University Hospital, and received uninterrupted dabigatran (n=173) or uninterrupted warfarin (n=190) for periprocedural anticoagulation." | 3.81 | Feasibility and safety of uninterrupted dabigatran therapy in patients undergoing ablation for atrial fibrillation. ( Fujita, M; Hirai, M; Inden, Y; Ishikawa, S; Kato, H; Miyoshi, A; Murohara, T; Nagao, T; Ohguchi, S; Okumura, S; Shimano, M; Yamamoto, T; Yanagisawa, S; Yoshida, N, 2015) |
| "Dabigatran is an oral thrombin inhibitor which has been approved for prevention of stroke or embolism in atrial fibrillation patients as an alternative to vitamin K antagonists." | 3.80 | Life-threatening epistaxis and red blood cell polyagglutination under dabigatran. ( Finsterer, J; Krutisch, G; Stöllberger, C, 2014) |
| "In the RE-LY trial dabigatran 150 mg twice daily (D150) showed significantly fewer strokes, and 110 mg (D110) significantly fewer major bleeding events (MBE) compared to well-controlled warfarin in patients with atrial fibrillation (AF)." | 3.80 | Patient outcomes using the European label for dabigatran. A post-hoc analysis from the RE-LY database. ( Clemens, A; Connolly, SJ; Ferreira, J; Lip, GY; Noack, H; Yusuf, S, 2014) |
| "Dabigatran may provide less protection against myocardial infarction than vitamin K antagonists (VKAs) in patients with atrial fibrillation." | 3.80 | Myocardial ischemic events in 'real world' patients with atrial fibrillation treated with dabigatran or warfarin. ( Gorst-Rasmussen, A; Lane, DA; Larsen, TB; Lip, GY; Rasmussen, LH; Rosenzweig, M; Skjøth, F, 2014) |
| "Dabigatran is a direct thrombin inhibitor indicated for stroke and systemic embolism prevention in patients with non-valvular atrial fibrillation." | 3.80 | [Patient with acute renal injury presenting dabigatran overdose: Hemodialysis for surgery]. ( Bachellerie, B; Conil, JM; Crognier, L; Fourcade, O; Georges, B; Ruiz, S; Seguin, T, 2014) |
| "Acute ischemic stroke thrombolysis in patients taking dabigatran is controversial because of a presumed increased risk of symptomatic hemorrhagic transformation." | 3.80 | Proposed approach to thrombolysis in dabigatran-treated patients presenting with ischemic stroke. ( Butcher, K; Kate, M; Shuaib, A; Szkotak, A; Witt, A, 2014) |
| " Therefore, we compared the incidence of bleeding and thrombo-embolic complications following cardiac rhythm device (CRD) implantations under dabigatran vs." | 3.80 | Treatment with novel oral anticoagulants in a real-world cohort of patients undergoing cardiac rhythm device implantations. ( Bollmann, A; Breithardt, OA; Dinov, B; Doering, M; Hindricks, G; Kosiuk, J; Koutalas, E; Nedios, S; Richter, S; Rolf, S; Sommer, P, 2014) |
| "Apixaban (5 mg BID), dabigatran (available as 150 mg and 110 mg BID in Europe), and rivaroxaban (20 mg once daily) are 3 novel oral anticoagulants (NOACs) currently approved for stroke prevention in patients with atrial fibrillation (AF)." | 3.80 | Cost-effectiveness of apixaban versus other new oral anticoagulants for stroke prevention in atrial fibrillation. ( Dorian, P; Hernandez, L; Iloeje, U; Kongnakorn, T; Kuznik, A; Lanitis, T; Lip, GY; Liu, LZ; Phatak, H, 2014) |
| "Advantages of dabigatran, a thrombin inhibitor, for stroke prevention in patients with atrial fibrillation are numerous." | 3.80 | Impaired renal function and bleeding in elderly treated with dabigatran. ( Assayag, P; Berthelot, E; Desconclois, C; Lavenu-Bombled, C; Orostegui-Giron, L, 2014) |
| "By using nationwide Danish prescription and patient registries, we identified 11,315 first-time dabigatran users with atrial fibrillation." | 3.80 | Bleeding events among new starters and switchers to dabigatran compared with warfarin in atrial fibrillation. ( Gorst-Rasmussen, A; Larsen, TB; Lip, GY; Rasmussen, LH; Rosenzweig, M; Skjøth, F, 2014) |
| "We report a case of life-threatening haemoptysis after administration of dabigatran in a patient with bronchiectasis." | 3.80 | Massive haemoptysis following dabigatran administration in a patient with bronchiectasis. ( Hayama, M; Inoue, H; Mio, T; Wada, H, 2014) |
| "Epistaxis resulted in severe anemia in an 89-year-old Caucasian woman under a therapy with dabigatran for 12 months because of atrial fibrillation." | 3.80 | Dabigatran-induced lupus temporarily preventing blood group determination. ( Finsterer, J; Krutisch, G; Stöllberger, C; Wolf, HM, 2014) |
| "Large Phase 3 clinical trials for stroke prevention in atrial fibrillation (AF) have compared non-vitamin K antagonist oral anticoagulants (NOACs) against warfarin, with the edoxaban trial only recently reported." | 3.80 | Efficacy and safety of edoxaban in comparison with dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation. An indirect comparison analysis. ( Larsen, TB; Lip, GY; Rasmussen, LH; Skjøth, F, 2014) |
| "The new oral anticoagulants (NOAC), dabigatran and rivaroxaban, have been demonstrated to be at least equivalent to warfarin for preventing cardiac thromboembolism (TE) in patients with atrial fibrillation (AF)." | 3.80 | Safety of new oral anticoagulants for patients undergoing atrial fibrillation ablation. ( Badhwar, N; Gerstenfeld, EP; Lee, BK; Lee, RJ; Marcus, GM; Olgin, J; Scheinman, M; Stepanyan, G; Tseng, ZH; Vedantham, V, 2014) |
| "The clinical data and treatment summaries of 9 intracranial bleeds that developed during dabigatran treatment in 8 patients with non-valvular atrial fibrillation were retrospectively reviewed." | 3.80 | Intracranial hemorrhage during dabigatran treatment. ( Ago, T; Fujimoto, S; Kameda, K; Kitazono, T; Kokuba, K; Komori, M; Matsuoka, H; Nagata, S; Okada, Y; Shono, T; Yasaka, M; Yoshida, M, 2014) |
| "Dabigatran is an oral anticoagulant from the class of the direct thrombin inhibitors, indicated for prevention of thromboembolic events in patients with non valvular atrial fibrillation." | 3.80 | [Hemodialysis to remove anticoagulant dabigatran during emergencies]. ( Campbell, S; Carrizo, A, 2014) |
| "New oral anticoagulants (NOACs) offer an alternative to warfarin for preventing stroke in patients with atrial fibrillation." | 3.80 | Perioperative management of patients on new oral anticoagulants. ( Davidson, N; Galloway, SW; Lai, A; Thachil, J, 2014) |
| "To conduct an economic evaluation of the currently prescribed treatments for stroke prevention in patients with non-valvular atrial fibrillation (NVAF) including warfarin, aspirin, and novel oral anticoagulants (NOACs) from a French payer perspective." | 3.80 | Stroke prevention in patients with atrial fibrillation in France: comparative cost-effectiveness of new oral anticoagulants (apixaban, dabigatran, and rivaroxaban), warfarin, and aspirin. ( Cotté, FE; Durand-Zaleski, I; Gaudin, AF; Kachaner, I; Kongnakorn, T; Lanitis, T, 2014) |
| "Dabigatran, rivaroxaban, and apixaban have been approved for use in patients with atrial fibrillation based upon randomized trials demonstrating their comparable or superior efficacy and safety relative to warfarin." | 3.80 | Patterns of initiation of oral anticoagulants in patients with atrial fibrillation- quality and cost implications. ( Avorn, J; Brennan, TA; Brill, G; Choudhry, NK; Desai, NR; Krumme, AA; Matlin, OS; Pezalla, EJ; Schneeweiss, S; Shrank, WH; Spettell, CM, 2014) |
| " Adherence to dabigatran was not associated with non-fatal bleeding or myocardial infarction." | 3.80 | Adherence to dabigatran therapy and longitudinal patient outcomes: insights from the veterans health administration. ( Barón, AE; Bradley, SM; Carey, EP; Cunningham, F; Grunwald, GK; Ho, PM; Jackevicius, CA; Maddox, TM; Marzec, LN; Pilote, L; Rumsfeld, JS; Schneider, PM; Shore, S; Turakhia, MP; Varosy, PD, 2014) |
| "In randomized trials, patients with atrial fibrillation (AF) receiving dabigatran, a direct oral anticoagulant, had lower risk of intracranial bleeding (ICB) than those on warfarin." | 3.80 | Intracranial hemorrhage mortality in atrial fibrillation patients treated with dabigatran or warfarin. ( Alonso, A; Bengtson, LG; Chen, LY; Lakshminarayan, K; Lutsey, PL; MacLehose, RF, 2014) |
| "Dabigatran is one of the three newer oral anticoagulants (OACs) recently approved in the United States for stroke prevention in non-valvular atrial fibrillation (NVAF) patients." | 3.80 | Characteristics affecting oral anticoagulant therapy choice among patients with non-valvular atrial fibrillation: a retrospective claims analysis. ( AbuDagga, A; Fu, AC; Kwong, WJ; Stephenson, JJ; Tan, H; Weintraub, WS, 2014) |
| "Dabigatran, an oral direct thrombin inhibitor, possesses several advantages over warfarin that can in principle simplify the management of stroke prevention in atrial fibrillation (AF)." | 3.80 | Continuation of dabigatran therapy in "real-world" practice in Hong Kong. ( Chan, EW; Chan, KH; Chan, PH; Cheung, E; Hai, JJ; Ho, CW; Ho, MH; Leung, GK; Siu, CW; Tse, HF, 2014) |
| "This study aims to estimate the cost-effectiveness of dabigatran 150 mg twice daily versus warfarin for stroke and systemic embolism risk reduction in patients with nonvalvular atrial fibrillation initiating treatment before age 75 (<75), at or after age 75 (≥ 75), and the overall population (All) from a US Medicare payer perspective." | 3.80 | Efficacy and cost-effectiveness of dabigatran etexilate versus warfarin in atrial fibrillation in different age subgroups. ( Brand, S; Brueckmann, M; Clemens, A; Kansal, A; Lim, J; Noack, H; Peng, S; Sander, S; Sorensen, S, 2014) |
| "Clinical trial data suggest that dabigatran and warfarin have similar rates of major bleeding but higher rates of gastrointestinal bleeding." | 3.80 | Bleeding rates in Veterans Affairs patients with atrial fibrillation who switch from warfarin to dabigatran. ( Chrischilles, E; Cram, P; Jones, M; Mazur, A; Vaughan Sarrazin, MS, 2014) |
| " The purpose of this study was to estimate the change in medical costs related to stroke and major bleeding for each NOAC (apixaban, dabigatran, and rivoraxaban) relative to warfarin in a RW NVAF population." | 3.80 | Estimated medical cost reductions associated with use of novel oral anticoagulants vs warfarin in a real-world non-valvular atrial fibrillation patient population. ( Amin, A; Lawrence, JH; Makenbaeva, D; Stokes, M; Wiederkehr, D; Wu, N, 2014) |
| "We applied enrollment criteria of 4 RCTs (RE-LY, ROCKET-AF, ARISTOTLE, and ENGAGE-AF-TIMI 48) to 695 patients with AF taking warfarin, prospectively and consecutively collected at a university medical center; 500 patients with and 195 patients without stroke." | 3.80 | Eligibility and preference of new oral anticoagulants in patients with atrial fibrillation: comparison between patients with versus without stroke. ( Bang, OY; Chung, CS; Kim, GM; Kim, JS; Kim, SJ; Lee, KH; Lee, MJ; Park, YK; Ryoo, S; Yoon, CH, 2014) |
| "The oral direct thrombin inhibitor dabigatran is increasingly used to prevent thromboembolic stroke in patients with atrial fibrillation (AF)." | 3.80 | On the monitoring of dabigatran treatment in "real life" patients with atrial fibrillation. ( Antovic, JP; Beck, O; Eintrei, J; Hjemdahl, P; Malmström, RE; Muhrbeck, J; Pohanka, A; Rönquist-Nii, Y; Skeppholm, M, 2014) |
| " New oral anticoagulants (apixaban, rivaroxaban and dabigatran) are recommended for antithrombotic therapy in patients with non-valvular atrial fibrillation (NVAF) with moderate and high risk of stroke." | 3.80 | [Cost-effectiveness of apixaban compared to other new oral anticoagulants in patients with non-valvular atrial fibrillation]. ( Rudakova, AV; Tatarskiĭ, BA, 2014) |
| "This register-based observational study compares dabigatran to warfarin for secondary stroke prevention in atrial fibrillation patients among both "new starters" on dabigatran and "switchers" to dabigatran from warfarin." | 3.80 | Dabigatran and warfarin for secondary prevention of stroke in atrial fibrillation patients: a nationwide cohort study. ( Gorst-Rasmussen, A; Lane, DA; Larsen, TB; Lip, GY; Rasmussen, LH; Skjøth, F, 2014) |
| "Left atrial appendage occlusion devices are cost effective for stroke prophylaxis in atrial fibrillation when compared with dabigatran or warfarin." | 3.80 | Identifying future research priorities using value of information analyses: left atrial appendage occlusion devices in atrial fibrillation. ( Bennell, MC; Krahn, M; Micieli, A; Pham, B; Singh, SM; Wijeysundera, HC, 2014) |
| " Dabigatran has emerged as a promising alternative to vitamin K antagonists (VKAs) in non-valvular atrial fibrillation (NVAF)." | 3.80 | [Eligibility for dabigatran therapy: the real-life experience of a Tuscany general hospital]. ( Banfi, R; Fallani, F; Palazzi, N; Pugi, A, 2014) |
| "This study aimed to evaluate the cost-effectiveness of dabigatran and rivaroxaban compared with warfarin for the prevention of stroke in patients with atrial fibrillation (AF) in Singapore." | 3.80 | Cost-effectiveness of dabigatran and rivaroxaban compared with warfarin for stroke prevention in patients with atrial fibrillation. ( Ko, Y; Kong, MC; Lee, LH; Ng, HJ; Wang, Y; Xie, F, 2014) |
| "Our objectives were to investigate the cost effectiveness of apixaban, rivaroxaban, and dabigatran compared with coumarin derivatives for stroke prevention in patients with atrial fibrillation in a country with specialized anticoagulation clinics (the Netherlands) and in a country without these clinics (the UK)." | 3.80 | Cost effectiveness of new oral anticoagulants for stroke prevention in patients with atrial fibrillation in two different European healthcare settings. ( de Boer, A; Hasrat, F; Maitland-van der Zee, AH; Redekop, WK; Verhoef, TI, 2014) |
| "Bleeding complications post-ablation were similar for warfarin, dabigatran, and rivaroxaban in patients undergoing cryoballoon ablation." | 3.80 | A comparison of bleeding complications between warfarin, dabigatran, and rivaroxaban in patients undergoing cryoballoon ablation. ( Duart, M; Kauffman, C; Kusumoto, F; Ray, JC; Snipelisky, D; Ung, R, 2014) |
| " A direct thrombin inhibitor, dabigatran etexilate (hereinafter referred to as dabigatran) was approved in the Russian Federation for prevention of thromboembolic complications in orthopaedic practice (2009), for prevention of ischaemic embologenic stroke in atrial fibrillation (2011) and for treatment of recurrent thrombosis of deep veins and pulmonary artery thromboembolism (2014)." | 3.80 | [Laboratory assessment of haemostatic parameters in patients taking a direct thrombin inhibitor]. ( Beliavskaia, OO; Vavilova, TV, 2014) |
| "We report a case of a patient receiving dabigatran who developed a life-threatening bleeding complication during cardiac ablation that rapidly resolved after administration of Factor Eight Inhibitor Bypassing Activity (FEIBA)." | 3.79 | Reversing dabigatran in life-threatening bleeding occurring during cardiac ablation with factor eight inhibitor bypassing activity. ( Dager, WE; Gosselin, RC; Roberts, AJ, 2013) |
| "To compare the management cost and cost-effectiveness of dabigatran with warfarin in patients with nonvalvular atrial fibrillation (AF) from the hospital's and patients' perspectives." | 3.79 | Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in patients with atrial fibrillation--a real patient data analysis in a Hong Kong teaching hospital. ( Chang, AM; Ho, JC; Lam, YY; Lee, VW; Yan, BP; Yu, CM, 2013) |
| "This was a prospective observational study of ED patients under treatment with dabigatran or warfarin who were admitted with bleeding complications during a 6-month period." | 3.79 | Hemorrhagic complications in emergency department patients who are receiving dabigatran compared with warfarin. ( Berger, R; Chase, M; Ganetsky, M; Salhanick, SD, 2013) |
| " On admission, a computed tomography angiogram revealed acute bilateral PE, despite use of dabigatran for atrial fibrillation for approximately 5 years prior to admission." | 3.79 | Acute pulmonary emboli in a patient on long-term dabigatran therapy. ( Kujawski, SZ; Prom, R; Rafferty, JA, 2013) |
| "Dabigatran is an oral anticoagulant direct thrombin inhibitor recently registered in South Africa (SA) to reduce the risk of stroke and systemic embolism in patients with atrial fibrillation (AF)." | 3.79 | Economic appraisal of dabigatran as first-line therapy for stroke prevention in atrial fibrillation. ( Bergh, M; Marais, CA; Miller-Jansön, H; Salie, F; Stander, MP, 2013) |
| "It is a case report of bleeding when using dabigatran in patient with renal failure caused by the concurrent use of spironolactone and angiotensin-converting enzyme (ACE) inhibitors." | 3.79 | [Bleeding in the appointment of dabigatran in the patients with renal insufficiency caused by coadministration of spironolactone and ACE inhibitors]. ( Andreev, DA; Gappoeva, ZK; Giliarov, MIu; Sychev, DA, 2013) |
| "To estimate the cost-effectiveness of stroke prevention in patients with nonvalvular atrial fibrillation by using novel oral anticoagulants apixaban 5 mg, dabigatran 150 mg, and rivaroxaban 20 mg compared with warfarin." | 3.79 | Cost-effectiveness of apixaban, dabigatran, rivaroxaban, and warfarin for stroke prevention in atrial fibrillation. ( Armstrong, EP; Harrington, AR; Malone, DC; Nolan, PE, 2013) |
| "Uninterrupted oral anticoagulant (OA) therapy with warfarin has become the standard of care at many centers performing catheter ablation of atrial fibrillation (AF)." | 3.79 | Dabigatran versus warfarin therapy for uninterrupted oral anticoagulation during atrial fibrillation ablation. ( Doppalapudi, H; Gunter, A; Kay, GN; Maddox, W; McElderry, HT; Osorio, J; Plumb, VJ; Yamada, T, 2013) |
| "Dabigatran is effective for both the prevention of stroke and bleeding in patients with atrial fibrillation (AF)." | 3.79 | Dabigatran in the peri-procedural period for radiofrequency ablation of atrial fibrillation: efficacy, safety, and impact on duration of hospital stay. ( Fujiwara, R; Fukuzawa, K; Hirata, K; Imamura, K; Itoh, M; Kiuchi, K; Matsumoto, A; Nakanishi, T; Suzuki, A; Takami, K; Takami, M; Takei, A; Yamashita, S; Yoshida, A, 2013) |
| "The use of dabigatran would lead to a significant reduction of strokes and deaths attributable to AF in France." | 3.79 | Modeling of the impact on health outcomes of the use of dabigatran in patients with atrial fibrillation. ( Chevalier, J; de Pouvourville, G; Giroud, M, 2013) |
| "A number of models exploring the cost-effectiveness of dabigatran versus warfarin for stroke prevention in atrial fibrillation have been published." | 3.79 | A comparative analysis of models used to evaluate the cost-effectiveness of dabigatran versus warfarin for the prevention of stroke in atrial fibrillation. ( Bradley-Kennedy, C; Kansal, AR; Monz, BU; Peng, S; Sorensen, SV, 2013) |
| "Alternative anticoagulants to warfarin (dabigatran, rivaroxaban, and apixaban) are becoming available for the prevention of thromboembolic stroke in atrial fibrillation (AF), but there is a lack of information on their comparative effectiveness." | 3.79 | Comparative effectiveness of dabigatran, rivaroxaban, apixaban, and warfarin in the management of patients with nonvalvular atrial fibrillation. ( Hughes, DA; Pink, J; Pirmohamed, M, 2013) |
| "In patients undergoing left atrial catheter ablation for AF or left atrial flutter, use of periprocedural dabigatran etexilate provides a safe and effective anticoagulation strategy compared to warfarin." | 3.79 | Continuous warfarin versus periprocedural dabigatran to reduce stroke and systemic embolism in patients undergoing catheter ablation for atrial fibrillation or left atrial flutter. ( Ellis, CR; Kaiser, DW; Nagarakanti, R; Streur, MM; Whalen, SP, 2013) |
| "Dabigatran was expected to replace warfarin for stroke prevention in patients with nonvalvular atrial fibrillation (AF) who are warfarin naive, difficult to maintain in therapeutic range, or at risk of warfarin-related bleeding complications." | 3.79 | Effect of dabigatran on referrals to and switching from warfarin in two academic anticoagulation management services. ( Atay, JK; Barnes, GD; Coatney, J; Ehle, M; Fanikos, J; Froehlich, JB; Goldhaber, SZ; Piazza, G, 2013) |
| " We evaluated the influence of the putative etiological variables and the bleeding score, HAS-BLED score, on APTT values: age greater than 70 years, renal function, gender, dose of dabigatran, and the concomitant prescription of a P-glycoprotein inhibitor." | 3.79 | Bleeding events and activated partial thromboplastin time with dabigatran in clinical practice. ( Hachiya, H; Hirao, K; Isobe, M; Kawabata, M; Nakamura, T; Sasano, T; Sugiyama, K; Suzuki, M; Tanaka, Y; Yagishita, A; Yokoyama, Y, 2013) |
| "Percutaneous left atrial appendage (LAA) occlusion and novel pharmacological therapies are now available to manage stroke risk in patients with nonvalvular atrial fibrillation; however, the cost-effectiveness of LAA occlusion compared with dabigatran and warfarin in patients with nonvalvular atrial fibrillation is unknown." | 3.79 | Economic evaluation of percutaneous left atrial appendage occlusion, dabigatran, and warfarin for stroke prevention in patients with nonvalvular atrial fibrillation. ( Micieli, A; Singh, SM; Wijeysundera, HC, 2013) |
| "Dabigatran is an oral direct thrombin inhibitor that is Food and Drug Administration-approved for prevention of stroke in patients with atrial fibrillation." | 3.79 | Extracorporeal therapy for dabigatran removal in the treatment of acute bleeding: a single center experience. ( Hallows, KR; Henry, BL; Maw, TT; Nolin, TD; Pastor-Soler, NM; Singh, T; Unruh, ML, 2013) |
| "Samples were obtained from 70 atrial fibrillation patients treated with dabigatran etexilate." | 3.79 | Evaluation of coagulation assays versus LC-MS/MS for determinations of dabigatran concentrations in plasma. ( Antovic, JP; Beck, O; Boija, EE; Eintrei, J; Hjemdahl, P; Malmström, RE; Norberg, EM; Onelöv, L; Pohanka, A; Rönquist-Nii, Y; Skeppholm, M; Söderblom, L, 2013) |
| "The results of a study to determine whether pharmacist monitoring in the crucial first months of dabigatran therapy in patients with atrial fibrillation or flutter can help optimize adherence and stroke-prevention outcomes are presented." | 3.79 | Adherence and outcomes of patients treated with dabigatran: pharmacist-managed anticoagulation clinic versus usual care. ( Han, SY; Lee, PY; Miyahara, RK, 2013) |
| "Between March 2011 and July 2012, dabigatran was prescribed to 404 Japanese patients with nonvalvular atrial fibrillation at The Cardiovascular Institute (Tokyo, Japan)." | 3.79 | "Blue letter effects": Changes in physicians' attitudes toward dabigatran after a safety advisory in a specialized hospital for cardiovascular care in Japan. ( Aizawa, T; Kano, H; Kirigaya, H; Koike, A; Matsuno, S; Nagashima, K; Oikawa, Y; Otsuka, T; Sagara, K; Sawada, H; Suzuki, S; Takai, H; Tanabe, H; Uejima, T; Yajima, J; Yamashita, T, 2013) |
| "Dabigatran is a direct thrombin inhibitor approved to help prevent thrombotic events in patients with atrial fibrillation." | 3.79 | Dental management considerations for a patient taking dabigatran etexilate: a case report. ( Henry, RG; Miller, CS; Romond, KK, 2013) |
| "The role of concomitant aspirin (ASA) therapy in patients with atrial fibrillation (AF) receiving oral anticoagulation (OAC) is unclear." | 3.79 | Use and associated risks of concomitant aspirin therapy with oral anticoagulation in patients with atrial fibrillation: insights from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Registry. ( Ansell, J; Chang, P; Ezekowitz, MD; Fonarow, GC; Gersh, B; Go, AS; Hylek, E; Kim, S; Kowey, P; Lopes, RD; Mahaffey, KW; Peterson, ED; Piccini, JP; Singer, DE; Steinberg, BA; Thomas, L, 2013) |
| "Based on clinical trials the oral anticoagulants (OACs) apixaban, dabigatran, and rivaroxaban are efficacious for reducing stroke risk for non-valvular atrial fibrillation (NVAF) patients." | 3.79 | Medical costs in the US of clinical events associated with oral anticoagulant (OAC) use compared to warfarin among non-valvular atrial fibrillation patients ≥75 and <75 years of age, based on the ARISTOTLE, RE-LY, and ROCKET-AF trials. ( Amin, A; Deitelzweig, S; Graham, J; Jing, Y; Lin, J; Makenbaeva, D; Wiederkehr, D, 2013) |
| "Cerebral microthromboembolism after atrial fibrillation (AF) ablation has been reported in 4-20% with perioperative warfarin." | 3.79 | The incidence of asymptomatic cerebral microthromboembolism after atrial fibrillation ablation: comparison of warfarin and dabigatran. ( Hamasaki, S; Ichiki, H; Iriki, Y; Ishida, S; Maenosono, R; Miyata, M; Namino, F; Ninomiya, Y; Oketani, N; Okui, H; Tei, C, 2013) |
| "Warfarin is the primary treatment for those with atrial fibrillation at increased risk for stroke." | 3.79 | A comparison of methods for estimating glomerular filtration rate for a population in Hawai'i with non-valvular atrial fibrillation. ( Azuma, S; Lum, CJ, 2013) |
| "Patients receiving dabigatran were younger and at a lower risk of stroke and bleeding." | 3.79 | Early adoption of dabigatran and its dosing in US patients with atrial fibrillation: results from the outcomes registry for better informed treatment of atrial fibrillation. ( Ansell, J; Chang, P; Ezekowitz, MD; Fonarow, GC; Gersh, B; Holmes, DN; Hylek, EM; Kowey, PR; Mahaffey, KW; Peterson, ED; Piccini, JP; Singer, DE; Steinberg, BA; Thomas, L, 2013) |
| "In an 89-year-old female with atrial fibrillation dabigatran had been started 11 days before admission, following a transitory ischemic attack." | 3.79 | Ischemic stroke and intestinal bleeding under dabigatran in metabolic myopathy. ( Bastovansky, A; Finsterer, J; Paul, G; Stöllberger, C, 2013) |
| "Dabigatran is a direct thrombin inhibitor that reduces the risk of systemic embolism in patients with nonvalvular atrial fibrillation." | 3.79 | A case of dabigatran-associated acute renal failure. ( Julius, CJ; Negrete, H; Roy, P; Sarac, E; Shafi, ST, 2013) |
| " Six months before presentation, the patient was placed on Dabigatran etexilate (Dabigatran) (110 mg BID) for atrial fibrillation." | 3.79 | The untold story of Dabigatran etexilate: alveolar hemorrhage in an elderly patient with interstitial pulmonary fibrosis. ( Beydoun, A; Husari, A; Maakaron, JE; Sheik Ammar, A; Taher, A, 2013) |
| "Dabigatran is a recently introduced direct thrombin inhibitor licensed for use as an oral anticoagulant for stroke prevention in non-valvular atrial fibrillation." | 3.79 | Dabigatran for anticoagulation in atrial fibrillation - early clinical experience in a hospital population and comparison to trial data. ( Boga, T; Michel, J; Mundell, D; Sasse, A, 2013) |
| "It is not clear whether dabigatran is as safe and effective as uninterrupted anticoagulation with warfarin during radiofrequency catheter ablation (RFA) of atrial fibrillation (AF)." | 3.79 | Dabigatran vs warfarin for radiofrequency catheter ablation of atrial fibrillation. ( Bogun, F; Carrigan, T; Chugh, A; Crawford, T; Ghanbari, H; Good, E; Jongnarangsin, K; Kennedy, R; Kim, JS; Latchamsetty, R; Morady, F; Oral, H; Pelosi, F; Saint-Phard, W; She, F; Sinno, M; Suwanagool, A; Yokokawa, M, 2013) |
| "Dabigatran, administered orally as the prodrug dabigatran etexilate (DE), is a direct thrombin inhibitor shown to be effective in the prevention of stroke and systemic embolism in patients with atrial fibrillation (AF)." | 3.78 | Dabigatran etexilate in atrial fibrillation patients with severe renal impairment: dose identification using pharmacokinetic modeling and simulation. ( Clemens, A; Friedman, J; Haertter, S; Lehr, T; Liesenfeld, KH; Reilly, PA; Staab, A, 2012) |
| "The concept of net clinical benefit has been used to quantify the balance between risk of ischaemic stroke (IS) and risk of intracranial haemorrhage (ICH) with the use oral anticoagulant therapy (OAC) in the setting of non-valvular atrial fibrillation (AF), and has shown that patients at highest risk of stroke and thromboembolism gain the greatest benefit from OAC with warfarin." | 3.78 | Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a 'real world' atrial fibrillation population: a modelling analysis based on a nationwide cohort study. ( Banerjee, A; Lane, DA; Lip, GY; Torp-Pedersen, C, 2012) |
| "To present a case of dabigatran use for nonvalvular atrial fibrillation in a patient from a population for whom it has not been studied." | 3.78 | Dabigatran use in a postoperative coronary artery bypass surgery patient with nonvalvular atrial fibrillation and heparin-PF4 antibodies. ( Fieland, D; Taylor, M, 2012) |
| "Dabigatran is a new oral anticoagulant recently approved for the prevention of stroke or systemic embolism in patients with atrial fibrillation (AF)." | 3.78 | Twice daily dosing of dabigatran for stroke prevention in atrial fibrillation: a pharmacokinetic justification. ( Brueckmann, M; Clemens, A; Friedman, J; Haertter, S; Lehr, T; Stangier, J; van Ryn, J, 2012) |
| "In patients undergoing AF ablation, periprocedural dabigatran use significantly increases the risk of bleeding or thromboembolic complications compared with uninterrupted warfarin therapy." | 3.78 | Feasibility and safety of dabigatran versus warfarin for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation: results from a multicenter prospective registry. ( Burkhardt, JD; Chalhoub, F; Coffey, J; D'Avila, A; Di Biase, L; Lakkireddy, D; Mansour, MC; Mohanty, P; Monir, G; Natale, A; Pimentel, R; Reddy, VY; Reddy, YM; Ruskin, J; Sanchez, JE; Santangeli, P; Shaik, N; Swarup, V; Vanga, SR, 2012) |
| "The cost-effectiveness of dabigatran for stroke prevention in patients with atrial fibrillation and prior stroke or transient ischemic attack has not been directly assessed." | 3.78 | Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in patients with atrial fibrillation and prior stroke or transient ischemic attack. ( Easton, JD; Johnston, SC; Kamel, H; Kim, AS, 2012) |
| "For patients with nonrheumatic AF, including those with paroxysmal AF, who are (1) at low risk of stroke (eg, CHADS(2) [congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischemic attack] score of 0), we suggest no therapy rather than antithrombotic therapy, and for patients choosing antithrombotic therapy, we suggest aspirin rather than oral anticoagulation or combination therapy with aspirin and clopidogrel; (2) at intermediate risk of stroke (eg, CHADS(2) score of 1), we recommend oral anticoagulation rather than no therapy, and we suggest oral anticoagulation rather than aspirin or combination therapy with aspirin and clopidogrel; and (3) at high risk of stroke (eg, CHADS(2) score of ≥ 2), we recommend oral anticoagulation rather than no therapy, aspirin, or combination therapy with aspirin and clopidogrel." | 3.78 | Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. ( Eckman, MH; Fang, MC; Go, AS; Halperin, JL; Howard, PA; Hughes, M; Hylek, EM; Lane, DA; Lip, GYH; Manning, WJ; Schulman, S; Singer, DE; Spencer, FA; You, JJ, 2012) |
| "According to the update of the Finnish guidelines for management of patients with atrial fibrillation (AF) dronedarone should be used only in patients with non-permanent AF as a second line medication." | 3.78 | [Update on current care guidelines: atrial fibrillation]. ( , 2012) |
| "A 66-year-old woman treated with dabigatran for atrial fibrillation developed acute renal failure and upper gastrointestinal bleeding." | 3.78 | Dabigatran-induced gastrointestinal bleeding in an elderly patient with moderate renal impairment. ( Kouides, PA; Wychowski, MK, 2012) |
| " Based on various everyday situations in clinical routine, the purpose of the present expert recommendations is to provide appropriate perioperative and periinterventional management for patients with atrial fibrillation undergoing long-term treatment with the thrombin inhibitor dabigatran." | 3.78 | Dabigatran in patients with atrial fibrillation: perioperative and periinterventional management. ( Brodmann, M; Domanovits, H; Eber, B; Gottsauner-Wolf, M; Halbmayer, WM; Hiesmayr, JM; Kyrle, PA; Längle, F; Roithinger, FX; Watzke, H; Weltermann, A; Windhager, R; Wolf, C; Zweiker, R, 2012) |
| "Dabigatran etexelate is a new oral direct thrombin inhibitor that has been approved by the US Food and Drug Administration to prevent stroke in patients with nonvalvular atrial fibrillation." | 3.78 | Acute ischemic stroke treated with intravenous tissue plasminogen activator in a patient taking dabigatran with radiographic evidence of recanalization. ( El Khoury, R; Lopez, G; Misra, V; Sangha, N, 2012) |
| "Dabigatran is a novel direct thrombin inhibitor that has recently been approved for primary and secondary stroke prevention and prevention of systemic embolism in patients with atrial fibrillation." | 3.78 | Dabigatran for stroke prevention in atrial fibrillation. ( Diener, HC; Hohnloser, SH, 2012) |
| "Dabigatran is associated with lower rate of stroke comparing to warfarin when anticoagulation control is sub-optimal." | 3.78 | Cost-effectiveness of dabigatran versus genotype-guided management of warfarin therapy for stroke prevention in patients with atrial fibrillation. ( Cheng, G; Tsui, KK; Wong, RS; You, JH, 2012) |
| "Dabigatran, an oral thrombin inhibitor, and rivaroxaban and apixaban, oral factor Xa inhibitors, have been found to be safe and effective in reducing stroke risk in patients with atrial fibrillation." | 3.78 | Comparative efficacy and safety of new oral anticoagulants in patients with atrial fibrillation. ( Avorn, J; Choudhry, NK; Gagne, JJ; Patrick, AR; Schneeweiss, S, 2012) |
| "We compared efficacy and safety of warfarin, direct thrombin inhibitor dabigatran and clopidogrel in prevention of stroke in 210 patients with nonvalvular atrial fibrillation (AF) aged 65-80 years." | 3.78 | [Comparison of three methods of antithrombotic therapy in elderly patients with nonvalvular atrial fibrillation]. ( Kanorskiĭ, SG; Shevelev, VI, 2012) |
| "This case report describes agranulocytosis immediately after oral administration of cibenzoline and dabigatran in a 70-year-old woman with paroxysmal atrial fibrillation (AF)." | 3.78 | Agranulocytosis immediately after oral administration of cibenzoline and dabigatran in a patient with paroxysmal atrial fibrillation. ( Hayashi, H; Horie, M; Kitoh, K; Mitsunami, K, 2012) |
| "In our cohort, bleeding-related complications 48 h and 1 week post-ablation were similar for warfarin and dabigatran." | 3.78 | A comparison of bleeding complications post-ablation between warfarin and dabigatran. ( Johns, G; Kauffman, C; Kusumoto, F; Prussak, K; Snipelisky, D; Venkatachalam, K, 2012) |
| "Canadian patients with atrial fibrillation (AF) in whom anticoagulation is appropriate have two new choices for anticoagulation for prevention of stroke and systemic embolism--dabigatran etexilate (dabigatran) and rivaroxaban." | 3.78 | Dabigatran versus rivaroxaban for the prevention of stroke and systemic embolism in atrial fibrillation in Canada. Comparative efficacy and cost-effectiveness. ( Bradley-Kennedy, C; Clemens, A; Kansal, AR; Monz, BU; Peng, S; Roskell, N; Sharma, M; Sorensen, SV, 2012) |
| "Dabigatran has been rapidly adopted into ambulatory practice in the United States, primarily for treatment of atrial fibrillation, but increasingly for off-label indications." | 3.78 | National trends in oral anticoagulant use in the United States, 2007 to 2011. ( Alexander, GC; Kirley, K; Kornfield, R; Qato, DM; Stafford, RS, 2012) |
| "Assessment of the cost-effectiveness of dabigatran for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation in Spain, from the perspective of the National Health System." | 3.78 | Cost-effectiveness of dabigatran for stroke prevention in non-valvular atrial fibrillation in Spain. ( Álvarez-Sabin, J; Becerra, V; González-Juanatey, JR; González-Rojas, N; Lobos, JM; Martínez-Rubio, A; Oyagüez, I; Reverter, JC, 2012) |
| "Dabigatran is an oral direct thrombin inhibitor recently approved for stroke prevention in atrial fibrillation (AF) as an alternative to warfarin." | 3.78 | Dabigatran compared with warfarin for stroke prevention with atrial fibrillation: experience in Hong Kong. ( Chang, AM; Ho, JC; Lam, YY; Lee, VW; Yan, BP; Yu, CM, 2012) |
| " She was on dabigatran for atrial fibrillation and aspirin, with intermittent intake of ibuprofen." | 3.78 | Direct thrombin inhibitors: a case indicating benefit from 'plasmapheresis' in toxicity: a call for establishing "guidelines" in overdose and to find an "antidote"! ( Cirra, VR; Kamboj, J; Kamboj, R; Kottalgi, M; Shah, N, 2012) |
| "Warfarin, at a dose adjusted according to the INR, is the standard prophylactic anticoagulant for patients with atrial fibrillation and a major risk of thrombosis." | 3.78 | Rivaroxaban and atrial fibrillation: continue to use warfarin or in some cases, dabigatran. ( , 2012) |
| "We compared the efficacy and safety of warfarin, dabigartan, and clopidogrel used to prevent tromboembolism in 210 elderly patients with non-valvular atrial fibrillation depending on the age." | 3.78 | [Safety and efficacy of various modalities of antiplatelet prophylaxis of ischemic stroke in elderly patients with non-valvular atrial fibrillation]. ( Kanorsky, SG; Shevelev, VI, 2012) |
| "To estimate the quality-adjusted survival, costs, and cost-effectiveness of dabigatran compared with adjusted-dose warfarin for preventing ischemic stroke in patients 65 years or older with nonvalvular AF." | 3.77 | Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation. ( Freeman, JV; Garber, AM; Go, AS; Hutton, DW; Owens, DK; Turakhia, MP; Wang, PJ; Zhu, RP, 2011) |
| "Dabigatran 150 mg (twice daily) was cost-effective in AF populations at high risk of hemorrhage or high risk of stroke unless international normalized ratio control with warfarin was excellent." | 3.77 | Cost-effectiveness of dabigatran for stroke prophylaxis in atrial fibrillation. ( Gage, BF; Shah, SV, 2011) |
| "Dabigatran etexilate is an oral direct thrombin inhibitor that is approved for use in thromboprophylaxis of atrial fibrillation and deep vein thrombosis." | 3.77 | Potential inaccuracy of point-of-care INR in dabigatran-treated patients. ( Baruch, L; Sherman, O, 2011) |
| "The central pharmacologic approach to stroke prevention in atrial fibrillation has recently changed with the approval of dabigatran by the US Food and Drug Administration (FDA)." | 3.77 | Dabigatran in atrial fibrillation: pharmacology and clinical trials. ( Ezekowitz, MD; Nagarakanti, R, 2011) |
| "To report an incident of a drug-induced exanthem during treatment with dabigatran in a patient without prior exposure to the drug." | 3.77 | Drug-induced exanthem following dabigatran. ( Blais, DM; Boyd, JM; Hummel, J; Whitehead, H, 2011) |
| "Clinical results of the European Action on Anticoagulation (EAA) computer-assisted dosage study and the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial have been compared." | 2.79 | Warfarin or dabigatran for treatment of atrial fibrillation. ( Ibrahim, S; Jespersen, J; Poller, L, 2014) |
| " Rywaroxaban more frequently causes minor bleeding, whereas treatment with dabigatran is associated with more frequent gastrointestinal adverse symptoms." | 2.79 | [Comparison of the safety of rivaroxaban versus dabigatran therapy in patients with persistent atrial fibrillation]. ( Broncel, M; Ciastkowska, A; Duraj, I; Gorzelak-Pabiś, P; Szlagowska, L, 2014) |
| "Dabigatran is a cost-effective treatment in Sweden, as its incremental cost-effectiveness ratio is below the normally accepted willingness to pay limit." | 2.78 | Cost-effectiveness of dabigatran compared with warfarin for patients with atrial fibrillation in Sweden. ( Davidson, T; Husberg, M; Janzon, M; Levin, LÅ; Oldgren, J, 2013) |
| "Dabigatran is a direct thrombin inhibitor, does not require blood coagulation monitoring and limitation of vitamin K intake as well as very few drug interactions, and thus expected to be an oral anticoagulant alternative to warfarin." | 2.76 | [Expectation to and problems of thrombin inhibitor]. ( Uchiyama, S, 2011) |
| "Dabigatran is a univalent low-molecular-weight direct thrombin inhibitor that has been developed as an alternative to vitamin K antagonists (VKAs)." | 2.50 | Meta-analysis of randomized controlled trials on the risk of bleeding with dabigatran. ( Atallah, R; Bloom, BJ; Eisenberg, MJ; Filion, KB, 2014) |
| " In contrast to warfarin, most NOACs need dosage adjustments in renal impairment and are contraindicated in severe liver impairment, and there are no specific antidotes for treating NOAC-related over-anticoagulation." | 2.50 | New oral anticoagulants in practice: pharmacological and practical considerations. ( Bajorek, B; Wang, Y, 2014) |
| " However, in elderly patients with impaired renal function or considerable bleeding risks, label advice regarding dosing needs strict observation." | 2.50 | Benefit-risk assessment of dabigatran in the treatment of stroke prevention in non-valvular atrial fibrillation. ( Harder, S; Meyer Dos Santos, S, 2014) |
| "Warfarin and heparins have been the predominant anticoagulants used until the past decade." | 2.50 | The newer direct oral anticoagulants: a practical guide. ( Thachil, J, 2014) |
| " The dosage of warfarin requires regular adjustment dependent on the INR, to keep within a narrow therapeutic range of 2." | 2.50 | Primary prevention of ischaemic stroke in atrial fibrillation: new oral anticoagulant drugs for all? ( Foley, J; Kirchhof, P; Lip, GY, 2014) |
| "Dabigatran was the first NOAC approved and is a direct thrombin inhibitor." | 2.50 | Novel oral anticoagulants in non-valvular atrial fibrillation. ( da Silva, RM, 2014) |
| "Ischemic stroke is a severe complication of AF often resulting in disability or death." | 2.50 | [The use of dabigatran for prevention of ischemic stroke in patiets with atrial fibrillation: special features of treatment in different clinical situations]. ( Shchendrygina, AA, 2014) |
| " Much remains to be learned about the optimal use of the novel oral anticoagulants in CKD patients; additional studies about optimal dosing of the novel oral anticoagulants and frequency of monitoring renal function in CKD patients with atrial fibrillation are needed." | 2.49 | Stroke prevention in atrial fibrillation patients with chronic kidney disease. ( Brimble, KS; Eikelboom, JW; Hart, RG; Ingram, AJ; McMurtry, MS, 2013) |
| "Stroke is the most feared complication among patients with atrial fibrillation." | 2.49 | Alternatives to warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a look back at the state of the field in 2012. ( Lopes, RD; Newby, LK; Truffa, AA, 2013) |
| "Dabigatran was the first of the agents to be widely available, and in the RE-LY study, dabigatran (150 mg dose) showed superiority to warfarin in preventing ischemic stroke and a significant reduction in intracranial bleeding." | 2.49 | New alternative anticoagulants in atrial fibrillation: the move beyond warfarin. ( Bhimani, AA; Hong, M, 2013) |
| "NOACs have shown a large reduction in intracranial hemorrhage compared with warfarin." | 2.49 | [Effective, safe stroke prevention with novel oral anticoagulants in patients with atrial fibrillation. Focus on dabigatran]. ( Bosnyák, E; Csécsei, P; Deli, G; Fehér, G; Szapary, L, 2013) |
| " Advantages and disadvantages to using these newer agents are presented, as are dosing adjustments for renal and hepatic impairment." | 2.49 | Outpatient management of oral anticoagulation in atrial fibrillation. ( Manning, JA, 2013) |
| "Stroke is a common disease, which is associated with high morbidity and high mortality." | 2.49 | [Anticoagulant therapy in stroke patients]. ( Grove, EL; Husted, SE; Kraglund, KL; Modrau, B, 2013) |
| "Warfarin has been the only available oral anticoagulant therapy for several decades." | 2.48 | Novel oral anticoagulation in management of venous thromboembolism, atrial fibrillation, and acute coronary syndrome. ( Khemasuwan, D; Suramaethakul, N, 2012) |
| "Dabigatran is a direct thrombin (factor IIa) inhibitor that overcomes many of the limitations associated with warfarin." | 2.48 | Dabigatran and factor Xa inhibitors for stroke prevention in patients with nonvalvular atrial fibrillation. ( Ibayashi, S; Matsumoto, M; Nagao, T; Nagata, K; Nakagawara, J; Tanahashi, N; Tanaka, K; Toyoda, K; Uchiyama, S; Yasaka, M, 2012) |
| "Dabigatran is a potent reversible, competitive direct thrombin inhibitor which is available as the prodrug, Dabigatran etexilate." | 2.48 | Dabigatran: a new chapter in anticoagulation. ( Ahmed, S; Levin, V; Malacoff, R; Martinez, MW, 2012) |
| "Dabigatran is an oral direct thrombin inhibitor." | 2.48 | [Clinical studies, the interests and limits of using dabigatran in atrial fibrillation]. ( Chatelain, B; Chatelain, C; Dogné, JM; Douxfils, J; Mullier, F; Spinewine, A; Sternotte, A, 2012) |
| " The emergence of new anticoagulants that offer equal or superior efficacy, greater safety and the convenience of fixed oral dosing may make warfarin the less preferred option." | 2.48 | Prevention of stroke in patients with atrial fibrillation: anticoagulant and antiplatelet options. ( Halperin, JL; Varughese, CJ, 2012) |
| "Cardioembolic cerebral ischemia can be prevented." | 2.48 | [Prevention of cardioembolic stroke]. ( Gil Núñez, A, 2012) |
| "Dabigatran is a direct thrombin inhibitor, which is not metabolized by cytochrome P450, and thus does not require blood coagulation monitoring or vitamin K intake limitation, or produce drug interaction." | 2.47 | [Dabigatran, a new oral anticoagulant]. ( Uchiyama, S, 2011) |
| " The vitamin K antagonist warfarin has traditionally been used in these patients but presents challenges in dosing and monitoring in these patients." | 2.47 | Dabigatran: an oral direct thrombin inhibitor for use in atrial fibrillation. ( Baker, WL; Bendel, SD; Bona, R, 2011) |
| "Dabigatran is an oral, reversible direct thrombin inhibitor approved in Europe and in several other countries for the prevention of venous thromboembolism after elective knee and hip replacement surgery." | 2.47 | Antithrombotic therapy in atrial fibrillation: evaluation and positioning of new oral anticoagulant agents. ( Aizawa, Y; Atarashi, H; Inoue, H; Kamakura, S; Koretsune, Y; Kumagai, K; Mitamura, H; Ogawa, S; Okumura, K; Sugi, K; Yamashita, T; Yasaka, M, 2011) |
| "Dabigatran is a direct thrombin (FIIa) inhibitor, whereas Rivaroxaban and Apixaban are direct factor Xa (FXa) inhibitors." | 2.47 | [The new Anticoagulants - Relevant Facts for the GP]. ( Asmis, LM, 2011) |
| "Dabigatran is an oral direct thrombin inhibitor with a rapid onset." | 2.47 | Advances in anticoagulation: focus on dabigatran, an oral direct thrombin inhibitor. ( Augoustides, JG, 2011) |
| "Stroke is associated with the greatest mortality and morbidity in patients with atrial fibrillation (AF)." | 2.47 | A new landscape for stroke prevention in atrial fibrillation: focus on new anticoagulants, antiarrhythmic drugs, and devices. ( Banerjee, A; Lip, GY; Marín, F, 2011) |
| "Dabigatran is an emerging oral anticoagulant which is a direct inhibitor of thrombin activity." | 2.47 | Pharmacological basis and clinical evidence of dabigatran therapy. ( Barez, A; Martínez, MP; Navarro-Dorado, J; Ramajo, M; Redondo, S; Tejerina, T, 2011) |
| "Dabigatran was administrated twice daily in a two dose regimens: 150 mg (5 patients) and 110 mg (14 patients)." | 1.42 | Monitoring of dabigatran therapy using Hemoclot(®) Thrombin Inhibitor assay in patients with atrial fibrillation. ( Dobrotová, M; Galajda, P; Ivanková, J; Kovář, F; Kubisz, P; Mokáň, M; Samoš, M; Stančiaková, L; Staško, J, 2015) |
| "Compared to Vitamin K antagonists (VKA), novel oral anticoagulants (NOACs) appear to be safer in terms of major bleeding risks with added advantage of having fixed dosing schedules when used in patients with non-valvular atrial fibrillation (AF)." | 1.42 | Evaluation of Trends of Inpatient Hospitalisation for Significant Haemorrhage in Patients Anticoagulated for Atrial Fibrillation before and after the Release of Novel Anticoagulants. ( Aryal, MR; Badal, M; Chaudhary, A; Donato, AA; Mege, J, 2015) |
| "Dabigatran was administered at a dose of 110-150 mg once or twice daily, depending on the renal function and age." | 1.42 | Efficacy of Dabigatran for Dissolving Deep Vein Thromboses in Outpatients With a Deteriorated General Condition. ( Fujino, T; Ikeda, T; Kabuki, T; Kiuchi, S; Kobayashi, K; Yamazaki, A; Yamazaki, J; Yamazaki, Y, 2015) |
| "Warfarin-related intracerebral hemorrhage carries a particularly high risk of neurologic deterioration and death because of a high rate of hematoma expansion of about 50%." | 1.40 | Dabigatran-related intracerebral hemorrhage resulting in hematoma expansion. ( Damgaard, D; Simonsen, CZ; Steiner, T; Tietze, A, 2014) |
| " The rate of occurrences of adverse effects and bleeding were lower than those seen in the RE-LY trial." | 1.40 | A single centre experience of the efficacy and safety of dabigatran etexilate used for stroke prevention in atrial fibrillation. ( Hussin, A; Kaur, S; Muhammad, Z; Omar, R; Rusani, BI; Umadevan, D; Yap, LB, 2014) |
| " The objective of the study was to validate a dosing regimen for use of dabigatran in patients with mechanical heart valves." | 1.40 | Dabigatran use in mechanical heart valve patients. ( Pai, RG; Tafreshi, J; Zough, F, 2014) |
| "Direct-current cardioversion (DCCV) for persistent atrial fibrillation or atrial flutter (AF) carries a risk of thromboembolic events (TEs)." | 1.40 | Safety of short-term use of dabigatran or rivaroxaban for direct-current cardioversion in patients with atrial fibrillation and atrial flutter. ( Groh, C; Passman, R; Yadlapati, A, 2014) |
| "Hypertension is the most frequent condition associated with atrial fibrillation (AF) and stroke, the most terrible complication of AF." | 1.39 | Can dabigatran improve blood pressure control? ( Barrios, V; Escobar, C, 2013) |
| " These drugs differ in a several important respects from warfarin; most notably they have a reliable dose-response effect which means they can be given without the need for monitoring." | 1.39 | New oral anticoagulants: their role and future. ( Laffan, M; Shapiro, S, 2013) |
| "Dabigatran is a new oral anticoagulant that does not require INR monitoring." | 1.39 | Cost-effectiveness of dabigatran for stroke prevention in atrial fibrillation in Switzerland. ( Eichler, K; Plessow, R; Pletscher, M; Wieser, S, 2013) |
| "Dabigatran is a new anticoagulant and may be useful after AF ablation to prevent thromboembolic events." | 1.38 | The use of dabigatran immediately after atrial fibrillation ablation. ( Engel, G; Kong, MH; Mead, RH; Patrawala, RA; Winkle, RA, 2012) |
| "Dabigatran is a direct thrombin inhibitor, acting like other members in its class (bivalirudin, argatroban) to impede the clotting process through selective and reversible binding with both free and clot-bound thrombin." | 1.38 | Spontaneous splenic hemorrhage after initiation of dabigatran (Pradaxa) for atrial fibrillation. ( Boniface, K; Moore, CH; Scott, J; Snashall, J, 2012) |
| "Dabigatran etexilate is an oral anticoagulant that acts as a direct, competitive thrombin inhibitor." | 1.38 | Neurosurgical complications of direct thrombin inhibitors--catastrophic hemorrhage after mild traumatic brain injury in a patient receiving dabigatran. ( Garber, ST; Schmidt, RH; Sivakumar, W, 2012) |
| "Dabigatran was stopped and dalteparin 5000 International Units/bid and 40 μg alprostadil infusions were started." | 1.38 | Fatal basilar artery occlusion under dabigatran occurring 13 days after femoral embolectomy. ( Finsterer, J; Reiter, M; Schäffl-Doweik, L; Stöllberger, C, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 542 (99.82) | 24.3611 |
| 2020's | 1 (0.18) | 2.80 |
| Authors | Studies |
|---|---|
| Aghoram, R | 1 |
| Kumar, SM | 1 |
| Rajasulochana, SR | 1 |
| Kar, SS | 1 |
| Aggarwal, R | 1 |
| Alonso, A | 2 |
| Lutsey, PL | 2 |
| Chen, LY | 2 |
| MacLehose, RF | 2 |
| Bengtson, LGS | 1 |
| Minhas, JS | 1 |
| Mistri, AK | 1 |
| Ummarino, D | 1 |
| Sugiyama, T | 1 |
| Lau, WCY | 1 |
| Wong, ICK | 1 |
| Chan, EW | 2 |
| Calkins, H | 4 |
| Nordaby, M | 1 |
| Seligman, SJ | 1 |
| Løfgren, B | 1 |
| Pareek, M | 1 |
| Larsen, JM | 1 |
| Fender, AC | 1 |
| Dobrev, D | 2 |
| Holm, J | 1 |
| Taskiran, M | 1 |
| Schulman, S | 7 |
| Berman, JP | 1 |
| Halperin, JL | 10 |
| Lenchus, JD | 1 |
| Kasmeridis, C | 1 |
| Lip, GY | 28 |
| Apostolakis, S | 1 |
| Fountzilas, C | 1 |
| George, J | 1 |
| Levine, R | 1 |
| Dager, WE | 1 |
| Gosselin, RC | 1 |
| Roberts, AJ | 1 |
| Chang, AM | 2 |
| Ho, JC | 2 |
| Yan, BP | 2 |
| Yu, CM | 2 |
| Lam, YY | 2 |
| Lee, VW | 2 |
| Hernández, M | 1 |
| Suárez, C | 1 |
| Masjuan, J | 2 |
| Pazmiño, PA | 1 |
| Kowey, PR | 4 |
| Naccarelli, GV | 3 |
| Berger, R | 1 |
| Salhanick, SD | 1 |
| Chase, M | 1 |
| Ganetsky, M | 1 |
| Rafferty, JA | 1 |
| Prom, R | 1 |
| Kujawski, SZ | 1 |
| Bergh, M | 1 |
| Marais, CA | 1 |
| Miller-Jansön, H | 1 |
| Salie, F | 1 |
| Stander, MP | 1 |
| Andreev, DA | 1 |
| Gappoeva, ZK | 1 |
| Sychev, DA | 1 |
| Giliarov, MIu | 1 |
| Harrington, AR | 1 |
| Armstrong, EP | 1 |
| Nolan, PE | 1 |
| Malone, DC | 1 |
| Bassiouny, M | 2 |
| Saliba, W | 2 |
| Rickard, J | 2 |
| Shao, M | 2 |
| Sey, A | 2 |
| Diab, M | 2 |
| Martin, DO | 2 |
| Hussein, A | 2 |
| Khoury, M | 2 |
| Abi-Saleh, B | 2 |
| Alam, S | 2 |
| Sengupta, J | 2 |
| Borek, PP | 2 |
| Baranowski, B | 2 |
| Niebauer, M | 2 |
| Callahan, T | 2 |
| Varma, N | 2 |
| Chung, M | 2 |
| Tchou, PJ | 2 |
| Kanj, M | 2 |
| Dresing, T | 2 |
| Lindsay, BD | 2 |
| Wazni, O | 2 |
| Stiefelhagen, P | 2 |
| Maddox, W | 1 |
| Kay, GN | 3 |
| Yamada, T | 1 |
| Osorio, J | 1 |
| Doppalapudi, H | 1 |
| Plumb, VJ | 1 |
| Gunter, A | 1 |
| McElderry, HT | 1 |
| Imamura, K | 1 |
| Yoshida, A | 1 |
| Takei, A | 1 |
| Fukuzawa, K | 1 |
| Kiuchi, K | 1 |
| Takami, K | 1 |
| Takami, M | 1 |
| Itoh, M | 1 |
| Fujiwara, R | 1 |
| Suzuki, A | 1 |
| Nakanishi, T | 1 |
| Yamashita, S | 1 |
| Matsumoto, A | 1 |
| Hirata, K | 1 |
| Ogbonna, KC | 1 |
| Jeffery, SM | 1 |
| Briongos Figuero, S | 1 |
| García Santos-Gallego, C | 1 |
| Badimón, JJ | 1 |
| Chevalier, J | 1 |
| Giroud, M | 1 |
| de Pouvourville, G | 1 |
| Sorensen, SV | 2 |
| Peng, S | 3 |
| Monz, BU | 3 |
| Bradley-Kennedy, C | 2 |
| Kansal, AR | 2 |
| Pink, J | 2 |
| Pirmohamed, M | 2 |
| Hughes, DA | 2 |
| Faria, R | 1 |
| Spackman, E | 1 |
| Burch, J | 1 |
| Corbacho, B | 1 |
| Todd, D | 1 |
| Pepper, C | 1 |
| Woolacott, N | 1 |
| Palmer, S | 1 |
| Harris, K | 1 |
| Mant, J | 1 |
| Hesselbjerg, LJ | 1 |
| Pedersen, HS | 1 |
| Asmussen, MB | 1 |
| Petersen, KD | 1 |
| Kaiser, DW | 1 |
| Streur, MM | 1 |
| Nagarakanti, R | 4 |
| Whalen, SP | 1 |
| Ellis, CR | 1 |
| Yasaka, M | 4 |
| Darius, H | 3 |
| Sommer, S | 1 |
| Atay, JK | 1 |
| Fanikos, J | 2 |
| Barnes, GD | 1 |
| Ehle, M | 1 |
| Coatney, J | 1 |
| Piazza, G | 1 |
| Froehlich, JB | 1 |
| Goldhaber, SZ | 2 |
| Pelargonio, G | 1 |
| Perna, F | 1 |
| Ahmad, Y | 2 |
| Bergman, E | 1 |
| Smith, JG | 1 |
| Wieloch, M | 1 |
| Braun, OÖ | 1 |
| Svensson, P | 1 |
| van der Pals, J | 1 |
| Connolly, SJ | 19 |
| Korhonen, M | 1 |
| Noack, H | 5 |
| Pooley, J | 1 |
| Barrios, V | 3 |
| Escobar, C | 3 |
| Wassef, SN | 1 |
| Abel, TJ | 1 |
| Grossbach, A | 1 |
| Viljoen, SV | 1 |
| Jackson, AW | 1 |
| Howard, MA | 1 |
| Greenlee, JD | 1 |
| Gallego, P | 1 |
| Roldan, V | 2 |
| Kawabata, M | 1 |
| Yokoyama, Y | 1 |
| Sasano, T | 1 |
| Hachiya, H | 1 |
| Tanaka, Y | 1 |
| Yagishita, A | 1 |
| Sugiyama, K | 1 |
| Nakamura, T | 1 |
| Suzuki, M | 1 |
| Isobe, M | 1 |
| Hirao, K | 1 |
| Luis, SA | 1 |
| Poon, K | 1 |
| Luis, C | 1 |
| Shukla, A | 1 |
| Bett, N | 1 |
| Hamilton-Craig, C | 1 |
| Singh, SM | 2 |
| Micieli, A | 2 |
| Wijeysundera, HC | 2 |
| Heidenreich, PA | 1 |
| Desai, J | 1 |
| Kolb, JM | 1 |
| Weitz, JI | 5 |
| Aisenberg, J | 2 |
| Singh, T | 1 |
| Maw, TT | 1 |
| Henry, BL | 1 |
| Pastor-Soler, NM | 1 |
| Unruh, ML | 1 |
| Hallows, KR | 1 |
| Nolin, TD | 1 |
| Bauer, KA | 1 |
| Folyovich, A | 1 |
| Varga, V | 1 |
| Béres-Molnár, KA | 1 |
| Vadasdi, K | 1 |
| Bereczki, D | 1 |
| Klein, HH | 1 |
| Haines, DE | 1 |
| Mead-Salley, M | 1 |
| Salazar, M | 1 |
| Marchlinski, FE | 2 |
| Zado, E | 1 |
| Yarmohammadi, H | 1 |
| Nademanee, K | 1 |
| Amnueypol, M | 1 |
| Skanes, AC | 2 |
| Saklani, P | 1 |
| Eikelboom, JW | 17 |
| Hart, RG | 6 |
| Wallentin, L | 15 |
| Reilly, P | 4 |
| Oldgren, J | 9 |
| Yang, S | 9 |
| Yusuf, S | 18 |
| Verheugt, FW | 1 |
| Ezekowitz, MD | 19 |
| Eikelboom, J | 9 |
| Reilly, PA | 10 |
| Brueckmann, M | 14 |
| Pogue, J | 3 |
| Alings, M | 3 |
| Amerena, JV | 1 |
| Avezum, A | 1 |
| Baumgartner, I | 1 |
| Budaj, AJ | 1 |
| Chen, JH | 1 |
| Dans, AL | 1 |
| Di Pasquale, G | 2 |
| Ferreira, J | 3 |
| Flaker, GC | 1 |
| Flather, MD | 1 |
| Franzosi, MG | 2 |
| Golitsyn, SP | 1 |
| Halon, DA | 1 |
| Heidbuchel, H | 1 |
| Hohnloser, SH | 9 |
| Huber, K | 2 |
| Jansky, P | 1 |
| Kamensky, G | 3 |
| Keltai, M | 1 |
| Kim, SS | 1 |
| Lau, CP | 2 |
| Le Heuzey, JY | 6 |
| Lewis, BS | 1 |
| Liu, L | 1 |
| Nanas, J | 1 |
| Omar, R | 2 |
| Pais, P | 1 |
| Pedersen, KE | 1 |
| Piegas, LS | 1 |
| Raev, D | 1 |
| Smith, PJ | 1 |
| Talajic, M | 1 |
| Tan, RS | 1 |
| Tanomsup, S | 1 |
| Toivonen, L | 1 |
| Vinereanu, D | 1 |
| Xavier, D | 1 |
| Zhu, J | 1 |
| Wang, SQ | 1 |
| Duffy, CO | 1 |
| Themeles, E | 3 |
| Antovic, JP | 2 |
| Skeppholm, M | 2 |
| Eintrei, J | 2 |
| Boija, EE | 1 |
| Söderblom, L | 1 |
| Norberg, EM | 1 |
| Onelöv, L | 1 |
| Rönquist-Nii, Y | 2 |
| Pohanka, A | 2 |
| Beck, O | 2 |
| Hjemdahl, P | 3 |
| Malmström, RE | 2 |
| Lee, PY | 1 |
| Han, SY | 1 |
| Miyahara, RK | 1 |
| Gong, IY | 1 |
| Kim, RB | 1 |
| Brimble, KS | 1 |
| McMurtry, MS | 2 |
| Ingram, AJ | 1 |
| Coyle, D | 1 |
| Coyle, K | 1 |
| Cameron, C | 1 |
| Lee, K | 1 |
| Kelly, S | 1 |
| Steiner, S | 1 |
| Wells, GA | 1 |
| Boos, CJ | 1 |
| Nam, M | 1 |
| Camm, AJ | 1 |
| Thachil, J | 3 |
| Pike, G | 1 |
| Keighley-Jones, L | 1 |
| Nash, MJ | 1 |
| Stöllberger, C | 8 |
| Finsterer, J | 8 |
| Diener, HC | 13 |
| Truffa, AA | 1 |
| Lopes, RD | 4 |
| Newby, LK | 1 |
| Jones, B | 1 |
| Suzuki, S | 2 |
| Sagara, K | 2 |
| Otsuka, T | 2 |
| Kano, H | 1 |
| Matsuno, S | 2 |
| Takai, H | 1 |
| Uejima, T | 2 |
| Oikawa, Y | 2 |
| Koike, A | 2 |
| Nagashima, K | 2 |
| Kirigaya, H | 2 |
| Yajima, J | 2 |
| Tanabe, H | 1 |
| Sawada, H | 2 |
| Aizawa, T | 2 |
| Yamashita, T | 4 |
| Fraessdorf, M | 3 |
| Romond, KK | 1 |
| Miller, CS | 2 |
| Henry, RG | 1 |
| Shortt, B | 1 |
| Robinson, M | 2 |
| Bhimani, AA | 1 |
| Hong, M | 1 |
| Steinberg, BA | 4 |
| Kim, S | 2 |
| Piccini, JP | 4 |
| Fonarow, GC | 2 |
| Thomas, L | 2 |
| Ansell, J | 3 |
| Kowey, P | 1 |
| Singer, DE | 3 |
| Gersh, B | 2 |
| Mahaffey, KW | 3 |
| Hylek, E | 1 |
| Go, AS | 3 |
| Chang, P | 2 |
| Peterson, ED | 2 |
| Kamran, SH | 1 |
| Muzammil, SM | 1 |
| Kamal, AK | 1 |
| Lowe, MP | 1 |
| Collins, J | 1 |
| Yehia, M | 1 |
| Eaddy, N | 1 |
| Deitelzweig, S | 2 |
| Amin, A | 3 |
| Jing, Y | 2 |
| Makenbaeva, D | 3 |
| Wiederkehr, D | 3 |
| Lin, J | 2 |
| Graham, J | 2 |
| Assiri, A | 1 |
| Al-Majzoub, O | 1 |
| Kanaan, AO | 1 |
| Donovan, JL | 1 |
| Silva, M | 1 |
| Bamimore, A | 1 |
| Mounsey, JP | 1 |
| Providência, R | 3 |
| Albenque, JP | 3 |
| Combes, S | 2 |
| Bouzeman, A | 1 |
| Casteigt, B | 1 |
| Combes, N | 2 |
| Narayanan, K | 1 |
| Marijon, E | 5 |
| Boveda, S | 3 |
| Atar, S | 1 |
| Wishniak, A | 1 |
| Shturman, A | 1 |
| Shtiwi, S | 1 |
| Brezins, M | 1 |
| Hasselblad, V | 1 |
| Atwater, BD | 1 |
| Bahnson, TD | 1 |
| Washam, JB | 1 |
| Alexander, JH | 2 |
| Daubert, JP | 1 |
| Noheria, A | 1 |
| Asirvatham, SJ | 1 |
| Aguilar, MI | 3 |
| Kuo, RS | 1 |
| Freeman, WD | 2 |
| May, MA | 1 |
| Gruel, Y | 1 |
| Fauchier, L | 1 |
| Szapary, L | 1 |
| Fehér, G | 1 |
| Bosnyák, E | 1 |
| Deli, G | 1 |
| Csécsei, P | 1 |
| Lega, JC | 1 |
| Bertoletti, L | 1 |
| Durupt, S | 1 |
| Epinat, M | 1 |
| Mismetti, P | 1 |
| Da Costa, A | 1 |
| Laporte, S | 1 |
| Dalen, JE | 1 |
| Müller, P | 1 |
| Topakian, R | 1 |
| Sonnberger, M | 1 |
| Nußbaumer, K | 1 |
| Windpessl, M | 1 |
| Eder, V | 1 |
| Nesser, HJ | 1 |
| Trenkler, J | 1 |
| Haring, HP | 1 |
| Zalesak, M | 1 |
| Siu, K | 1 |
| Francis, K | 1 |
| Yu, C | 1 |
| Alvrtsyan, H | 1 |
| Rao, Y | 1 |
| Walker, D | 1 |
| Sander, S | 2 |
| Miyasato, G | 1 |
| Matchar, D | 1 |
| Sanchez, H | 1 |
| Wanat, MA | 1 |
| Avorn, J | 4 |
| Barry, M | 1 |
| Ichiki, H | 1 |
| Oketani, N | 1 |
| Ishida, S | 1 |
| Iriki, Y | 1 |
| Okui, H | 1 |
| Maenosono, R | 1 |
| Namino, F | 1 |
| Ninomiya, Y | 1 |
| Miyata, M | 1 |
| Hamasaki, S | 1 |
| Tei, C | 1 |
| Potpara, TS | 3 |
| Easton, JD | 2 |
| Hankey, GJ | 1 |
| Van Gelder, IC | 1 |
| Van Veldhuisen, DJ | 1 |
| Hylek, EM | 4 |
| Granger, CB | 3 |
| Kappetein, AP | 1 |
| Mack, MJ | 1 |
| Blatchford, J | 1 |
| Devenny, K | 1 |
| Friedman, J | 3 |
| Guiver, K | 1 |
| Harper, R | 1 |
| Khder, Y | 1 |
| Lobmeyer, MT | 1 |
| Maas, H | 1 |
| Voigt, JU | 1 |
| Simoons, ML | 1 |
| Van de Werf, F | 3 |
| Shurrab, M | 1 |
| Morillo, CA | 1 |
| Kansal, N | 1 |
| Danon, A | 1 |
| Newman, D | 1 |
| Lashevsky, I | 1 |
| Healey, JS | 4 |
| Crystal, E | 1 |
| Connolly, S | 4 |
| Ezekowitz, M | 6 |
| Roberts, A | 1 |
| Lum, CJ | 1 |
| Azuma, S | 1 |
| Lane, S | 1 |
| Artang, R | 1 |
| Rome, E | 1 |
| Nielsen, JD | 1 |
| Vidaillet, HJ | 1 |
| Sairaku, A | 2 |
| Yoshida, Y | 2 |
| Ando, M | 1 |
| Hirayama, H | 2 |
| Nakano, Y | 1 |
| Kihara, Y | 1 |
| Majeed, A | 2 |
| Hwang, HG | 2 |
| Ghanima, W | 1 |
| Atar, D | 1 |
| Sandset, PM | 1 |
| Simonsen, CZ | 1 |
| Steiner, T | 2 |
| Tietze, A | 1 |
| Damgaard, D | 1 |
| Kornej, J | 1 |
| Potpara, T | 1 |
| Bin Abdulhak, AA | 2 |
| Khan, AR | 2 |
| Tleyjeh, IM | 1 |
| Wimmer, AP | 3 |
| Troncoso, A | 1 |
| Diogène, E | 1 |
| Rognoni, C | 1 |
| Marchetti, M | 1 |
| Quaglini, S | 1 |
| Liberato, NL | 1 |
| Cove, CL | 1 |
| Hong, C | 1 |
| Curnew, G | 1 |
| Pullenayegum, E | 1 |
| Holbrook, A | 1 |
| Yap, LB | 1 |
| Rusani, BI | 1 |
| Umadevan, D | 1 |
| Muhammad, Z | 1 |
| Hussin, A | 1 |
| Kaur, S | 1 |
| Canestaro, WJ | 1 |
| Patrick, AR | 2 |
| Ito, K | 1 |
| Matlin, OS | 2 |
| Brennan, TA | 2 |
| Shrank, WH | 2 |
| Choudhry, NK | 3 |
| Wood, P | 2 |
| Krutisch, G | 2 |
| Ribés-Cruz, JJ | 1 |
| Torregrosa-Maicas, I | 1 |
| Ramos-Tomás, C | 1 |
| Solís-Salguero, MA | 1 |
| Puchades-Montesa, MJ | 1 |
| González-Rico, MA | 1 |
| Juan-García, I | 1 |
| Tomás-Simó, P | 1 |
| Tejedor-Alonso, S | 1 |
| Zambrano-Esteves, P | 1 |
| Miguel-Carrasco, A | 1 |
| Sidman, E | 1 |
| Probst, LA | 1 |
| Darko, W | 1 |
| Miller, CD | 1 |
| Manning, JA | 1 |
| Holmes, DN | 1 |
| Paul, G | 1 |
| Bastovansky, A | 1 |
| Kitazono, T | 2 |
| Shapiro, S | 1 |
| Laffan, M | 1 |
| Hijazi, Z | 2 |
| Andersson, U | 2 |
| Siegbahn, A | 2 |
| Clemens, A | 7 |
| Kolias, TJ | 1 |
| Zough, F | 1 |
| Tafreshi, J | 1 |
| Pai, RG | 1 |
| Herrmann, R | 1 |
| Thom, J | 1 |
| Wood, A | 1 |
| Phillips, M | 1 |
| Muhammad, S | 1 |
| Baker, R | 1 |
| Larsen, TB | 7 |
| Rasmussen, LH | 6 |
| Gorst-Rasmussen, A | 4 |
| Skjøth, F | 6 |
| Rosenzweig, M | 3 |
| Lane, DA | 8 |
| Christensen, TD | 1 |
| Bachellerie, B | 1 |
| Ruiz, S | 1 |
| Conil, JM | 1 |
| Crognier, L | 1 |
| Seguin, T | 1 |
| Georges, B | 1 |
| Fourcade, O | 1 |
| Cheng, JW | 1 |
| Barillari, G | 1 |
| Kate, M | 1 |
| Szkotak, A | 1 |
| Witt, A | 1 |
| Shuaib, A | 1 |
| Butcher, K | 1 |
| Weber, R | 3 |
| Bloom, BJ | 1 |
| Filion, KB | 2 |
| Atallah, R | 1 |
| Eisenberg, MJ | 2 |
| Sharma, S | 1 |
| Singh, S | 3 |
| Stratta, P | 1 |
| Battista, M | 1 |
| Guglielmetti, G | 1 |
| Gasparovic, H | 1 |
| Petricevic, M | 1 |
| Biocina, B | 1 |
| Speirs, A | 1 |
| Deakin, A | 1 |
| Chin, PK | 2 |
| Wright, DF | 2 |
| Begg, EJ | 1 |
| Wang, Y | 2 |
| Bajorek, B | 1 |
| Stewart, RA | 1 |
| Hanon, O | 1 |
| Liew, A | 3 |
| Darvish-Kazem, S | 1 |
| Douketis, JD | 2 |
| Carley, B | 1 |
| Griesbach, S | 1 |
| Larson, T | 1 |
| Krueger, K | 1 |
| Kosiuk, J | 2 |
| Koutalas, E | 2 |
| Doering, M | 2 |
| Sommer, P | 2 |
| Rolf, S | 2 |
| Breithardt, OA | 2 |
| Nedios, S | 2 |
| Dinov, B | 2 |
| Hindricks, G | 2 |
| Richter, S | 2 |
| Bollmann, A | 2 |
| Giglio, AF | 1 |
| Basile, E | 1 |
| Santangeli, P | 2 |
| Di Biase, L | 2 |
| Trotta, F | 1 |
| Natale, A | 2 |
| Gonzalez-Quesada, CJ | 1 |
| Giugliano, RP | 2 |
| Kongnakorn, T | 2 |
| Phatak, H | 1 |
| Kuznik, A | 1 |
| Lanitis, T | 2 |
| Liu, LZ | 1 |
| Iloeje, U | 1 |
| Hernandez, L | 1 |
| Dorian, P | 2 |
| Berthelot, E | 1 |
| Lavenu-Bombled, C | 1 |
| Orostegui-Giron, L | 1 |
| Desconclois, C | 1 |
| Assayag, P | 1 |
| Sardar, P | 1 |
| Nairooz, R | 1 |
| Chatterjee, S | 1 |
| Wetterslev, J | 1 |
| Ghosh, J | 1 |
| Aronow, WS | 1 |
| Jourda, F | 1 |
| Hireche, H | 1 |
| Morais, J | 1 |
| Capodanno, D | 1 |
| Angiolillo, DJ | 1 |
| Chan, NC | 1 |
| Paikin, JS | 1 |
| Hirsh, J | 1 |
| Lauw, MN | 1 |
| Ginsberg, JS | 1 |
| Hayama, M | 1 |
| Inoue, H | 2 |
| Wada, H | 1 |
| Mio, T | 1 |
| Undas, A | 2 |
| Pasierski, T | 1 |
| Windyga, J | 1 |
| Crowther, M | 2 |
| Wolf, HM | 1 |
| Huisman, MV | 3 |
| Dubner, SJ | 1 |
| Ma, CS | 1 |
| Rothman, KJ | 1 |
| Teutsch, C | 1 |
| Zint, K | 2 |
| Ackermann, D | 1 |
| Bartels, DB | 1 |
| Yadlapati, A | 1 |
| Groh, C | 1 |
| Passman, R | 1 |
| Brunetti, L | 1 |
| Chen, C | 1 |
| White, J | 1 |
| Antoniazzi, S | 1 |
| Berdaï, D | 1 |
| Conti, V | 1 |
| Clementi, E | 1 |
| Salvo, F | 1 |
| Stepanyan, G | 1 |
| Badhwar, N | 1 |
| Lee, RJ | 1 |
| Marcus, GM | 1 |
| Lee, BK | 1 |
| Tseng, ZH | 1 |
| Vedantham, V | 1 |
| Olgin, J | 1 |
| Scheinman, M | 1 |
| Gerstenfeld, EP | 2 |
| Komori, M | 1 |
| Kokuba, K | 1 |
| Matsuoka, H | 1 |
| Fujimoto, S | 1 |
| Yoshida, M | 1 |
| Kameda, K | 1 |
| Shono, T | 1 |
| Nagata, S | 1 |
| Ago, T | 1 |
| Okada, Y | 1 |
| Salazar, CA | 1 |
| del Aguila, D | 1 |
| Cordova, EG | 1 |
| Meyer Dos Santos, S | 1 |
| Harder, S | 1 |
| Inaishi, J | 1 |
| Nogawa, S | 1 |
| Mano, Y | 1 |
| Yoshizaki, T | 1 |
| Okada, S | 1 |
| Wisløff, T | 1 |
| Hagen, G | 1 |
| Klemp, M | 1 |
| Shafi, ST | 1 |
| Negrete, H | 1 |
| Roy, P | 1 |
| Julius, CJ | 1 |
| Sarac, E | 1 |
| Carrizo, A | 1 |
| Campbell, S | 1 |
| Poller, L | 1 |
| Jespersen, J | 1 |
| Ibrahim, S | 1 |
| Souto, JC | 1 |
| Ruyra, X | 1 |
| Bayes-Genis, A | 1 |
| González-Juanatey, JR | 3 |
| Lobos, JM | 2 |
| Reverter, JC | 2 |
| Becerra, V | 2 |
| Soler-Martínez, S | 1 |
| Martínez-Rubio, A | 3 |
| González-Rojas, N | 2 |
| Lai, A | 1 |
| Davidson, N | 1 |
| Galloway, SW | 1 |
| Brannath, W | 1 |
| Schmidt, S | 1 |
| Brieger, D | 1 |
| Hirano, T | 1 |
| Cotté, FE | 1 |
| Gaudin, AF | 1 |
| Kachaner, I | 1 |
| Durand-Zaleski, I | 1 |
| Birnie, DH | 1 |
| Essebag, V | 2 |
| Alegret, JM | 1 |
| Viñolas, X | 1 |
| Arias, MA | 1 |
| Rebollo, P | 1 |
| Ràfols, C | 1 |
| Martínez-Sande, JL | 1 |
| Foley, J | 1 |
| Kirchhof, P | 1 |
| Desai, NR | 1 |
| Krumme, AA | 1 |
| Schneeweiss, S | 2 |
| Brill, G | 1 |
| Pezalla, EJ | 1 |
| Spettell, CM | 1 |
| Noll, G | 1 |
| Noll, S | 1 |
| Hürlimann, D | 1 |
| Tkacheva, ON | 1 |
| Akasheva, DU | 1 |
| Fontaine, GV | 1 |
| Mathews, KD | 1 |
| Woller, SC | 1 |
| Stevens, SM | 1 |
| Lloyd, JF | 1 |
| Evans, RS | 1 |
| Spahr, J | 1 |
| Ghosh, P | 1 |
| Corelli, K | 1 |
| Diogo, C | 1 |
| Duarte, J | 1 |
| Sobral, S | 1 |
| Pestana, P | 1 |
| Nzwalo, H | 1 |
| Rita, H | 1 |
| Sousa E Costa, J | 1 |
| Zotova, IV | 1 |
| Zateĭshchikov, DA | 1 |
| Somani, R | 1 |
| Mohajer, K | 1 |
| Haley, C | 1 |
| Simpson, CS | 2 |
| Abdollah, H | 2 |
| Baranchuk, A | 1 |
| Redfearn, DP | 2 |
| Michael, K | 1 |
| Shore, S | 2 |
| Carey, EP | 2 |
| Turakhia, MP | 3 |
| Jackevicius, CA | 1 |
| Cunningham, F | 2 |
| Pilote, L | 1 |
| Bradley, SM | 1 |
| Maddox, TM | 1 |
| Grunwald, GK | 1 |
| Barón, AE | 1 |
| Rumsfeld, JS | 1 |
| Varosy, PD | 1 |
| Schneider, PM | 1 |
| Marzec, LN | 1 |
| Ho, PM | 2 |
| Fernández de Velasco Pérez, D | 1 |
| Konturek, P | 1 |
| Hess, T | 1 |
| Baker, WL | 2 |
| Chamberlin, KW | 1 |
| Tran, H | 1 |
| Joseph, J | 1 |
| Young, L | 1 |
| McRae, S | 1 |
| Curnow, J | 1 |
| Nandurkar, H | 1 |
| McLintock, C | 2 |
| Bengtson, LG | 1 |
| Lakshminarayan, K | 1 |
| Aryal, MR | 2 |
| Ukaigwe, A | 1 |
| Pandit, A | 1 |
| Karmacharya, P | 1 |
| Pradhan, R | 1 |
| Mainali, NR | 1 |
| Pathak, R | 1 |
| Jalota, L | 1 |
| Bhandari, Y | 1 |
| Donato, A | 1 |
| Hana, A | 2 |
| Berthold, C | 1 |
| Gunness, VR | 1 |
| Dooms, G | 1 |
| Standhardt, H | 1 |
| Koy, J | 1 |
| Matgé, G | 1 |
| Boecher-Schwarz, H | 1 |
| Hertel, F | 1 |
| Raatikainen, P | 1 |
| Askonen, K | 1 |
| Halinen, M | 1 |
| Huikuri, H | 1 |
| Koistinen, J | 1 |
| Parikka, H | 1 |
| Puurunen, M | 1 |
| Virtanen, V | 1 |
| AbuDagga, A | 1 |
| Stephenson, JJ | 1 |
| Fu, AC | 1 |
| Kwong, WJ | 1 |
| Tan, H | 1 |
| Weintraub, WS | 1 |
| Ho, MH | 2 |
| Ho, CW | 2 |
| Cheung, E | 2 |
| Chan, PH | 3 |
| Hai, JJ | 3 |
| Chan, KH | 2 |
| Leung, GK | 2 |
| Tse, HF | 2 |
| Siu, CW | 3 |
| Orso, F | 1 |
| Barucci, R | 1 |
| Fracchia, S | 1 |
| Mannarino, G | 1 |
| Pratesi, A | 1 |
| Fattirolli, F | 1 |
| Turagam, MK | 1 |
| Velagapudi, P | 1 |
| Bongu, NR | 1 |
| Kocheril, AG | 1 |
| Samoš, M | 1 |
| Stančiaková, L | 1 |
| Ivanková, J | 1 |
| Staško, J | 1 |
| Kovář, F | 1 |
| Dobrotová, M | 1 |
| Galajda, P | 1 |
| Kubisz, P | 1 |
| Mokáň, M | 1 |
| Brand, S | 1 |
| Kansal, A | 1 |
| Lim, J | 1 |
| Sorensen, S | 1 |
| Vaughan Sarrazin, MS | 2 |
| Jones, M | 1 |
| Mazur, A | 1 |
| Chrischilles, E | 1 |
| Cram, P | 1 |
| Badal, M | 1 |
| Mege, J | 1 |
| Chaudhary, A | 1 |
| Donato, AA | 1 |
| Winkle, RA | 3 |
| Mead, RH | 3 |
| Engel, G | 3 |
| Kong, MH | 3 |
| Patrawala, RA | 3 |
| Sarvananthan, S | 1 |
| Punjabi, PP | 1 |
| Stokes, M | 1 |
| Wu, N | 1 |
| Lawrence, JH | 1 |
| Yoon, CH | 1 |
| Park, YK | 1 |
| Kim, SJ | 1 |
| Lee, MJ | 1 |
| Ryoo, S | 1 |
| Kim, GM | 1 |
| Chung, CS | 1 |
| Lee, KH | 1 |
| Kim, JS | 2 |
| Bang, OY | 1 |
| Seitz, J | 1 |
| Beurtheret, S | 1 |
| Muhrbeck, J | 1 |
| Strack, A | 1 |
| Konstantinides, S | 1 |
| Rudakova, AV | 1 |
| Tatarskiĭ, BA | 1 |
| Senoo, K | 1 |
| Czubek, U | 1 |
| Góralczyk, T | 1 |
| Zalewski, J | 1 |
| Hifumi, T | 1 |
| Takada, H | 1 |
| Kiriu, N | 1 |
| Bennell, MC | 1 |
| Pham, B | 1 |
| Krahn, M | 1 |
| Pugi, A | 1 |
| Fallani, F | 1 |
| Palazzi, N | 1 |
| Banfi, R | 1 |
| Olesen, JB | 2 |
| Sørensen, R | 1 |
| Hansen, ML | 1 |
| Lamberts, M | 1 |
| Weeke, P | 1 |
| Mikkelsen, AP | 1 |
| Køber, L | 1 |
| Gislason, GH | 1 |
| Torp-Pedersen, C | 2 |
| Fosbøl, EL | 1 |
| Pollack, CV | 1 |
| Levy, JH | 1 |
| Sellke, FW | 1 |
| Kamphuisen, P | 1 |
| Bernstein, RA | 1 |
| Darma, A | 1 |
| Plitt, A | 1 |
| Strasser, KM | 1 |
| Qasem, A | 1 |
| Madhusudhana, S | 1 |
| Verma, A | 2 |
| Cairns, JA | 2 |
| Mitchell, LB | 1 |
| Macle, L | 1 |
| Stiell, IG | 1 |
| Gladstone, D | 1 |
| Cox, JL | 1 |
| Ivers, N | 1 |
| Leblanc, K | 1 |
| Nattel, S | 1 |
| Ammollo, CT | 1 |
| Zaccaria, F | 1 |
| Visino, F | 1 |
| Testa, S | 3 |
| Semeraro, N | 1 |
| Colucci, M | 1 |
| Messori, A | 2 |
| Fadda, V | 2 |
| Maratea, D | 2 |
| Trippoli, S | 2 |
| Marinai, C | 1 |
| Kovács, T | 1 |
| Shah, R | 1 |
| Xie, F | 1 |
| Kong, MC | 1 |
| Lee, LH | 1 |
| Ng, HJ | 1 |
| Ko, Y | 1 |
| Verhoef, TI | 1 |
| Redekop, WK | 1 |
| Hasrat, F | 1 |
| de Boer, A | 1 |
| Maitland-van der Zee, AH | 1 |
| Kent, AP | 1 |
| Ulrich, LR | 1 |
| Mergenthal, K | 1 |
| Petersen, JJ | 1 |
| Roehl, I | 1 |
| Rauck, S | 1 |
| Kemperdick, B | 1 |
| Schulz-Rothe, S | 1 |
| Berghold, A | 1 |
| Siebenhofer, A | 1 |
| Graham, DJ | 1 |
| Reichman, ME | 1 |
| Wernecke, M | 1 |
| Zhang, R | 1 |
| Southworth, MR | 1 |
| Levenson, M | 1 |
| Sheu, TC | 1 |
| Mott, K | 1 |
| Goulding, MR | 1 |
| Houstoun, M | 1 |
| MaCurdy, TE | 1 |
| Worrall, C | 1 |
| Kelman, JA | 1 |
| Redberg, RF | 1 |
| Hernandez, I | 2 |
| Baik, SH | 1 |
| Piñera, A | 1 |
| Zhang, Y | 2 |
| Baber, U | 1 |
| Mastoris, I | 1 |
| Mehran, R | 1 |
| Snipelisky, D | 2 |
| Ray, JC | 1 |
| Ung, R | 1 |
| Duart, M | 1 |
| Kauffman, C | 2 |
| Kusumoto, F | 2 |
| Douketis, J | 2 |
| Bell, AD | 3 |
| Yeung, CY | 1 |
| Lau, KK | 1 |
| Florkowski, CM | 1 |
| Carney, EF | 1 |
| Schilling, R | 1 |
| Willems, S | 1 |
| Owada, S | 1 |
| Tomita, H | 1 |
| Kinjo, T | 1 |
| Ishida, Y | 1 |
| Itoh, T | 1 |
| Sasaki, K | 1 |
| Horiuchi, D | 1 |
| Kimura, M | 1 |
| Sasaki, S | 1 |
| Okumura, K | 2 |
| da Silva, RM | 1 |
| Beliavskaia, OO | 1 |
| Vavilova, TV | 1 |
| Hajhosseiny, R | 1 |
| Sabir, I | 1 |
| Armbruster, HL | 1 |
| Lindsley, JP | 1 |
| Moranville, MP | 1 |
| Habibi, M | 1 |
| Khurram, IM | 1 |
| Spragg, DD | 1 |
| Berger, RD | 1 |
| Marine, JE | 1 |
| Pontillo, D | 1 |
| Patruno, N | 1 |
| Gorzelak-Pabiś, P | 1 |
| Duraj, I | 1 |
| Szlagowska, L | 1 |
| Ciastkowska, A | 1 |
| Broncel, M | 1 |
| Moustafa, F | 1 |
| Milhaud, G | 1 |
| Dublanchet, N | 1 |
| Lebreton, A | 1 |
| Dutheil, F | 1 |
| Schmidt, J | 1 |
| Forslund, T | 1 |
| von Euler, M | 1 |
| Johnsson, H | 1 |
| Holmström, M | 1 |
| Wettermark, B | 1 |
| Arepally, GM | 1 |
| Ortel, TL | 1 |
| Chan, KE | 1 |
| Edelman, ER | 1 |
| Wenger, JB | 1 |
| Thadhani, RI | 1 |
| Maddux, FW | 1 |
| Rockey, DC | 1 |
| Einecke, D | 1 |
| Hasler, S | 1 |
| Feng, X | 1 |
| Huan, Y | 1 |
| Lv, Y | 1 |
| Garg, P | 1 |
| Ripley, DP | 1 |
| Shchendrygina, AA | 1 |
| Brais, C | 1 |
| Larochelle, J | 1 |
| Turgeon, M | 1 |
| Tousignant, A | 1 |
| Blais, L | 1 |
| Perreault, S | 1 |
| Farand, P | 1 |
| Letemplier, G | 1 |
| Beauchesne, M | 1 |
| Patel, AD | 1 |
| Tan, MK | 1 |
| Angaran, P | 1 |
| Berall, M | 1 |
| Bucci, C | 1 |
| Demchuk, AM | 1 |
| Goldin, L | 1 |
| Green, MS | 1 |
| Gregoire, JC | 1 |
| Gross, PL | 1 |
| Heilbron, B | 1 |
| Lin, PJ | 1 |
| Ramanathan, K | 1 |
| Skanes, A | 1 |
| Wheeler, BH | 1 |
| Goodman, SG | 1 |
| Krishnamoorthy, A | 1 |
| Sherwood, MW | 1 |
| Becker, RC | 1 |
| Yeh, CH | 1 |
| Hogg, K | 1 |
| Scheppach, W | 1 |
| Meesmann, M | 1 |
| Bosch, J | 1 |
| Lambert-Kerzner, A | 1 |
| Glorioso, TJ | 1 |
| Longo, L | 1 |
| Jackevicius, C | 1 |
| Rose, A | 2 |
| Kmietowicz, Z | 1 |
| Wood, K | 1 |
| Abraham, NS | 1 |
| Alexander, GC | 3 |
| Heien, H | 1 |
| Haas, LR | 1 |
| Crown, W | 1 |
| Shah, ND | 1 |
| Chang, HY | 1 |
| Zhou, M | 1 |
| Tang, W | 1 |
| Okubo, K | 1 |
| Kuwahara, T | 1 |
| Takagi, K | 1 |
| Takigawa, M | 1 |
| Nakajima, J | 1 |
| Watari, Y | 1 |
| Nakashima, E | 1 |
| Yamao, K | 1 |
| Fujino, T | 2 |
| Tsutsui, H | 1 |
| Takahashi, A | 1 |
| Park, CI | 1 |
| Pruvot, E | 1 |
| Jadidi, A | 1 |
| Lehrmann, H | 1 |
| Arentz, T | 1 |
| Zimmermann, M | 1 |
| Phillips, R | 1 |
| Nagao, T | 2 |
| Inden, Y | 2 |
| Shimano, M | 1 |
| Fujita, M | 1 |
| Yanagisawa, S | 1 |
| Kato, H | 1 |
| Ishikawa, S | 1 |
| Miyoshi, A | 1 |
| Okumura, S | 1 |
| Ohguchi, S | 1 |
| Yamamoto, T | 1 |
| Yoshida, N | 1 |
| Hirai, M | 1 |
| Murohara, T | 2 |
| Hilpert, U | 1 |
| Ameri, AA | 1 |
| Lythgoe, M | 1 |
| Yamazaki, Y | 1 |
| Yamazaki, A | 1 |
| Kabuki, T | 1 |
| Kiuchi, S | 1 |
| Kobayashi, K | 1 |
| Yamazaki, J | 1 |
| Ikeda, T | 1 |
| Lewis, LS | 1 |
| Miyares, MA | 1 |
| Horjus, DL | 1 |
| van Montfrans, GA | 1 |
| Brewster, LM | 1 |
| Klil-Drori, A | 1 |
| Azoulay, L | 1 |
| Kreuzer, J | 1 |
| Liu, S | 1 |
| Kim, CO | 1 |
| Lucyk, SN | 1 |
| Henriksen, DP | 1 |
| Hansen, MR | 1 |
| Damkier, P | 1 |
| Zeus, T | 1 |
| Kelm, M | 1 |
| Bode, C | 3 |
| Koretz, RL | 1 |
| Lavine, JB | 1 |
| Schaefer, JK | 1 |
| McBane, RD | 1 |
| Wysokinski, WE | 1 |
| Torjesen, I | 1 |
| Jimenez, D | 1 |
| Jamil-Copley, S | 1 |
| Kanagaratnam, P | 1 |
| Broukhim, M | 1 |
| Gil Núñez, A | 2 |
| Freeman, JV | 1 |
| Zhu, RP | 1 |
| Owens, DK | 1 |
| Garber, AM | 1 |
| Hutton, DW | 1 |
| Wang, PJ | 1 |
| Messinger-Rapport, B | 1 |
| Miranda, RI | 1 |
| Michael, KA | 1 |
| Baranchuk, AM | 1 |
| Chernick, M | 1 |
| Aikens, TH | 2 |
| Flaker, G | 2 |
| Brugada, J | 1 |
| Parekh, A | 1 |
| Ahrens, I | 1 |
| Peter, K | 1 |
| Giorgi, MA | 1 |
| Cohen Arazi, H | 1 |
| Gonzalez, CD | 1 |
| Di Girolamo, G | 1 |
| Wann, LS | 5 |
| Curtis, AB | 5 |
| Ellenbogen, KA | 5 |
| Estes, NA | 3 |
| Jackman, WM | 3 |
| January, CT | 3 |
| Lowe, JE | 5 |
| Page, RL | 3 |
| Slotwiner, DJ | 3 |
| Stevenson, WG | 5 |
| Tracy, CM | 3 |
| Fuster, V | 3 |
| Rydén, LE | 2 |
| Cannom, DS | 2 |
| Crijns, HJ | 4 |
| Olsson, SB | 2 |
| Prystowsky, EN | 2 |
| Tamargo, JL | 2 |
| Jacobs, AK | 2 |
| Anderson, JL | 2 |
| Albert, N | 2 |
| Creager, MA | 2 |
| Ettinger, SM | 2 |
| Guyton, RA | 2 |
| Hochman, JS | 2 |
| Kushner, FG | 2 |
| Ohman, EM | 2 |
| Yancy, CW | 2 |
| Calvo Romero, JM | 1 |
| Samama, CM | 1 |
| Kirsch, B | 1 |
| Hori, M | 1 |
| Uchiyama, S | 3 |
| Gums, JG | 1 |
| Beasley, BN | 1 |
| Unger, EF | 1 |
| Temple, R | 1 |
| Edwards, DB | 1 |
| Silverberg, J | 1 |
| Berg, AM | 1 |
| Cannon, CP | 2 |
| Stecker, EC | 1 |
| Bendel, SD | 1 |
| Bona, R | 1 |
| Kaatz, S | 1 |
| Varrone, J | 1 |
| Kooiman, J | 1 |
| van de Peppel, WR | 1 |
| van der Meer, FJ | 1 |
| Rutzen-Lopez, H | 1 |
| Khanna, V | 1 |
| Vkhanna, V | 1 |
| Reynolds, MR | 1 |
| Reynolds, M | 1 |
| Shah, SV | 1 |
| Gage, BF | 1 |
| Dumont, B | 1 |
| Faille, D | 1 |
| Ajzenberg, N | 1 |
| Sawaya, FJ | 1 |
| Musallam, KM | 1 |
| Arnaout, S | 1 |
| Rabah, A | 1 |
| Sawaya, J | 1 |
| Rahme, RJ | 1 |
| Bernstein, R | 1 |
| Batjer, HH | 1 |
| Bendok, BR | 1 |
| Ogawa, S | 1 |
| Koretsune, Y | 1 |
| Aizawa, Y | 1 |
| Atarashi, H | 1 |
| Kamakura, S | 1 |
| Kumagai, K | 2 |
| Mitamura, H | 1 |
| Sugi, K | 1 |
| Viles-Gonzalez, JF | 1 |
| Lee, TH | 1 |
| Baruch, L | 1 |
| Sherman, O | 1 |
| Shapiro, T | 1 |
| Gage, L | 1 |
| Shin, DI | 1 |
| Eckardt, L | 1 |
| del Zoppo, GJ | 1 |
| Eliasziw, M | 1 |
| Asmis, LM | 1 |
| Ganjehei, L | 1 |
| Massumi, A | 1 |
| Razavi, M | 1 |
| Rasekh, A | 1 |
| Eerenberg, ES | 1 |
| van Es, J | 1 |
| Sijpkens, MK | 1 |
| Büller, HR | 1 |
| Kamphuisen, PW | 1 |
| Mega, JL | 1 |
| Averkov, OV | 1 |
| Whitehead, H | 1 |
| Boyd, JM | 1 |
| Blais, DM | 1 |
| Hummel, J | 1 |
| Riva, L | 1 |
| Pernod, G | 1 |
| Hunchuck, JE | 1 |
| Lake, JD | 1 |
| Pengo, V | 2 |
| Crippa, L | 2 |
| Falanga, A | 2 |
| Finazzi, G | 2 |
| Marongiu, F | 2 |
| Palareti, G | 3 |
| Poli, D | 2 |
| Tiraferri, E | 2 |
| Tosetto, A | 2 |
| Tripodi, A | 3 |
| Manotti, C | 2 |
| Lehr, T | 2 |
| Haertter, S | 2 |
| Liesenfeld, KH | 1 |
| Staab, A | 1 |
| Weimar, C | 1 |
| Kaeufer, T | 1 |
| Henry, DM | 1 |
| Augoustides, JG | 1 |
| Acharjee, S | 1 |
| Banerjee, A | 2 |
| Marín, F | 2 |
| Yates, SW | 1 |
| Beyth, RJ | 1 |
| Landefeld, CS | 1 |
| Al-Khatib, SM | 1 |
| Patel, MR | 1 |
| Panchenko, EP | 1 |
| Garwood, CL | 1 |
| Hwang, JM | 1 |
| Moser, LR | 1 |
| Moser, M | 1 |
| Casado Naranjo, I | 1 |
| Portilla-Cuenca, JC | 1 |
| Jiménez Caballero, PE | 1 |
| Calle Escobar, ML | 1 |
| Romero Sevilla, RM | 1 |
| Redondo, S | 1 |
| Martínez, MP | 1 |
| Ramajo, M | 1 |
| Navarro-Dorado, J | 1 |
| Barez, A | 1 |
| Tejerina, T | 1 |
| Moore, CH | 1 |
| Snashall, J | 1 |
| Boniface, K | 1 |
| Scott, J | 1 |
| Fieland, D | 1 |
| Taylor, M | 1 |
| Stangier, J | 1 |
| van Ryn, J | 1 |
| Golwala, H | 1 |
| Dib, C | 1 |
| Tafur, A | 1 |
| Abu-Fadel, MS | 1 |
| Parry, PV | 1 |
| Engh, JA | 1 |
| Hacke, W | 1 |
| Govindarajan, R | 1 |
| Salgado, E | 1 |
| Reynolds, S | 1 |
| Parra, D | 1 |
| Rosenstein, RS | 1 |
| Reiffel, JA | 1 |
| Morales-Vidal, S | 1 |
| Schneck, MJ | 1 |
| Flaster, M | 1 |
| Biller, J | 1 |
| Funada, R | 1 |
| Tendera, M | 1 |
| Syzdół, M | 1 |
| Parma, Z | 1 |
| Knight, BP | 1 |
| Lakkireddy, D | 1 |
| Reddy, YM | 1 |
| Vanga, SR | 1 |
| Swarup, V | 1 |
| Pimentel, R | 1 |
| Mansour, MC | 1 |
| D'Avila, A | 1 |
| Sanchez, JE | 1 |
| Burkhardt, JD | 1 |
| Chalhoub, F | 1 |
| Mohanty, P | 1 |
| Coffey, J | 1 |
| Shaik, N | 1 |
| Monir, G | 1 |
| Reddy, VY | 1 |
| Ruskin, J | 1 |
| Kamel, H | 1 |
| Johnston, SC | 1 |
| Kim, AS | 1 |
| You, JJ | 1 |
| Howard, PA | 1 |
| Eckman, MH | 1 |
| Fang, MC | 1 |
| Hughes, M | 1 |
| Spencer, FA | 1 |
| Manning, WJ | 1 |
| Lip, GYH | 1 |
| Goto, S | 1 |
| Soff, GA | 1 |
| Quinlan, DJ | 2 |
| Adcock, AK | 1 |
| Lee-Iannotti, JK | 1 |
| Hoffman-Snyder, CR | 1 |
| Wingerchuk, DM | 1 |
| Wellik, KE | 1 |
| Demaerschalk, BM | 1 |
| Ali, A | 1 |
| Bailey, C | 1 |
| Abdelhafiz, AH | 1 |
| Khemasuwan, D | 1 |
| Suramaethakul, N | 1 |
| Garber, ST | 1 |
| Sivakumar, W | 1 |
| Schmidt, RH | 1 |
| Okada, M | 1 |
| Okada, K | 1 |
| DiNicolantonio, JJ | 1 |
| Ibayashi, S | 1 |
| Matsumoto, M | 1 |
| Nagata, K | 1 |
| Nakagawara, J | 1 |
| Tanahashi, N | 1 |
| Tanaka, K | 1 |
| Toyoda, K | 1 |
| Katsnelson, M | 1 |
| Sacco, RL | 1 |
| Moscucci, M | 1 |
| Ahmed, S | 1 |
| Levin, V | 2 |
| Malacoff, R | 1 |
| Martinez, MW | 2 |
| Wychowski, MK | 1 |
| Kouides, PA | 1 |
| Reiter, M | 1 |
| Schäffl-Doweik, L | 1 |
| Baker, RI | 1 |
| Harper, P | 1 |
| Moey, AW | 1 |
| Koblar, SA | 1 |
| Chryssidis, S | 1 |
| Jannes, J | 1 |
| Sternotte, A | 1 |
| Douxfils, J | 1 |
| Chatelain, B | 1 |
| Chatelain, C | 1 |
| Mullier, F | 1 |
| Dogné, JM | 1 |
| Spinewine, A | 1 |
| Duh, PD | 1 |
| Leuckx, PS | 1 |
| Warnez, PM | 1 |
| Grandi, SM | 1 |
| Shimony, A | 1 |
| Weltermann, A | 1 |
| Brodmann, M | 1 |
| Domanovits, H | 1 |
| Eber, B | 1 |
| Gottsauner-Wolf, M | 1 |
| Halbmayer, WM | 1 |
| Hiesmayr, JM | 1 |
| Kyrle, PA | 1 |
| Längle, F | 1 |
| Roithinger, FX | 1 |
| Watzke, H | 1 |
| Windhager, R | 1 |
| Wolf, C | 1 |
| Zweiker, R | 1 |
| Lee, VH | 1 |
| Conners, JJ | 2 |
| Prabhakaran, S | 2 |
| Varughese, CJ | 1 |
| Kuo, R | 1 |
| Lewalter, T | 1 |
| Shaheen, MH | 1 |
| Das, P | 1 |
| Koshy, SK | 1 |
| Jha, SK | 1 |
| Kabra, R | 1 |
| Sangha, N | 1 |
| El Khoury, R | 1 |
| Misra, V | 1 |
| Lopez, G | 1 |
| Polovina, MM | 1 |
| Licina, MM | 1 |
| Stojanovic, RM | 1 |
| Prostran, MS | 1 |
| Davidson, T | 1 |
| Husberg, M | 1 |
| Janzon, M | 1 |
| Levin, LÅ | 1 |
| Rakusan, S | 1 |
| Wimpissinger, FT | 1 |
| Mantha, S | 1 |
| You, JH | 1 |
| Tsui, KK | 1 |
| Wong, RS | 1 |
| Cheng, G | 1 |
| LaHaye, SA | 1 |
| Gibbens, SL | 1 |
| Ball, DG | 1 |
| Day, AG | 1 |
| Testa, L | 1 |
| Agnifili, M | 1 |
| Latini, RA | 1 |
| Mattioli, R | 1 |
| Lanotte, S | 1 |
| De Marco, F | 1 |
| Oreglia, J | 1 |
| Latib, A | 1 |
| Pizzocri, S | 1 |
| Laudisa, ML | 1 |
| Brambilla, N | 1 |
| Bedogni, F | 1 |
| Lillo-Le Louët, A | 1 |
| Wolf, M | 1 |
| Soufir, L | 1 |
| Galbois, A | 1 |
| Dumenil, AS | 1 |
| Offenstadt, G | 1 |
| Samama, MM | 1 |
| Kaseno, K | 1 |
| Naito, S | 1 |
| Nakamura, K | 2 |
| Sakamoto, T | 1 |
| Sasaki, T | 1 |
| Tsukada, N | 1 |
| Hayano, M | 1 |
| Nishiuchi, S | 1 |
| Fuke, E | 1 |
| Miki, Y | 1 |
| Yamashita, E | 1 |
| Oshima, S | 1 |
| Tada, H | 1 |
| Gagne, JJ | 1 |
| Reinke, T | 1 |
| Kalodiki, E | 1 |
| Lewis, B | 1 |
| Fareed, J | 1 |
| Harenberg, J | 2 |
| Marx, S | 2 |
| Marder, VJ | 1 |
| Wehling, M | 2 |
| Weiss, C | 1 |
| Reed, SD | 1 |
| Moia, M | 1 |
| Siragusa, S | 1 |
| Huang, C | 1 |
| Siu, M | 1 |
| Vu, L | 1 |
| Wong, S | 1 |
| Shin, J | 1 |
| Shevelev, VI | 2 |
| Kanorskiĭ, SG | 1 |
| Husari, A | 1 |
| Beydoun, A | 1 |
| Sheik Ammar, A | 1 |
| Maakaron, JE | 1 |
| Taher, A | 1 |
| Zhang, S | 1 |
| Destephan, C | 1 |
| Waller, AH | 1 |
| Patel, RJ | 1 |
| Dhruvakumar, S | 1 |
| Mazza, V | 1 |
| Gerula, C | 1 |
| Maher, J | 1 |
| Kaluski, E | 1 |
| Hayashi, H | 1 |
| Kitoh, K | 1 |
| Mitsunami, K | 1 |
| Horie, M | 1 |
| Testai, FD | 1 |
| Prussak, K | 1 |
| Johns, G | 1 |
| Venkatachalam, K | 1 |
| Taylor, J | 3 |
| Kosar, L | 1 |
| Jin, M | 1 |
| Kamrul, R | 1 |
| Schuster, B | 1 |
| Sharma, M | 1 |
| Roskell, N | 1 |
| Lee, V | 1 |
| Pisters, R | 2 |
| Ten Cate, H | 1 |
| Alonso-Coello, P | 1 |
| Zhou, Q | 1 |
| Guyatt, G | 1 |
| Seiffge, D | 1 |
| Nedeltchev, K | 1 |
| Lyrer, P | 1 |
| Kirley, K | 1 |
| Qato, DM | 1 |
| Kornfield, R | 1 |
| Stafford, RS | 1 |
| Álvarez-Sabin, J | 1 |
| Oyagüez, I | 1 |
| Rochwerg, B | 1 |
| Xenodemetropoulos, T | 1 |
| Spyropoulos, A | 1 |
| Yokoi, K | 1 |
| Isoda, K | 1 |
| Kimura, T | 1 |
| Adachi, T | 1 |
| Turpie, AG | 1 |
| Kreutz, R | 1 |
| Llau, J | 1 |
| Norrving, B | 1 |
| Haas, S | 1 |
| Konduru, SV | 1 |
| Cheema, AA | 1 |
| Jones, P | 1 |
| Li, Y | 1 |
| Ramza, B | 1 |
| Esmon, CT | 1 |
| Moubarak, G | 1 |
| Badenco, N | 1 |
| Dreyfus, J | 1 |
| Simion, C | 1 |
| Delos Paquet, A | 1 |
| Cazeau, S | 1 |
| Cador, R | 1 |
| Gonzalez, MD | 1 |
| Michel, J | 1 |
| Mundell, D | 1 |
| Boga, T | 1 |
| Sasse, A | 1 |
| Koziński, M | 1 |
| Obońska, K | 1 |
| Kubica, A | 1 |
| Navarese, EP | 1 |
| Kubica, J | 1 |
| Aalbers, J | 3 |
| Hardy, G | 1 |
| Durin, O | 1 |
| Donato, G | 1 |
| Nanetti, M | 1 |
| Foffa, A | 1 |
| Inama, G | 1 |
| Furman, NV | 1 |
| Kuvshinova, LE | 1 |
| Dovgalevskiĭ, IaP | 1 |
| Bytzer, P | 1 |
| Formella, S | 1 |
| Blanco-Molina, A | 1 |
| Nin, T | 1 |
| Kamiya, H | 1 |
| Tatematsu, Y | 1 |
| Nanasato, M | 1 |
| Kamboj, J | 1 |
| Kottalgi, M | 1 |
| Cirra, VR | 1 |
| Shah, N | 1 |
| Kamboj, R | 1 |
| Dabitz, R | 1 |
| Ochs, G | 1 |
| Nieuwlaat, R | 1 |
| Boehlen, F | 1 |
| de Moerloose, P | 1 |
| Shamoun, FE | 1 |
| Martin, EN | 1 |
| Money, SR | 1 |
| She, F | 1 |
| Jongnarangsin, K | 1 |
| Chugh, A | 1 |
| Latchamsetty, R | 1 |
| Ghanbari, H | 1 |
| Crawford, T | 1 |
| Suwanagool, A | 1 |
| Sinno, M | 1 |
| Carrigan, T | 1 |
| Kennedy, R | 1 |
| Saint-Phard, W | 1 |
| Yokokawa, M | 1 |
| Good, E | 1 |
| Bogun, F | 1 |
| Pelosi, F | 1 |
| Morady, F | 1 |
| Oral, H | 1 |
| Coccheri, S | 1 |
| Orlando, D | 1 |
| Kanorsky, SG | 1 |
| Deitelzweig, SB | 1 |
| Pletscher, M | 1 |
| Plessow, R | 1 |
| Eichler, K | 1 |
| Wieser, S | 1 |
| Brill, D | 1 |
| Greenspon, AJ | 1 |
| Kraglund, KL | 1 |
| Husted, SE | 1 |
| Modrau, B | 1 |
| Grove, EL | 1 |
| de Gea-García, JH | 1 |
| Alvarez, M | 1 |
| Ruiz-Villa, G | 1 |
| Jiménez-Parra, JD | 1 |
| Brem, E | 1 |
| Koyfman, A | 1 |
| Foran, M | 1 |
| Contractor, T | 1 |
| Kis, Z | 1 |
| Földesi, C | 1 |
| Pál, M | 1 |
| Som, Z | 1 |
| Csillik, A | 1 |
| Abrahám, P | 1 |
| Temesvári, A | 1 |
| Fontos, G | 1 |
| Szatmári, A | 1 |
| Andréka, P | 1 |
| Kardos, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Randomized Evaluation of Decision Support Interventions for Atrial Fibrillation[NCT04357288] | 1,200 participants (Anticipated) | Interventional | 2020-12-16 | Active, not recruiting | |||
| Efficacy and Safety of Apixaban in Patients With Active Malignancy and Acute Deep Venous Thrombosis.[NCT04462003] | Phase 3 | 100 participants (Anticipated) | Interventional | 2019-07-03 | Recruiting | ||
| Randomized Evaluation of Long Term Anticoagulant Therapy (RE-LY) Comparing the Efficacy and Safety of Two Blinded Doses of Dabigatran Etexilate With Open Label Warfarin for the Prevention of Stroke and Systemic Embolism in Patients With Non-valvular Atria[NCT00262600] | Phase 3 | 18,113 participants (Actual) | Interventional | 2005-12-31 | Completed | ||
| RELY-ABLE Long Term Multi-center Extension of Dabigatran Treatment in Patients With Atrial Fibrillation Who Completed the RE-LY Trial and a Cluster Randomised Trial to Assess the Effect of a Knowledge Translation Intervention on Patient Outcomes[NCT00808067] | Phase 3 | 5,897 participants (Actual) | Interventional | 2008-11-30 | Completed | ||
| An Epidemiological Study to Evaluate the Use of Vitamin K Antagonists and New Oral Anticoagulants Among Nonvalvular Atrial Fibrillation Patients in Turkey[NCT02354456] | 4,100 participants (Anticipated) | Observational [Patient Registry] | 2015-01-31 | Recruiting | |||
| Prospective Study of the Assessment of the Dental Protocol for Tooth Extraction in Patients With Atrial Fibrillation in Continuous Use of New Oral Anticoagulants: A Pilot Study[NCT03181386] | Phase 3 | 60 participants (Actual) | Interventional | 2017-05-03 | Completed | ||
| Better Outcomes for Anticoagulation Treatment Through Observation of Atrial Rhythm (BOAT OAR)[NCT03515083] | 100 participants (Actual) | Interventional | 2017-07-17 | Completed | |||
| Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)[NCT01165710] | 10,179 participants (Actual) | Observational | 2010-06-30 | Completed | |||
| This is a Prospective, Open-label Phase 2 Pilot Study With Independent Evaluation of All Outcomes and a Historical Control Group to Determine if Rivaroxaban (Xarelto) is Feasible and Safe for Prevention of Major Complications in Patients Undergoing a Mech[NCT02128841] | Phase 2 | 12 participants (Actual) | Interventional | 2012-09-30 | Terminated (stopped due to not enough patients) | ||
| A Prospective, Randomized, Active (Warfarin) Controlled, Parallel-arm Clinical Trial to Determine if Participants With an On-X Aortic Valve Can be Maintained Safely and Effectively on Apixaban[NCT04142658] | Phase 3 | 863 participants (Actual) | Interventional | 2020-05-01 | Terminated (stopped due to Safety) | ||
| Pharmacogenetic Algorithm of Response to Warfarin During Initial Anticoagulation in Chinese Elderly Patients[NCT02211326] | 660 participants (Actual) | Interventional | 2014-09-01 | Completed | |||
| Evaluation of the Long Term Safety of the Use of Dabigatran Etexilate in Patients With a Bileaflet Mechanical Heart Valve[NCT01505881] | Phase 2 | 158 participants (Actual) | Interventional | 2011-12-31 | Terminated | ||
| A Randomised, Phase II Study to Evaluate the sAfety and Pharmacokinetics of oraL dabIGatran Etexilate in Patients After Heart Valve replacemeNt[NCT01452347] | Phase 2 | 328 participants (Actual) | Interventional | 2011-10-31 | Terminated | ||
| Twice-daily Oral Direct Thrombin Inhibitor Dabigatran Etexilate in the Long-term Prevention of Recurrent Symptomatic Proximal Venous Thromboembolism in Patients With Symptomatic Deep-vein Thrombosis or Pulmonary Embolism.[NCT00558259] | Phase 3 | 1,353 participants (Actual) | Interventional | 2007-11-30 | Completed | ||
| A Phase III, Randomised, Double Blind, Parallel-group Study of the Efficacy and Safety of Oral Dabigatran Etexilate (150 mg Bid) Compared to Warfarin (INR 2.0-3.0) for 6 Month Treatment of Acute Symptomatic Venous Thromboembolism, Following Initial Treatm[NCT00680186] | Phase 3 | 2,589 participants (Actual) | Interventional | 2008-04-30 | Completed | ||
| A Phase III, Randomised, Multicenter, Double-blind, Parallel-group, Active Controlled Study to Evaluate the Efficacy and Safety of Oral Dabigatran Etexilate (150 mg Bid) Compared to Warfarin (INR 2.0-3.0) for the Secondary Prevention of Venous Thromboembo[NCT00329238] | Phase 3 | 2,867 participants (Actual) | Interventional | 2006-05-31 | Completed | ||
| A Phase III, Randomised, Double Blind, Parallel-group Study of the Efficacy and Safety of Oral Dabigatran Etexilate 150 mg Twice Daily Compared to Warfarin (INR 2.0-3.0) for 6 Month Treatment of Acute Symptomatic Venous Thromboembolism (VTE), Following In[NCT00291330] | Phase 3 | 2,564 participants (Actual) | Interventional | 2006-02-28 | Completed | ||
| GLORIA-AF: Global Registry on Long-Term Oral Anti-thrombotic TReatment In PAtients With Atrial Fibrillation (Phase I)[NCT01428765] | 1,096 participants (Actual) | Observational | 2011-05-31 | Completed | |||
| GLORIA - AF: Global Registry on Long-Term Oral Anti-thrombotic TReatment In PAtients With Atrial Fibrillation (Phase II/III - EU/EEA Member States)[NCT01671007] | 10,471 participants (Actual) | Observational | 2012-08-22 | Completed | |||
| GLORIA - AF: Global Registry on Long-Term Oral Anti-thrombotic Treatment In Patients With Atrial Fibrillation (Phase II/III)[NCT01468701] | 37,235 participants (Actual) | Observational | 2011-11-07 | Completed | |||
| Effectivity of a Joint Didactic Intervention by School for Patients on Inappropriate Control Prothrombin Time Anticoagulated Patients. Protocol for Developing a Randomized and Controlled Clinical Trial[NCT03647254] | 1 participants (Anticipated) | Interventional | 2018-09-01 | Recruiting | |||
| A Monitor System for the Safety of Dabigatran Anticoagulation Treatment in Nonvalvular Atrial Fibrillation[NCT02414035] | 1,496 participants (Actual) | Observational | 2015-03-22 | Completed | |||
| Pilot Intervention to Improve Adherence to Dabigatran for Patients With Atrial Fibillation[NCT01578044] | 12 participants (Actual) | Interventional | 2012-01-31 | Completed | |||
| Italian Registry In the Setting of AF Ablation With Rivaroxaban[NCT04315974] | 250 participants (Anticipated) | Observational [Patient Registry] | 2020-05-15 | Recruiting | |||
| Pharmacokinetics and Pharmacodynamics of Apixaban in End-stage Renal Disease Patients on Hemodialysis[NCT02672709] | Phase 4 | 7 participants (Actual) | Interventional | 2016-04-30 | Completed | ||
| The Effect of Nurse Practitioner-Led Care on Health Related Quality Of Life in Adult Patients With Atrial Fibrillation - A Randomized Trial[NCT02745236] | 150 participants (Actual) | Interventional | 2016-07-31 | Completed | |||
| RENal Hemodialysis Patients ALlocated Apixaban Versus Warfarin in Atrial Fibrillation (RENAL-AF) Randomized Clinical Trial[NCT02942407] | Phase 4 | 154 participants (Actual) | Interventional | 2016-12-31 | Completed | ||
| SPRINT-AF: Stroke Prevention and Rhythm Interventions in Atrial Fibrillation[NCT01733160] | 2,499 participants (Actual) | Observational | 2013-11-30 | Completed | |||
| Comparison of Accidents and Their Circumstances With Oral Anticoagulants. The CACAO Study[NCT02376777] | 4,162 participants (Actual) | Observational | 2014-04-30 | Completed | |||
| Optimal Delay Time to Initiate Anticoagulation After Ischemic Stroke in Atrial Fibrillation[NCT03021928] | Phase 3 | 200 participants (Actual) | Interventional | 2017-06-14 | Active, not recruiting | ||
| Anticoagulant-associated Intracranial Hemorrhage: Patient Characteristics and Outcomes From National Institute of Neurology and Neurosurgery Manuel Velasco: Single-Center Observational Study[NCT06168838] | 1,200 participants (Anticipated) | Observational | 2023-08-09 | Recruiting | |||
| Direct Oral Anticoagulants Pharmacodynamics in Octogenarian Patients With Atrial Fibrillation[NCT02623049] | 150 participants (Anticipated) | Observational | 2015-11-30 | Recruiting | |||
| Correlation Between Bleeding Complication and Treatment Failure of DOAC and Its Predictions Based on Cipherome's Pharmacogenomic Technology[NCT04597593] | 200 participants (Actual) | Observational | 2020-10-07 | Completed | |||
| Investigation of Genetic Variations on Patients With Adverse Events While on Direct Oral Anticoagulants (DOACs)[NCT04580589] | 210 participants (Actual) | Observational | 2021-02-01 | Completed | |||
| Antithrombotic Therapy After Left Atrial Appendage Occlusion: Double Antiplatelet Therapy vs Apixaban[NCT05632445] | Phase 4 | 160 participants (Actual) | Interventional | 2019-05-01 | Completed | ||
| Investigation of Genetic Variations on Patients With Adverse Drug Events While on Direct Oral Anticoagulants (DOACs)[NCT04247919] | 3 participants (Actual) | Observational | 2020-01-10 | Terminated (stopped due to Limitations to recruitment due to COVID-19) | |||
| Prospective Observational Study of the Direct Oral Anticoagulants Periprocedural Management[NCT03182218] | 1,100 participants (Actual) | Observational | 2015-02-28 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Number of subjects with abnormal liver function test (LFT), i.e., ALT/AST>3xULN and total bilirubin > 2 x ULN (NCT00262600)
Timeframe: 36 months
| Intervention | participants (Number) |
|---|---|
| Dabigatran 110 mg | 11 |
| Dabigatran 150 mg | 14 |
| Warfarin | 21 |
Time to first occurrence of stroke or systemic embolic event. Yearly event rate (%) = number of subjects with event / subject-years * 100. Subject years = sum(date of study termination - date of randomization + 1) of all randomized subjects / 365.25 (NCT00262600)
Timeframe: 36 months
| Intervention | yearly event rate (percentage) (Number) |
|---|---|
| Dabigatran 110 mg | 1.54 |
| Dabigatran 150 mg | 1.11 |
| Warfarin | 1.71 |
Time to first occurrence of stroke, SEE or all cause death. Yearly event rate (%) = number of subjects with event / subject-years * 100. Subject years = sum(date of study termination - date of randomization + 1) of all randomized subjects / 365.25 (NCT00262600)
Timeframe: 36 months
| Intervention | yearly event rate (percentage) (Number) |
|---|---|
| Dabigatran 110 mg | 4.85 |
| Dabigatran 150 mg | 4.32 |
| Warfarin | 5.20 |
Time to first occurrence of stroke, systemic embolic event, pulmonary embolism, myocardial infarction including silent myocardial infarction or vascular death. Yearly event rate (%) = number of subjects with event / subject-years * 100. Subject years = sum(date of study termination - date of randomization + 1) of all randomized subjects / 365.25 (NCT00262600)
Timeframe: 36 months
| Intervention | yearly event rate (percentage) (Number) |
|---|---|
| Dabigatran 110 mg | 4.26 |
| Dabigatran 150 mg | 3.68 |
| Warfarin | 4.35 |
"Yearly event rate of bleeds. Yearly event rate (%) = number of subjects with event / subject-years * 100. Subject years = sum(date of study termination - date of randomization + 1) of all randomized subjects / 365.25~Major bleeds are adjudicated, whereas minor bleeds are investigator reported." (NCT00262600)
Timeframe: 36 months
| Intervention | yearly event rate (percentage) (Number) | |
|---|---|---|
| Major bleeds | Minor bleeds | |
| Dabigatran 110 mg | 2.99 | 13.16 |
| Dabigatran 150 mg | 3.55 | 14.85 |
| Warfarin | 3.81 | 16.37 |
Patients with clinical relevant abnormalities for intracerebral hemorrhage, other intracranial hemorrhage (ICH) (NCT00262600)
Timeframe: 36 months
| Intervention | yearly event rate (percentage)] (Number) | |
|---|---|---|
| intracerebral hemorrhage | intracranial hemorrhage (ICH) | |
| Dabigatran 110 mg | 0.12 | 0.23 |
| Dabigatran 150 mg | 0.10 | 0.32 |
| Warfarin | 0.38 | 0.76 |
"Annualized event rate (%) = 100 * No. subjects with event / subject-years. Subject-years = Sum (date of last visit - date of first dose + 1) of all subjects / 365.25.~a. In subjects not undergoing PCI or CABG a subject should have fulfilled at least 2 of the following: i. Typical prolonged severe chest pain or related symptoms or signs suggestive of MI. ii. Elevation of troponin or CK-MB to more than upper level of normal (ULN) or, if CK-MB was elevated at baseline, re-elevation to more than 50% increase above the previous level. iii. Development of significant Q-waves in at least 2 adjacent ECG leads. b. After percutaneous coronary intervention (within 24h). c. After coronary artery bypass grafting (within 72h). d. Silent myocardial infarction. e. Myocardial infarction could also have been demonstrated at autopsy." (NCT00808067)
Timeframe: up to 43 months
| Intervention | percentage of subject-years (Number) |
|---|---|
| Dabigatran 110 mg | 0.72 |
| Dabigatran 150 mg | 0.66 |
Annualized event rate (%) = 100 * No. subjects with event / subject-years. Subject-years = Sum (date of last visit - date of first dose + 1) of all subjects / 365.25. (NCT00808067)
Timeframe: up to 43 months
| Intervention | percentage of subject-years (Number) |
|---|---|
| Dabigatran 110 mg | 9.44 |
| Dabigatran 150 mg | 11.20 |
Annualized event rate (%) = 100 * No. subjects with event / subject-years. Subject-years = Sum (date of last visit - date of first dose + 1) of all subjects / 365.25. (NCT00808067)
Timeframe: up to 43 months
| Intervention | percentage of subject-years (Number) |
|---|---|
| Dabigatran 110 mg | 1.60 |
| Dabigatran 150 mg | 1.47 |
Annualized event rate (%) = 100 * No. subjects with event / subject-years. Subject-years = Sum (date of last visit - date of first dose + 1) of all subjects / 365.25. (NCT00808067)
Timeframe: up to 43 months
| Intervention | percentage of subject-years (Number) |
|---|---|
| Dabigatran 110 mg | 4.40 |
| Dabigatran 150 mg | 4.02 |
Annualized event rate (%) = 100 * No. subjects with event / subject-years. Subject-years = Sum (date of last visit - date of first dose + 1) of all subjects / 365.25. (NCT00808067)
Timeframe: up to 43 months
| Intervention | percentage of subject-years (Number) |
|---|---|
| Dabigatran 110 mg | 6.65 |
| Dabigatran 150 mg | 7.14 |
Annualized event rate (%) = 100 * No. subjects with event / subject-years. Subject-years = Sum (date of last visit - date of first dose + 1) of all subjects / 365.25. (NCT00808067)
Timeframe: up to 43 months
| Intervention | percentage of subject-years (Number) |
|---|---|
| Dabigatran 110 mg | 3.51 |
| Dabigatran 150 mg | 3.32 |
Annualized event rate (%) = 100 * No. subjects with event / subject-years. Subject-years = Sum (date of last visit - date of first dose + 1) of all subjects / 365.25. (NCT00808067)
Timeframe: up to 43 months
| Intervention | percentage of subject-years (Number) |
|---|---|
| Dabigatran 110 mg | 0.28 |
| Dabigatran 150 mg | 0.33 |
"Annualized event rate (%) = 100 * No. subjects with event / subject-years. Subject-years = Sum (date of last visit - date of first dose + 1) of all subjects / 365.25.~Minor bleeds were clinical bleeds that did not fulfill the criteria for major bleeds. Minor bleeds were classified as associated with study medication discontinuation (temporary or permanent) or not." (NCT00808067)
Timeframe: up to 43 months
| Intervention | percentage of subject-years (Number) |
|---|---|
| Dabigatran 110 mg | 7.49 |
| Dabigatran 150 mg | 8.98 |
"Annualized event rate (%) = 100 * No. subjects with event / subject-years. Subject-years = Sum (date of last visit - date of first dose + 1) of all subjects / 365.25.~Deaths were classified as being vascular (sudden/arrhythmic, pump failure death, or other vascular, including bleeding) or non-vascular, due to other specified causes (e.g., malignancy), or of unknown etiology." (NCT00808067)
Timeframe: up to 43 months
| Intervention | percentage of subject-years (Number) |
|---|---|
| Dabigatran 110 mg | 3.18 |
| Dabigatran 150 mg | 2.99 |
"Annualized event rate (%) = 100 * No. subjects with event / subject-years. Subject-years = Sum (date of last visit - date of first dose + 1) of all subjects / 365.25.~Deep Vein Thrombosis (DVT) was generally documented by one of the following:~abnormal compression ultrasound (CUS),~an intraluminal filling defect on venography." (NCT00808067)
Timeframe: up to 43 months
| Intervention | percentage of subject-years (Number) |
|---|---|
| Dabigatran 110 mg | 0.06 |
| Dabigatran 150 mg | 0.11 |
"Annualized event rate (%) = 100 * No. subjects with event / subject-years. Subject-years = Sum (date of last visit - date of first dose + 1) of all subjects / 365.25.~Major bleeding must have satisfied one or more of the following criteria:~Bleeding associated with a reduction in hemoglobin of at least 20 g/L~Required transfusion of at least 2 units of blood or packed cells~Symptomatic bleeding in a critical area or organ: intraocular, intraspinal, intramuscular with compartment syndrome, retroperitoneal, intra-articular, pericardial, gastrointestinal~Major bleed were classified as life-threatening if they met one or more of the following criteria:~Reduction in hemoglobin of at least 50 g/L~Transfusion of at least 4 units of blood or packed cells~Symptomatic intracranial bleeding, either subdural or intracerebral~Associated with hypotension requiring use of intravenous inotropic agents~Required surgical intervention to stop bleeding~Resulted in death" (NCT00808067)
Timeframe: up to 43 months
| Intervention | percentage of subject-years (Number) |
|---|---|
| Dabigatran 110 mg | 2.79 |
| Dabigatran 150 mg | 3.59 |
"Annualized event rate (%) = 100 * No. subjects with event / subject-years. Subject-years = Sum (date of last visit - date of first dose + 1) of all subjects / 365.25.~Systemic embolism was an acute vascular occlusion of the extremities or any organ (kidneys, mesenteric arteries, spleen, retina or grafts), and was to be documented by angiography, surgery, scintigraphy, or autopsy." (NCT00808067)
Timeframe: up to 43 months
| Intervention | percentage of subject-years (Number) |
|---|---|
| Dabigatran 110 mg | 0.25 |
| Dabigatran 150 mg | 0.23 |
"Annualized event rate (%) = 100 * No. subjects with event / subject-years. Subject-years = Sum (date of last visit - date of first dose + 1) of all subjects / 365.25.~Pulmonary Embolism was generally documented by one of the following:~an intraluminal filling defect in segmental or more proximal branches on spiral CT scan~an intraluminal filling defect or an extension of an existing defect or a sudden cutoff of vessels more than 2.5 mm in diameter on the pulmonary angiogram~a perfusion defect of at least 75% of a segment with a local normal ventilation result (high-probability) on ventilation/perfusion lung scan (VPLS)~inconclusive spiral CT, pulmonary angiography or lung scintigraphy with demonstration of DVT in the lower extremities by compression ultrasound or venography." (NCT00808067)
Timeframe: up to 43 months
| Intervention | percentage of subject-years (Number) |
|---|---|
| Dabigatran 110 mg | 0.10 |
| Dabigatran 150 mg | 0.12 |
"Annualized event rate (%) = 100 * No. subjects with event / subject-years. Subject-years = Sum (date of last visit - date of first dose + 1) of all subjects / 365.25.~Stroke was an acute onset of a focal neurological deficit of presumed vascular origin lasting for 24 hours or more or resulting in death. The stroke was categorized as ischemic or hemorrhagic or cause unknown based on computerized tomography (CT), magnetic resonance (MR) scanning or autopsy. Fatal stroke was defined as death from any cause within 30 days of stroke. Severity of stroke was assessed by modified Rankin score at discharge from hospital" (NCT00808067)
Timeframe: up to 43 months
| Intervention | percentage of subject-years (Number) |
|---|---|
| Dabigatran 110 mg | 1.39 |
| Dabigatran 150 mg | 1.26 |
"Percentage of patients with Adverse Events leading to discontinuation of trial drug.~Prespecified clinical outcome events were not recorded as Adverse Events." (NCT01505881)
Timeframe: From first intake of study drug until last intake of study drug plus 6 days (Up to 272 days)
| Intervention | percentage of participants (Number) |
|---|---|
| Dabigatran Etexilate (DE) | 5.1 |
| Warfarin | 1.7 |
Percentage of patients with Adverse Events. Prespecified clinical outcome events were not recorded as Adverse Events. (NCT01505881)
Timeframe: From first intake of study drug until last intake of study drug plus 6 days (Up to 272 days)
| Intervention | percentage of participants (Number) |
|---|---|
| Dabigatran Etexilate (DE) | 39.4 |
| Warfarin | 37.3 |
Percentage of patients with Serious Adverse Events (SAE). Prespecified clinical outcome events were not recorded as Adverse Events. (NCT01505881)
Timeframe: From first intake of study drug until last intake of study drug plus 6 days (Up to 272 days)
| Intervention | percentage of participants (Number) |
|---|---|
| Dabigatran Etexilate (DE) | 3.0 |
| Warfarin | 6.8 |
"Clinical efficacy outcome events presented are:~Death, Venous thromboembolism (VTE), Myocardial Infarction (MI), Transient Ischaemic Attack (TIA), Stroke, Systemic embolism and Valve thrombosis" (NCT01505881)
Timeframe: From first intake of study drug until last intake of study drug plus 6 days (Up to 272 days)
| Intervention | percentage of participants (Number) | ||||||
|---|---|---|---|---|---|---|---|
| Death | Venous thromboembolism | Myocardial Infarction | Transient Ischaemic Attack | Stroke | Systemic embolism | Valve thrombosis | |
| Dabigatran Etexilate (DE) | 0.0 | 0.0 | 1.0 | 1.0 | 3.0 | 0.0 | 2.0 |
| Warfarin | 1.7 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
"Comparisons between dabigatran trough plasma levels as predicted by simulations to those observed in the study are performed to validate the dosing algorithm for Dabigatran Etexilate (DE).~(As the trial was stopped prematurely, EOT may not be 12 weeks after randomisation for most of the patients)~Despite the primary endpoint only being assessed in patients who received dabigatran etexilate, Warfarin was included as a comparator treatment in this study in order to facilitate informal comparisons of outcome events, and to look for efficacy signals in this previously unexplored population." (NCT01452347)
Timeframe: Week 12
| Intervention | ng/mL (Geometric Mean) |
|---|---|
| Observed | 108.21 |
| Predicted | 104.80 |
"Comparisons between dabigatran trough plasma levels as predicted by simulations to those observed in the study are performed to validate the dosing algorithm for Dabigatran Etexilate (DE).~Despite the primary endpoint only being assessed in patients who received dabigatran etexilate, Warfarin was included as a comparator treatment in this study in order to facilitate informal comparisons of outcome events, and to look for efficacy signals in this previously unexplored population." (NCT01452347)
Timeframe: Week 2
| Intervention | ng/mL (Geometric Mean) |
|---|---|
| Observed | 84.08 |
| Predicted | 99.55 |
"Comparisons between dabigatran trough plasma levels as predicted by simulations to those observed in the study are performed to validate the dosing algorithm for Dabigatran Etexilate (DE).~Despite the primary endpoint only being assessed in patients who received dabigatran etexilate, Warfarin was included as a comparator treatment in this study in order to facilitate informal comparisons of outcome events, and to look for efficacy signals in this previously unexplored population." (NCT01452347)
Timeframe: Week 4
| Intervention | ng/mL (Geometric Mean) |
|---|---|
| Observed | 104.43 |
| Predicted | 109.36 |
"Comparisons between dabigatran trough plasma levels as predicted by simulations to those observed in the study are performed to validate the dosing algorithm for Dabigatran Etexilate (DE) .~Despite the primary endpoint only being assessed in patients who received dabigatran etexilate, Warfarin was included as a comparator treatment in this study in order to facilitate informal comparisons of outcome events, and to look for efficacy signals in this previously unexplored population." (NCT01452347)
Timeframe: Week 1
| Intervention | ng/mL (Geometric Mean) |
|---|---|
| Observed | 73.86 |
| Predicted | 99.52 |
Percentage of patients with observed Ctrough,ss value < 50 ng/mL (As the trial was stopped prematurely, EOT may not be 12 weeks after randomisation for most of the patients) This outcome measure was only analysed for all patients together and not by dose group. (NCT01452347)
Timeframe: Week 12
| Intervention | percentage of participants (Number) |
|---|---|
| Patients Evaluated | 7.4 |
Percentage of patients with observed Ctrough,ss value < 50 ng/mL are presented. This outcome measure was only analysed for all patients together and not by dose group. (NCT01452347)
Timeframe: Week 1
| Intervention | percentage of participants (Number) |
|---|---|
| Patients Evaluated | 26.9 |
Percentage of patients with observed Ctrough,ss value < 50 ng/mL are presented. This outcome measure was only analysed for all patients together and not by dose group. (NCT01452347)
Timeframe: Week 2
| Intervention | percentage of participants (Number) |
|---|---|
| Patients Evaluated | 19.2 |
Percentage of patients with observed Ctrough,ss value < 50 ng/mL are presented. This outcome measure was only analysed for all patients together and not by dose group. (NCT01452347)
Timeframe: Week 4
| Intervention | percentage of participants (Number) |
|---|---|
| Patients Evaluated | 9.8 |
Cardiovascular events that occurred during the treatment period + 3 days were summarised by treatment groups. (NCT00558259)
Timeframe: 6 months
| Intervention | participants (Number) |
|---|---|
| Dabigatran | 3 |
| Placebo | 2 |
Number of participants with centrally confirmed symptomatic pulmonary embolism (PE) events during the intended treatment period were described. (NCT00558259)
Timeframe: 6 months
| Intervention | Participants (Number) |
|---|---|
| Dabigatran | 1 |
| Placebo | 14 |
Number of the participants with centrally confirmed symptomatic recurrent deep venous thrombotic (DVT) events during the intended treatment period were described. (NCT00558259)
Timeframe: 6 months
| Intervention | Participants (Number) |
|---|---|
| Dabigatran | 2 |
| Placebo | 23 |
Symptomatic recurrent VTE is the composite of recurrent deep vein thrombosis (DVT) , fatal or non-fatal pulmonary embolism (PE). Whilst the endpoint is time to event, the measured values present the number of participant with event and the hazard ratio presents the time to event. (NCT00558259)
Timeframe: 6 months
| Intervention | Participants (Number) |
|---|---|
| Dabigatran | 3 |
| Placebo | 35 |
Symptomatic recurrent VTE is the composite of recurrent deep vein thrombosis (DVT) , fatal or non-fatal pulmonary embolism (PE). Whilst the endpoint is time to event, the measured values present the number of participant with event and the hazard ratio presents the time to event. (NCT00558259)
Timeframe: 6 months
| Intervention | Participants (Number) |
|---|---|
| Dabigatran | 3 |
| Placebo | 37 |
Number of participants with centrally confirmed unexplained deaths during the intended treatment period were described. (NCT00558259)
Timeframe: 6 months
| Intervention | participants (Number) |
|---|---|
| Dabigatran | 0 |
| Placebo | 2 |
"Major bleeding events (MBE) had to fulfil at least 1 of the following criteria:~Fatal bleeding~Associated with a fall in haemoglobin of ≥2 g/dL~Led to the transfusion of ≥2 units packed cells or whole blood~Occurred in a critical site: intracranial, intraspinal, intraocular, pericardial, intra-articular, intramuscular with compartment syndrome, retroperitoneal~Other clinically relevant bleeding was defined as overt bleeding not meeting the criteria for an MBE but associated with medical intervention, unscheduled contact with a physician, (temporary) cessation of study treatment, or associated with discomfort such as pain, or impairment of activities of daily life.~Examples of these bleedings were:~Bleeding that compromised haemodynamics~Bleeding that led to hospitalisation~Trivial bleeding events were defined as all other bleeding events that did not fulfil the criteria of MBEs or CRBEs.~All bleeding events include MBEs, CRBEs, and trivial bleeding events." (NCT00558259)
Timeframe: 6 months
| Intervention | participants (Number) | ||
|---|---|---|---|
| MBE | MBE or CRBE | All Bleeding | |
| Dabigatran | 2 | 36 | 72 |
| Placebo | 0 | 12 | 39 |
Number of participants with possible clinically significant abnormalities during the treatment period. (NCT00558259)
Timeframe: 6 months
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| AST increase (N=655, 629) | ALT increase (N=655, 629) | Alkaline phosphatase increase (N=658, 629) | Total bilirubin increase (N=658, 628) | |
| Dabigatran | 2 | 3 | 0 | 1 |
| Placebo | 2 | 5 | 0 | 1 |
Frequency of patients with possible clinically significant abnormalities. (NCT00680186)
Timeframe: From first intake of study drug to last intake of study drug + 6 days washout
| Intervention | participants (Number) | |||||
|---|---|---|---|---|---|---|
| AST increase | AST decrease | ALT increase | ALT decrease | Bilirubin increase | Bilirubin decrease | |
| Dabigatran 150 mg | 29 | 0 | 31 | 0 | 8 | 0 |
| Warfarin | 27 | 0 | 40 | 0 | 6 | 0 |
Any deaths which occured from randomisation to end of ptp. All suspected recurrent VTEs and all deaths and bleeding events were evaluated by an independent central adjudication committee, and all analyses are based on the events that were centrally confirmed by this committee. (NCT00680186)
Timeframe: For statistical analysis 1: from randomisation to 6 months (up to day 180) For statistical analysis 2: from randomisation to end of ptp, planned to be up to day 224.
| Intervention | participants (Number) | |
|---|---|---|
| Participants with event (up to day 180) | Participants with event (up to end of ptp) | |
| Dabigatran 150 mg | 25 | 29 |
| Warfarin | 25 | 26 |
VTE - related deaths which occured from randomisation to end of ptp. All suspected recurrent VTEs and all deaths and bleeding events were evaluated by an independent central adjudication committee, and all analyses are based on the events that were centrally confirmed by this committee. Hazard ratios and 95% CI were not calculated because of insufficient number of events. (NCT00680186)
Timeframe: From randomisation to 6 months (up to day 180) and to end of ptp (planned to be up to day 224)
| Intervention | participants (Number) | |
|---|---|---|
| Participants with event (up to day 180) | Participants with event (up to end of ptp) | |
| Dabigatran 150 mg | 3 | 3 |
| Warfarin | 0 | 0 |
Any ACS occurring during the conduct of the study (centrally adjudicated as definite). Patients having a centrally adjudicated definite ACS during intake of study drug and after stopping study drug, according to treatment group. ACS assessments pre-specified in the protocol without adjudication. Prior to database lock, the steering committee asked to have ACS events adjudicated by an independent committee. After database lock, the committee was provided with source documentation that was blinded to the patient's treatment assignment. ACS results presented are based on adjudication findings. (NCT00680186)
Timeframe: From first intake of study drug to last contact date
| Intervention | participants (Number) | |
|---|---|---|
| During intake of study drug | After stopping study drug | |
| Dabigatran 150 mg | 3 | 2 |
| Warfarin | 0 | 1 |
"Major bleeding events (MBE) are defined as~Fatal bleeding~Symptomatic bleeding in a critical area or organ~Bleeding causing a fall in haemoglobin level of 20 g/L (1.24 mmol/L) or more, or leading to transfusion of 2 or more units of whole blood or red cells~Clinically-relevant bleeding events (CRBE) are defined as~spontaneous skin hematoma >=25 cm²~wound hematoma >=100 cm²~spontaneous nose bleed >5 min~macroscopic hematuria spontaneous or >24 hours if associated with an intervention~spontaneous rectal bleeding~gingival bleeding >5 min~leading to hospitalisation and / or requiring surgical treatment~leading to a transfusion of <2 units of whole blood or red cells~any other bleeding event considered clinically relevant by the investigator~Any bleeding events were defined as major, clinically-relevant and nuisance bleeding events. Nuisance bleeding events were defined as all other bleeding events that did not fulfil the criteria from above." (NCT00680186)
Timeframe: From first intake of study drug to last intake of study drug + 6 days washout
| Intervention | participants (Number) | ||
|---|---|---|---|
| MBE | MBE and/or CRBE | Any bleeding event | |
| Dabigatran 150 mg | 15 | 64 | 200 |
| Warfarin | 22 | 102 | 285 |
Symptomatic DVT which occured from randomisation to end of ptp. All suspected recurrent VTEs and all deaths and bleeding events were evaluated by an independent central adjudication committee, and all analyses are based on the events that were centrally confirmed by this committee. (NCT00680186)
Timeframe: For statistical analysis 1: from randomisation to 6 months (up to day 180) For statistical analysis 2: from randomisation to end of ptp, planned to be up to day 224.
| Intervention | participants (Number) | |
|---|---|---|
| Participants with event (up to day 180) | Participants with event (up to end of ptp) | |
| Dabigatran 150 mg | 25 | 28 |
| Warfarin | 17 | 17 |
Symptomatic fatal and non-fatal PE which occured from randomisation to end of ptp. All suspected recurrent VTEs and all deaths and bleeding events were evaluated by an independent central adjudication committee, and all analyses are based on the events that were centrally confirmed by this committee. (NCT00680186)
Timeframe: For statistical analysis 1: from randomisation to 6 months (up to day 180). For statistical analysis 2: from randomisation to end of ptp, planned to be up to day 224.
| Intervention | participants (Number) | |
|---|---|---|
| Participants with event (up to day 180) | Participants with event (up to end of ptp) | |
| Dabigatran 150 mg | 8 | 10 |
| Warfarin | 13 | 15 |
Symptomatic non-fatal PE which occured from randomisation to end of ptp. All suspected recurrent VTEs and all deaths and bleeding events were evaluated by an independent central adjudication committee, and all analyses are based on the events that were centrally confirmed by this committee. (NCT00680186)
Timeframe: For statistical analysis 1: from randomisation to 6 months (up to day 180). For statistical analysis 2: from randomisation to end of ptp, planned to be up to day 224.
| Intervention | participants (Number) | |
|---|---|---|
| Participants with event (up to day 180) | Participants with event (up to end of ptp) | |
| Dabigatran 150 mg | 7 | 9 |
| Warfarin | 13 | 15 |
All suspected recurrent VTEs and all deaths and bleeding events were evaluated by an independent central adjudication committee, and all analyses are based on the events that were centrally confirmed by this committee. (NCT00680186)
Timeframe: For statistical analysis 1: from randomisation to end of post treatment period (ptp), planned to be up to day 224. For statistical analysis 2: from randomisation to 6 months (up to day 180)
| Intervention | participants (Number) | |
|---|---|---|
| Participants with event (up to day 180) | Participants with event (up to end of ptp) | |
| Dabigatran 150 mg | 30 | 34 |
| Warfarin | 28 | 30 |
VTE or any death which occured from randomisation to end of ptp. All suspected recurrent VTEs and all deaths and bleeding events were evaluated by an independent central adjudication committee, and all analyses are based on the events that were centrally confirmed by this committee. (NCT00680186)
Timeframe: For statistical analysis 1: from randomisation to 6 months (up to day 180) For statistical analysis 2: from randomisation to end of ptp, planned to be up to day 224.
| Intervention | participants (Number) | |
|---|---|---|
| Participants with event (up to day 180) | Participants with event (up to end of ptp) | |
| Dabigatran 150 mg | 51 | 57 |
| Warfarin | 48 | 51 |
Endpoint is a composite of recurrent Venous Thromboembolic Event (VTE) and all cause death. VTE was defined as the composite of symptomatic Deep Vein Thrombosis (DVT) of the leg and Pulmonary embolism (PE). All recurrent VTEs required objective verification by definitive diagnostic evaluation. (NCT00329238)
Timeframe: 18 months
| Intervention | Participants (Number) | |
|---|---|---|
| Number of participants with event | Number of participants with no event | |
| Dabigatran | 36 | 1394 |
| Warfarin | 32 | 1394 |
Endpoint is a composite of recurrent Venous Thromboembolic Event (VTE) and all cause death. VTE was defined as the composite of symptomatic Deep Vein Thrombosis (DVT) of the leg and Pulmonary embolism (PE). All recurrent VTEs required objective verification by definitive diagnostic evaluation. (NCT00329238)
Timeframe: 36 months
| Intervention | Participants (Number) | |
|---|---|---|
| Number of participants with event | Number of participants with no event | |
| Dabigatran | 42 | 1388 |
| Warfarin | 36 | 1390 |
Endpoint is a composite of recurrent Venous Thromboembolic Event (VTE) and death related to VTE. VTE was defined as the composite of symptomatic Deep Vein Thrombosis (DVT) of the leg and Pulmonary embolism (PE). All recurrent VTEs required objective verification by definitive diagnostic evaluation. In case of death, autopsy was an additional way to confirm VTE. (NCT00329238)
Timeframe: 18 months
| Intervention | Participants (Number) | |
|---|---|---|
| Number of participants with event | Number of participants with no event | |
| Dabigatran | 22 | 1408 |
| Warfarin | 17 | 1409 |
Endpoint is a composite of recurrent Venous Thromboembolic Event (VTE) and death related to VTE. VTE was defined as the composite of symptomatic Deep Vein Thrombosis (DVT) of the leg and Pulmonary embolism (PE). All recurrent VTEs required objective verification by definitive diagnostic evaluation. In case of death, autopsy was an additional way to confirm VTE. (NCT00329238)
Timeframe: 36 months
| Intervention | Participants (Number) | |
|---|---|---|
| Number of participants with event | Number of participants with no event | |
| Dabigatran | 26 | 1404 |
| Warfarin | 18 | 1408 |
Deaths of all causes at 18 Months. All components of the primary efficacy endpoint and all deaths were centrally adjudicated by the Independent Central Adjudication Committee for VTE and death without knowledge of any individual treatment assignments. (NCT00329238)
Timeframe: 18 months
| Intervention | Participants (Number) | |
|---|---|---|
| Number of participants with event | Number of participants with no event | |
| Dabigatran | 15 | 1415 |
| Warfarin | 16 | 1410 |
Deaths of all causes at 36 Months. All components of the primary efficacy endpoint and all deaths were centrally adjudicated by the Independent Central Adjudication Committee for VTE and death without knowledge of any individual treatment assignments. (NCT00329238)
Timeframe: 36 months
| Intervention | Participants (Number) | |
|---|---|---|
| Number of participants with event | Number of participants with no event | |
| Dabigatran | 17 | 1413 |
| Warfarin | 19 | 1407 |
Deaths related to VTE (i.e. fatal PE) at 18 Months. All deaths were centrally adjudicated by the Independent Central Adjudication Committee for VTE and death in a treatment-blinded way. (NCT00329238)
Timeframe: 18 months
| Intervention | Participants (Number) | |
|---|---|---|
| Number of participants with event | Number of participants with no event | |
| Dabigatran | 1 | 1429 |
| Warfarin | 1 | 1425 |
Deaths related to VTE (i.e. fatal PE) at 36 Months. Deaths related to VTE (i.e. fatal PE) at 18 Months. All deaths were centrally adjudicated by the Independent Central Adjudication Committee for VTE and death in a treatment-blinded way. (NCT00329238)
Timeframe: 36 months
| Intervention | Participants (Number) | |
|---|---|---|
| Number of participants with event | Number of participants with no event | |
| Dabigatran | 1 | 1429 |
| Warfarin | 1 | 1425 |
Symptomatic Deep vein thrombosis (DVT). All DVT events required objective verification through definitive diagnostic evaluation. (NCT00329238)
Timeframe: 36 months
| Intervention | Participants (Number) | |
|---|---|---|
| Number of participants with event | Number of participants with no event | |
| Dabigatran | 17 | 1413 |
| Warfarin | 13 | 1413 |
Symptomatic Deep vein thrombosis (DVT). All DVT events required objective verification through definitive diagnostic evaluation. (NCT00329238)
Timeframe: 18 months
| Intervention | Participants (Number) | |
|---|---|---|
| Number of participants with event | Number of participants with no event | |
| Dabigatran | 15 | 1415 |
| Warfarin | 12 | 1414 |
Patients with LFT (liver function tests) increases of possible clinical significance during treatment. Increases of possible clinical significance were defined as: ≥3 x ULN (AST, ALT), ≥2 x ULN (AP), and ≥2 mg/dL (total bilirubin). Only patients with a baseline value which was not of possible clinical significance (or without any baseline value) could have a PCSA (Possible clinically significant abnormality). (NCT00329238)
Timeframe: 18 months + 30 days follow up
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| ALT increase | AST increase | Alkaline phosphatase | Total bilirubin | |
| Dabigatran | 26 | 23 | 9 | 9 |
| Warfarin | 30 | 23 | 14 | 8 |
"MBE (major bleeding event) if it fulfilled at least one of the following criteria~Fatal bleeding~Symptomatic bleeding in a critical area or organ.~Bleeding causing a fall in haemoglobin level of 20 g/L (1.24 mmol/L) or more, or leading to transfusion of 2 or more units of whole blood or red cells.~Minor bleeding event was any bleeding that did not fulfil any of the criteria for MBEs~CRBE (clinically relevant bleeding event) if it is a minor bleeding events which fulfilled at least one of the following criteria~Spontaneous skin haematoma ≥25 cm2~Spontaneous nose bleed >5 min duration~Macroscopic haematuria, either spontaneous or, if associated with an intervention, lasting >24 h~Spontaneous rectal bleeding~Gingival bleeding >5 min~Bleeding leading to hospitalisation or requiring surgical treatment~Bleeding leading to a transfusion of <2 units of whole blood or red cells~Any other bleeding event considered clinically relevant by the investigator" (NCT00329238)
Timeframe: first intake of study drug until 6 days following last intake of study drug
| Intervention | participants (Number) | ||
|---|---|---|---|
| patients with MBE | patients with MBE and /or CRBE | patients with any bleeding event | |
| Dabigatran | 13 | 80 | 277 |
| Warfarin | 25 | 145 | 373 |
All suspected ACS occurring during the trial were to be recorded on the CRF and were to be centrally adjudicated by an independent ACS/AC in a treatment-blinded manner. (NCT00329238)
Timeframe: day of first study drug intake until last day of study drug intake; from the day after last intake of study drug until trial termination
| Intervention | participants (Number) | |
|---|---|---|
| During intake of study drug, N=1430 , N=1415 | After stopping study drug, N=1426, N=1400 | |
| Dabigatran | 12 | 1 |
| Warfarin | 2 | 5 |
Symptomatic pulmonary embolism (PE) at 18 Months (fatal or non-fatal). All suspected PEs required confirmation by one of the following: ventilation-perfusion (V-Q) lung scan, pulmonary angiography, or spiral (helical) Computed tomography. (NCT00329238)
Timeframe: 18 months
| Intervention | Participants (Number) | |
|---|---|---|
| Number of participants with event | Number of participants with no event | |
| Dabigatran | 8 | 1422 |
| Warfarin | 5 | 1421 |
Symptomatic pulmonary embolism (PE) at 36 Months (fatal or non-fatal). All suspected PEs required confirmation by one of the following: ventilation-perfusion (V-Q) lung scan, pulmonary angiography, or spiral (helical) Computed tomography. (NCT00329238)
Timeframe: 36 months
| Intervention | Participants (Number) | |
|---|---|---|
| Number of participants with event | Number of participants with no event | |
| Dabigatran | 10 | 1420 |
| Warfarin | 5 | 1421 |
Frequency of patients with possible clinically significant abnormalities. (NCT00291330)
Timeframe: From first intake of study drug to last intake of study drug + 6 days washout (washout time can be reduced until 0 day if the patient takes an other anti-coagulant therapy on and after last intake of active study drug)
| Intervention | participants (Number) | |||||
|---|---|---|---|---|---|---|
| AST increase | AST decrease | ALT increase | ALT decrease | Bilirubin increase | Bilirubin decrease | |
| Dabigatran 150 mg | 21 | 0 | 26 | 0 | 7 | 0 |
| Warfarin | 22 | 0 | 38 | 0 | 13 | 0 |
Any deaths which occured from randomisation to end of post treatment period. All suspected recurrent VTEs and all deaths and bleeding events were evaluated by an independent central adjudication committee, and all analyses are based on the events that were centrally confirmed by this committee. (NCT00291330)
Timeframe: For statistical analysis 1: from randomisation to 6 months (up to day 180) For statistical analysis 2: from randomisation to end of ptp, planned to be up to day 224.
| Intervention | participants (Number) | |
|---|---|---|
| Participants with event (up to day 180) | Participants with event (up to end of ptp) | |
| Dabigatran 150 mg | 21 | 25 |
| Warfarin | 21 | 25 |
"VTE - related deaths which occured from randomisation to end of post treatment period.~All suspected recurrent VTEs and all deaths and bleeding events were evaluated by an independent central adjudication committee, and all analyses are based on the events that were centrally confirmed by this committee." (NCT00291330)
Timeframe: For statistical analysis 1: from randomisation to 6 months (up to day 180) For statistical analysis 2: from randomisation to end of ptp, planned to be up to day 224.
| Intervention | participants (Number) | |
|---|---|---|
| Participants with event (up to day 180) | Participants with event (up to end of ptp) | |
| Dabigatran 150 mg | 1 | 1 |
| Warfarin | 3 | 3 |
"Any ACS occurring during the conduct of the study (centrally adjudicated as definite).~Counts of patients having a centrally adjudicated definite ACS during intake of active study drug, after stopping active study drug and before or without intake of active study drug, according to treatment group.~All suspected recurrent VTEs and all deaths and bleeding events were evaluated by an independent central adjudication committee, and all analyses are based on the events that were centrally confirmed by this committee." (NCT00291330)
Timeframe: From first intake of study drug to end of study conduct
| Intervention | participants (Number) | ||
|---|---|---|---|
| During intake of active study drug | After stopping active study drug | Before/without intake of active study drug | |
| Dabigatran 150 mg | 5 | 4 | 2 |
| Warfarin | 3 | 2 | 0 |
"Major bleeding events (MBE) were defined as~Fatal bleeding~Symptomatic bleeding in a critical area or organ~Bleeding causing a fall in haemoglobin level of 20 g/L (1.24 mmol/L) or more, or leading to transfusion of 2 or more units of whole blood or red cells~Clinically-relevant bleeding events (CRBE) was defined as~spontaneous skin hematoma >=25 cm²~spontaneous nose bleed >5 min~macroscopic hematuria spontaneous or >24 hours if associated with an intervention~spontaneous rectal bleeding (more than spotting on toilet paper)~gingival bleeding >5 min~leading to hospitalisation and / or requiring surgical treatment~leading to a transfusion of <2 units of whole blood or red cells~any other bleeding event considered clinically relevant by the investigator~Any bleeding events were defined as major, clinically-relevant and nuisance bleeding events. Nuisance bleeding events were defined as all other bleeding events that did not fulfil the criteria from above." (NCT00291330)
Timeframe: From first intake of study drug to last intake of study drug + 6 days washout (washout time can be reduced until 0 day if the patient takes an other anti-coagulant therapy on and after last intake of active study drug)
| Intervention | participants (Number) | ||
|---|---|---|---|
| Major bleeding events | MBE and/or CRBE | Any bleeding events | |
| Dabigatran 150 mg | 20 | 71 | 207 |
| Warfarin | 24 | 111 | 280 |
"Symptomatic DVT which occured from randomisation to end of post treatment period.~All suspected recurrent VTEs and all deaths and bleeding events were evaluated by an independent central adjudication committee, and all analyses are based on the events that were centrally confirmed by this committee." (NCT00291330)
Timeframe: For statistical analysis 1: from randomisation to 6 months (up to day 180) For statistical analysis 2: from randomisation to end of ptp, planned to be up to day 224.
| Intervention | participants (Number) | |
|---|---|---|
| Participants with event (up to day 180) | Participants with event (up to end of ptp) | |
| Dabigatran 150 mg | 16 | 17 |
| Warfarin | 18 | 22 |
"Symptomatic non-fatal PE which occured from randomisation to end of post treatment period.~All suspected recurrent VTEs and all deaths and bleeding events were evaluated by an independent central adjudication committee, and all analyses are based on the events that were centrally confirmed by this committee." (NCT00291330)
Timeframe: For statistical analysis 1: from randomisation to 6 months (up to day 180) For statistical analysis 2: from randomisation to end of ptp, planned to be up to day 224.
| Intervention | participants (Number) | |
|---|---|---|
| Participants with event (up to day 180) | Participants with event (up to end of ptp) | |
| Dabigatran 150 mg | 13 | 16 |
| Warfarin | 7 | 8 |
All suspected recurrent VTEs and all deaths and bleeding events were evaluated by an independent central adjudication committee, and all analyses are based on the events that were centrally confirmed by this committee. (NCT00291330)
Timeframe: For statistical analysis 1: from randomisation to end of post treatment period (ptp), planned to be up to day 224. For statistical analysis 2: from randomisation to 6 months (up to day 180)
| Intervention | Participants (Number) | |
|---|---|---|
| Participants with event (up to day 180) | Participants with event (up to end of ptp) | |
| Dabigatran 150 mg | 30 | 34 |
| Warfarin | 27 | 32 |
"VTE or any death which occured from randomisation to end of post treatment period.~All suspected recurrent VTEs and all deaths and bleeding events were evaluated by an independent central adjudication committee, and all analyses are based on the events that were centrally confirmed by this committee." (NCT00291330)
Timeframe: For statistical analysis 1: from randomisation to 6 months (up to day 180) For statistical analysis 2: from randomisation to end of ptp, planned to be up to day 224.
| Intervention | Participants (Number) | |
|---|---|---|
| Participants with event (up to day 180) | Participants with event (up to end of ptp) | |
| Dabigatran 150 mg | 48 | 55 |
| Warfarin | 44 | 53 |
(NCT01428765)
Timeframe: Baseline
| Intervention | participants (Number) | ||
|---|---|---|---|
| <65 years | 65 to <75 years | >= 75 years | |
| All Patients | 382 | 314 | 367 |
(NCT01428765)
Timeframe: Baseline
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| None | Vitamin K Antagonist (VKA) | Acetylsalicylic Acid (ASA) | Antiplatelet agents other than ASA | Other | |
| All Patients | 215 | 349 | 443 | 36 | 20 |
"The CHA2DS2-VASc risk score is based on a point system in which 2 points are assigned for a history of stroke or TIA, or age ≥75; and 1 point each is assigned for age 65-74 years, a hypertension, diabetes, cardiac failure, vascular disease and female sex. On the basis of the risk strata defined in previous guidelines, a CHA2DS2-VASc score of 0 corresponds to low risk, a score of 1 corresponds to intermediate risk, and a score of 2 or more corresponds to high risk." (NCT01428765)
Timeframe: Baseline
| Intervention | participants (Number) | ||
|---|---|---|---|
| Low (Score=0) | Moderate (Score=1) | High (Score >=2) | |
| All Patients | 0 | 226 | 837 |
CHADS2 score is based on a point system in which 2 points are assigned for a history of stroke or transient ischemic attack and 1 point each is assigned for age equal to or greater more than 75 years, hypertension, diabetes, or clinical heart failure or impaired left ventricular systolic function (generally interpreted as an ejection fraction ≤ 40%). (NCT01428765)
Timeframe: Baseline
| Intervention | participants (Number) | ||
|---|---|---|---|
| Low (Score=0) | Moderate (Score=1) | High (Score >=2) | |
| All Patients | 102 | 386 | 575 |
(NCT01428765)
Timeframe: Baseline
| Intervention | participants (Number) | |
|---|---|---|
| Antihypertensive/heart failure and antiarrhythmic | Metabolic and anti-inflammatory therapy | |
| All Patients | 739 | 395 |
(NCT01428765)
Timeframe: Baseline
| Intervention | participants (Number) | |
|---|---|---|
| Female | Male | |
| All Patients | 486 | 577 |
The HAS-BLED score is based on a point system in which 1 point is assigned for hypertension (systolic blood pressure >160 mmHg), 1 point for each of abnormal renal (presence of chronic dialysis or renal transplantation or serum creatinine ≥200 μmol/L) and liver (chronic hepatic disease or biochemical evidence of significant hepatic derangement) function, 1 point each is assigned for stroke, bleeding (previous bleeding history and/or predisposition to bleeding), labile Internation Normalized Ratios (INRs,unstable/high INRs or poor time in therapeutic range), age >65 years and 1 point each for drugs (such as antiplatelet agents, non-steroidal anti-inflammatory drugs) or alcohol. (NCT01428765)
Timeframe: Baseline
| Intervention | participants (Number) | ||
|---|---|---|---|
| Low (Score <3) | High (Score >=3) | Missing | |
| All Patients | 860 | 121 | 82 |
(NCT01428765)
Timeframe: Baseline
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| Previous stroke | Coronary artery disease (CAD) | Congestive heart failure | History of hypertension | Diabetes mellitus | |
| All Patients | 110 | 256 | 256 | 795 | 240 |
Incidence rate of all-cause death on restricted set that included Dabigatran etexilate (DE) and Vitamin K Antagonist (VKA) only. (NCT01671007)
Timeframe: From baseline visit until end of initial treatment regimen episode (minimum date of permanent stop of DE + 3 days/ VKA+ 6 days, start date of other treatments - 1 day, and date of study completion/discontinuation), up to 3 years.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Dabigatran Etexilate - Baseline | 2.08 |
| Vitamin K Antagonist (VKA) - Baseline | 3.27 |
Incidence rate of composite outcome which includes events of Stroke, systemic embolism, myocardial infarction, life-threatening bleeding events and vascular death on restricted set that included Dabigatran etexilate (DE) and Vitamin K Antagonist (VKA) only. In case of multiple events for a patient, the first event was considered. Unknown death was imputed by multiple imputation. The average of the 20 incidence rates from the 20 imputed datasets were used to obtain the point estimate of the incidence rate that is reported here. The bootstrapping approach was used to obtain the 95% confidence interval of the incidence rate. (NCT01671007)
Timeframe: From baseline visit until end of initial treatment regimen episode (minimum date of permanent stop of DE + 3 days/ VKA+ 6 days, start date of other treatments - 1 day, and date of study completion/discontinuation), up to 3 years.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Dabigatran Etexilate - Baseline | 2.30 |
| Vitamin K Antagonist (VKA) - Baseline | 3.02 |
Incidence rate of life-threatening bleeding events on restricted set that included Dabigatran etexilate (DE) and Vitamin K Antagonist (VKA) only. Life-threatening bleeding was defined as meeting one or more of the following criteria: Symptomatic intracranial bleed; Reduction in haemoglobin of at least 50 grams per liter; Transfusion of at least 4 units of blood or packed cells, associated with hypotension requiring the use of intravenous inotropic agents; Necessitated surgical intervention; Fatal bleeding. (NCT01671007)
Timeframe: From baseline visit until end of initial treatment regimen episode (minimum date of permanent stop of DE + 3 days/ VKA+ 6 days, start date of other treatments - 1 day, and date of study completion/discontinuation), up to 3 years.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Dabigatran Etexilate - Baseline | 0.50 |
| Vitamin K Antagonist (VKA) - Baseline | 1.04 |
Incidence rate of major bleeding events on restricted set that included Dabigatran etexilate (DE) and Vitamin K Antagonist (VKA) only. Major bleeding was defined as meeting one or more of the following criteria: Overt bleeding associated with a reduction in haemoglobin of at least 20 grams per liter or leading to a transfusion of at least 2 units of blood or packed cells; Symptomatic bleeding in a critical area or organ: Intraocular, intracranial, intraspinal or intramuscular with compartment syndrome, retroperitoneal bleeding, intra-articular bleeding or pericardial bleeding; Life-threatening bleeding. (NCT01671007)
Timeframe: From baseline visit until end of initial treatment regimen episode (minimum date of permanent stop of DE + 3 days/ VKA+ 6 days, start date of other treatments - 1 day, and date of study completion/discontinuation), up to 3 years.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Dabigatran Etexilate - Baseline | 0.73 |
| Vitamin K Antagonist (VKA) - Baseline | 1.42 |
Incidence rate of myocardial infarction on restricted set that included Dabigatran etexilate (DE) and Vitamin K Antagonist (VKA) only. (NCT01671007)
Timeframe: From baseline visit until end of initial treatment regimen episode (minimum date of permanent stop of DE + 3 days/ VKA+ 6 days, start date of other treatments - 1 day, and date of study completion/discontinuation), up to 3 years.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Dabigatran Etexilate - Baseline | 0.34 |
| Vitamin K Antagonist (VKA) - Baseline | 0.45 |
Incidence rate of pulmonary embolism (PE) on restricted set that included Dabigatran etexilate (DE) and Vitamin K Antagonist (VKA) only. (NCT01671007)
Timeframe: From baseline visit until end of initial treatment regimen episode (minimum date of permanent stop of DE + 3 days/ VKA+ 6 days, start date of other treatments - 1 day, and date of study completion/discontinuation), up to 3 years.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Dabigatran Etexilate - Baseline | 0.09 |
| Vitamin K Antagonist (VKA) - Baseline | 0.06 |
Incidence rate of stroke on restricted set that included Dabigatran etexilate (DE) and Vitamin K Antagonist (VKA) only. Stroke is an acute onset of a focal neurological deficit of presumed vascular origin lasting for 24 hours or more or resulting in death. The stroke included ischemic or hemorrhagic or uncertain classification. (NCT01671007)
Timeframe: From baseline visit until end of initial treatment regimen episode (minimum date of permanent stop of DE + 3 days/ VKA+ 6 days, start date of other treatments - 1 day, and date of study completion/discontinuation), up to 3 years.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Dabigatran Etexilate - Baseline | 0.64 |
| Vitamin K Antagonist (VKA) - Baseline | 0.96 |
Incidence rate of stroke or systemic embolism on restricted set that included Dabigatran etexilate (DE) and Vitamin K Antagonist (VKA) only. (NCT01671007)
Timeframe: From baseline visit until end of initial treatment regimen episode (minimum date of permanent stop of DE + 3 days/ VKA+ 6 days, start date of other treatments - 1 day, and date of study completion/discontinuation), up to 3 years.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Dabigatran Etexilate - Baseline | 0.69 |
| Vitamin K Antagonist (VKA) - Baseline | 1.01 |
Incidence rate of systemic embolism (SEE) on restricted set that included Dabigatran etexilate (DE) and Vitamin K Antagonist (VKA) only. (NCT01671007)
Timeframe: From baseline visit until end of initial treatment regimen episode (minimum date of permanent stop of DE + 3 days/ VKA+ 6 days, start date of other treatments - 1 day, and date of study completion/discontinuation), up to 3 years.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Dabigatran Etexilate - Baseline | 0.07 |
| Vitamin K Antagonist (VKA) - Baseline | 0.06 |
Incidence rate of transient ischaemic attack (TIA) on restricted set that included Dabigatran etexilate (DE) and Vitamin K Antagonist (VKA) only. (NCT01671007)
Timeframe: From baseline visit until end of initial treatment regimen episode (minimum date of permanent stop of DE + 3 days/ VKA+ 6 days, start date of other treatments - 1 day, and date of study completion/discontinuation), up to 3 years.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Dabigatran Etexilate - Baseline | 0.30 |
| Vitamin K Antagonist (VKA) - Baseline | 0.26 |
Incidence rate of vascular composite outcome including events of stroke, systemic embolism, myocardial infarction and vascular death on restricted set that included Dabigatran etexilate (DE) and Vitamin K Antagonist (VKA) only. In case of multiple events for a patient, the first event was considered. Unknown death was imputed by multiple imputation. The average of the 20 incidence rates from the 20 imputed datasets were used to obtain the point estimate of the incidence rate that is reported here. The bootstrapping approach was used to obtain the 95% confidence interval of the incidence rate. (NCT01671007)
Timeframe: From baseline visit until end of initial treatment regimen episode (minimum date of permanent stop of DE + 3 days/ VKA+ 6 days, start date of other treatments - 1 day, and date of study completion/discontinuation), up to 3 years.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Dabigatran Etexilate - Baseline | 1.91 |
| Vitamin K Antagonist (VKA) - Baseline | 2.36 |
Incidence rate of vascular death on restricted set that included Dabigatran etexilate (DE) and Vitamin K Antagonist (VKA) only. (NCT01671007)
Timeframe: From baseline visit until end of initial treatment regimen episode (minimum date of permanent stop of DE + 3 days/ VKA+ 6 days, start date of other treatments - 1 day, and date of study completion/discontinuation), up to 3 years.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Dabigatran Etexilate - Baseline | 0.76 |
| Vitamin K Antagonist (VKA) - Baseline | 1.00 |
Incidence rate of all-cause death on all eligible patients excluding prescribed but not taken set that included Dabigatran etexilate (DE) of phase II only is presented. (NCT01468701)
Timeframe: From baseline visit of Phase II until end of initial treatment regimen episode (minimum date of permanent stop of DE + 3 days, start date of other treatments - 1 day, and date of study completion/discontinuation), up to 2 years.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Dabigatran Etexilate - Baseline (Phase II) | 2.48 |
Incidence rate of all-cause death on restricted set that included Dabigatran etexilate (DE) of phase III and Vitamin K Antagonist (VKA) of phase III only. (NCT01468701)
Timeframe: From baseline visit of phase III until end of initial treatment regimen episode (minimum date of permanent stop of DE + 3 days/ VKA+ 6 days, start date of other treatments - 1 day, and date of study completion/discontinuation), up to 3 years.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Dabigatran Etexilate - Baseline (Phase III) | 2.16 |
| Vitamin K Antagonist (VKA) - Baseline (Phase III) | 3.57 |
Incidence rate of composite outcome which includes events of Stroke, systemic embolism, myocardial infarction, life-threatening bleeding events and vascular death on all eligible patients excluding prescribed but not taken set that included Dabigatran etexilate (DE) of phase II only. In case of multiple events for a patient, the first event was considered. (NCT01468701)
Timeframe: From baseline visit of Phase II until end of initial treatment regimen episode (minimum date of permanent stop of DE + 3 days, start date of other treatments - 1 day, and date of study completion/discontinuation), up to 2 years.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Dabigatran Etexilate - Baseline (Phase II) | 2.06 |
Incidence rate of composite outcome which includes events of Stroke, systemic embolism, myocardial infarction, life-threatening bleeding events and vascular death on restricted set that included Dabigatran etexilate (DE) of phase III and Vitamin K Antagonist (VKA) of phase III only. In case of multiple events for a patient, the first event was considered. Unknown cause of death was imputed by multiple imputation. Counts were based on the average of the 20 restricted data sets. The average of the 20 incidence rates from the 20 imputed datasets were used to obtain the point estimate of the incidence rate that is reported here. The bootstrapping approach was used to obtain the 95% confidence interval of the incidence rate. (NCT01468701)
Timeframe: From baseline visit of phase III until end of initial treatment regimen episode (minimum date of permanent stop of DE + 3 days/ VKA+ 6 days, start date of other treatments - 1 day, and date of study completion/discontinuation), up to 3 years.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Dabigatran Etexilate - Baseline (Phase III) | 2.21 |
| Vitamin K Antagonist (VKA) - Baseline (Phase III) | 3.23 |
Incidence rate of life-threatening bleeding events on all eligible patients excluding prescribed but not taken set that included Dabigatran etexilate (DE) of phase II only is presented. Life-threatening bleeding was defined as meeting one or more of the following criteria: Symptomatic intracranial bleed; Reduction in haemoglobin of at least 50 grams per liter; Transfusion of at least 4 units of blood or packed cells, associated with hypotension requiring the use of intravenous inotropic agents; Necessitated surgical intervention; Fatal bleeding. (NCT01468701)
Timeframe: From baseline visit of Phase II until end of initial treatment regimen episode (minimum date of permanent stop of DE + 3 days, start date of other treatments - 1 day, and date of study completion/discontinuation), up to 2 years.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Dabigatran Etexilate - Baseline (Phase II) | 0.46 |
Incidence rate of life-threatening bleeding events on restricted set that included Dabigatran etexilate (DE) of phase III and Vitamin K Antagonist (VKA) of phase III only. Life-threatening bleeding was defined as meeting one or more of the following criteria: Symptomatic intracranial bleed; Reduction in haemoglobin of at least 50 grams per liter; Transfusion of at least 4 units of blood or packed cells, associated with hypotension requiring the use of intravenous inotropic agents; Necessitated surgical intervention; Fatal bleeding. (NCT01468701)
Timeframe: From baseline visit of phase III until end of initial treatment regimen episode (minimum date of permanent stop of DE + 3 days/ VKA+ 6 days, start date of other treatments - 1 day, and date of study completion/discontinuation), up to 3 years.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Dabigatran Etexilate - Baseline (Phase III) | 0.47 |
| Vitamin K Antagonist (VKA) - Baseline (Phase III) | 1.07 |
Incidence rate of major bleeding events (MBE) on all eligible patients excluding prescribed but not taken set that included Dabigatran etexilate (DE) of phase II only is presented. Major bleeding was defined as meeting one or more of the following criteria: Overt bleeding associated with a reduction in haemoglobin of at least 20 grams per liter or leading to a transfusion of at least 2 units of blood or packed cells; Symptomatic bleeding in a critical area or organ: Intraocular, intracranial, intraspinal or intramuscular with compartment syndrome, retroperitoneal bleeding, intra-articular bleeding or pericardial bleeding; Life-threatening bleeding. (NCT01468701)
Timeframe: From baseline visit of Phase II until end of initial treatment regimen episode (minimum date of permanent stop of DE + 3 days, start date of other treatments - 1 day, and date of study completion/discontinuation), up to 2 years.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Dabigatran Etexilate - Baseline (Phase II) | 0.97 |
Incidence rate of major bleeding events on restricted set that included Dabigatran etexilate (DE) of phase III and Vitamin K Antagonist (VKA) of phase III only. Major bleeding was defined as meeting one or more of the following criteria: Overt bleeding associated with a reduction in haemoglobin of at least 20 grams per liter or leading to a transfusion of at least 2 units of blood or packed cells; Symptomatic bleeding in a critical area or organ: Intraocular, intracranial, intraspinal or intramuscular with compartment syndrome, retroperitoneal bleeding, intra-articular bleeding or pericardial bleeding; Life-threatening bleeding. (NCT01468701)
Timeframe: From baseline visit of phase III until end of initial treatment regimen episode (minimum date of permanent stop of DE + 3 days/ VKA+ 6 days, start date of other treatments - 1 day, and date of study completion/discontinuation), up to 3 years.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Dabigatran Etexilate - Baseline (Phase III) | 0.69 |
| Vitamin K Antagonist (VKA) - Baseline (Phase III) | 1.44 |
Incidence rate of myocardial infarction (MI) on all eligible patients excluding prescribed but not taken set that included Dabigatran etexilate (DE) of phase II only is presented. (NCT01468701)
Timeframe: From baseline visit of Phase II until end of initial treatment regimen episode (minimum date of permanent stop of DE + 3 days, start date of other treatments - 1 day, and date of study completion/discontinuation), up to 2 years.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Dabigatran Etexilate - Baseline (Phase II) | 0.50 |
Incidence rate of myocardial infarction on restricted set that included Dabigatran etexilate (DE) of phase III and Vitamin K Antagonist (VKA) of phase III only. (NCT01468701)
Timeframe: From baseline visit of phase III until end of initial treatment regimen episode (minimum date of permanent stop of DE + 3 days/ VKA+ 6 days, start date of other treatments - 1 day, and date of study completion/discontinuation), up to 3 years.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Dabigatran Etexilate - Baseline (Phase III) | 0.40 |
| Vitamin K Antagonist (VKA) - Baseline (Phase III) | 0.53 |
Incidence rate of pulmonary embolism (PE) on all eligible patients excluding prescribed but not taken set that included Dabigatran etexilate (DE) of phase II only is presented. (NCT01468701)
Timeframe: From baseline visit of Phase II until end of initial treatment regimen episode (minimum date of permanent stop of DE + 3 days, start date of other treatments - 1 day, and date of study completion/discontinuation), up to 2 years.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Dabigatran Etexilate - Baseline (Phase II) | 0.07 |
Incidence rate of pulmonary embolism (PE) on restricted set that included Dabigatran etexilate (DE) of phase III and Vitamin K Antagonist (VKA) of phase III only. (NCT01468701)
Timeframe: From baseline visit of phase III until end of initial treatment regimen episode (minimum date of permanent stop of DE + 3 days/ VKA+ 6 days, start date of other treatments - 1 day, and date of study completion/discontinuation), up to 3 years.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Dabigatran Etexilate - Baseline (Phase III) | 0.07 |
| Vitamin K Antagonist (VKA) - Baseline (Phase III) | 0.06 |
Incidence rate of stroke on all eligible patients excluding prescribed but not taken set for Dabigatran etexilate (DE) of phase II only is presented. Stroke is an acute onset of a focal neurological deficit of presumed vascular origin lasting for 24 hours or more or resulting in death. The stroke included ischemic or hemorrhagic or uncertain classification. (NCT01468701)
Timeframe: From baseline visit of Phase II until end of initial treatment regimen episode (minimum date of permanent stop of DE + 3 days, start date of other treatments - 1 day, and date of study completion/discontinuation), up to 2 years.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Dabigatran Etexilate - Baseline (Phase II) | 0.65 |
Incidence rate of stroke on restricted set that included Dabigatran etexilate (DE) of phase III and Vitamin K Antagonist (VKA) of phase III only. Stroke is an acute onset of a focal neurological deficit of presumed vascular origin lasting for 24 hours or more or resulting in death. The stroke included ischemic or hemorrhagic or uncertain classification. (NCT01468701)
Timeframe: From baseline visit of phase III until end of initial treatment regimen episode (minimum date of permanent stop of DE + 3 days/ VKA+ 6 days, start date of other treatments - 1 day, and date of study completion/discontinuation), up to 3 years.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Dabigatran Etexilate - Baseline (Phase III) | 0.77 |
| Vitamin K Antagonist (VKA) - Baseline (Phase III) | 0.96 |
Incidence rate of stroke or systemic embolism on restricted set that included Dabigatran etexilate (DE) of phase III and Vitamin K Antagonist (VKA) of phase III only. (NCT01468701)
Timeframe: From baseline visit of phase III until end of initial treatment regimen episode (minimum date of permanent stop of DE + 3 days/ VKA+ 6 days, start date of other treatments - 1 day, and date of study completion/discontinuation), up to 3 years.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Dabigatran Etexilate - Baseline (Phase III) | 0.80 |
| Vitamin K Antagonist (VKA) - Baseline (Phase III) | 1.00 |
Incidence rate of systemic embolism (SE) on all eligible patients excluding prescribed but not taken set that included Dabigatran etexilate (DE) of phase II only is presented. (NCT01468701)
Timeframe: From baseline visit of Phase II until end of initial treatment regimen episode (minimum date of permanent stop of DE + 3 days, start date of other treatments - 1 day, and date of study completion/discontinuation), up to 2 years.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Dabigatran Etexilate - Baseline (Phase II) | 0.04 |
Incidence rate of systemic embolism (SE) on restricted set that included Dabigatran etexilate (DE) of phase III and Vitamin K Antagonist (VKA) of phase III only. (NCT01468701)
Timeframe: From baseline visit of phase III until end of initial treatment regimen episode (minimum date of permanent stop of DE + 3 days/ VKA+ 6 days, start date of other treatments - 1 day, and date of study completion/discontinuation), up to 3 years.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Dabigatran Etexilate - Baseline (Phase III) | 0.04 |
| Vitamin K Antagonist (VKA) - Baseline (Phase III) | 0.05 |
Incidence rate of transient ischaemic attack (TIA) on on all eligible patients excluding prescribed but not taken set that included Dabigatran etexilate (DE) of phase II only is presented. (NCT01468701)
Timeframe: From baseline visit of Phase II until end of initial treatment regimen episode (minimum date of permanent stop of DE + 3 days, start date of other treatments - 1 day, and date of study completion/discontinuation), up to 2 years.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Dabigatran Etexilate - Baseline (Phase II) | 0.21 |
Incidence rate of transient ischaemic attack (TIA) on restricted set that included Dabigatran etexilate (DE) of phase III and Vitamin K Antagonist (VKA) of phase III only. (NCT01468701)
Timeframe: From baseline visit of phase III until end of initial treatment regimen episode (minimum date of permanent stop of DE + 3 days/ VKA+ 6 days, start date of other treatments - 1 day, and date of study completion/discontinuation), up to 3 years.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Dabigatran Etexilate - Baseline (Phase III) | 0.29 |
| Vitamin K Antagonist (VKA) - Baseline (Phase III) | 0.32 |
Incidence rate of vascular composite outcome including events of stroke, systemic embolism, myocardial infarction and vascular death on all eligible patients excluding prescribed but not taken set that included Dabigatran etexilate (DE) of phase II only. In case of multiple events for a patient, the first event was considered. (NCT01468701)
Timeframe: From baseline visit of Phase II until end of initial treatment regimen episode (minimum date of permanent stop of DE + 3 days, start date of other treatments - 1 day, and date of study completion/discontinuation), up to 2 years.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Dabigatran Etexilate - Baseline (Phase II) | 1.74 |
Incidence rate of vascular composite outcome including events of stroke, systemic embolism, myocardial infarction and vascular death on restricted set that included Dabigatran etexilate (DE) of phase III and Vitamin K Antagonist (VKA) of phase III only. In case of multiple events for a patient, the first event was considered. Unknown death was imputed by multiple imputation. Counts were based on the average of the 20 restricted data sets. The average of the 20 incidence rates from the 20 imputed datasets were used to obtain the point estimate of the incidence rate that is reported here. The bootstrapping approach was used to obtain the 95% confidence interval of the incidence rate. (NCT01468701)
Timeframe: From baseline visit of phase III until end of initial treatment regimen episode (minimum date of permanent stop of DE + 3 days/ VKA+ 6 days, start date of other treatments - 1 day, and date of study completion/discontinuation), up to 3 years.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Dabigatran Etexilate - Baseline (Phase III) | 1.91 |
| Vitamin K Antagonist (VKA) - Baseline (Phase III) | 2.62 |
Incidence rate of vascular death on all eligible patients excluding prescribed but not taken set that included Dabigatran etexilate (DE) of phase II only is presented. (NCT01468701)
Timeframe: From baseline visit of Phase II until end of initial treatment regimen episode (minimum date of permanent stop of DE + 3 days, start date of other treatments - 1 day, and date of study completion/discontinuation), up to 2 years.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Dabigatran Etexilate - Baseline (Phase II) | 0.85 |
Incidence rate of vascular death on restricted set that included Dabigatran etexilate (DE) of phase III and Vitamin K Antagonist (VKA) of phase III only. (NCT01468701)
Timeframe: From baseline visit of phase III until end of initial treatment regimen episode (minimum date of permanent stop of DE + 3 days/ VKA+ 6 days, start date of other treatments - 1 day, and date of study completion/discontinuation), up to 3 years.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Dabigatran Etexilate - Baseline (Phase III) | 0.75 |
| Vitamin K Antagonist (VKA) - Baseline (Phase III) | 1.26 |
The investigators will calculate the # of gap days between refills for dabigatran/rivaroxaban/apixaban for each3 and 6 months of the pilot intervention. This will be based on pharmacy refill data and calculated using the date dabigatran/rivaroxaban/apixaban was dispensed and the # of days supplied for that prescription. We will add the # of gap days for each 3 and 6 months of the pilot for each patient, and compare the total # of gaps days between intervention and usual care patients. The gap days between refills is a validated measure of adherence and identifies patients with sub-optimal adherence.A negative gap day value indicates that participants received the refill prior to completion of the previous prescription. (NCT01578044)
Timeframe: 3 and 6 months
| Intervention | days (Number) | |
|---|---|---|
| # of Patient gap days for 3-months of intervention | # of Patient gap days for 6-months of intervention | |
| Intervention Group | 43 | 41 |
| Usual Care Group | 51 | -5 |
Evaluate the pharmacokinetics of apixaban in ESRD NVAF patients on hemodialysis. The measurement was done from 0-12 hours after the dose was given on Day 1. (NCT02942407)
Timeframe: 0-12 hours post-dose
| Intervention | ng/mL (Geometric Mean) |
|---|---|
| Apixaban 2.5 mg | 59.7 |
| Apixaban 5 mg | 97.9 |
Evaluate the pharmacokinetics of apixaban in ESRD NVAF patients on hemodialysis. The measurement was done from 0-12 hours after the dose was given on Day 1. (NCT02942407)
Timeframe: 0-12 hours post-dose
| Intervention | ng/mL (Geometric Mean) |
|---|---|
| Apixaban 2.5 mg | 28.2 |
| Apixaban 5mg | 49.7 |
Evaluate the pharmacokinetics of apixaban in ESRD NVAF patients on hemodialysis. The measurement was done from 0 to 12 hours after dose was given on Day 1. (NCT02942407)
Timeframe: 0-12 hours post-dose
| Intervention | ng*h/mL (Geometric Mean) |
|---|---|
| Apixaban 2.5 mg | 507 |
| Apixaban 5mg | 868 |
"Assess the safety of apixaban versus warfarin regarding ISTH major bleeding or clinically relevant non-major bleeding events in patients with NVAF (nonvalvular atrial fibrillation) and ESRD (end-stage renal disease) on hemodialysis.~Major bleeding event is defined as:Acute clinically overt bleeding (including access site related bleeding) accompanied by 1 or more of the following: Decrease in Hgb of 2g/dL or more with overt bleeding; Transfusion of 2 or more units of packed RBCs in the setting of an overt bleeding event; Bleeding within a critical site. Hemorrhagic stroke (primary or infarction with hemorrhagic conversion) were classified as major bleeds.~Non-major bleeding event is defined as: Acute or sub-acute clinically overt bleeding (including access site related bleeding) that does not meet criteria for major bleeding & results in Hospital admission for bleeding, physician guided medical or surgical treatment for bleeding, or change in antithrombotic therapy" (NCT02942407)
Timeframe: Randomization up to Month 15/Final Visit
| Intervention | Participants (Count of Participants) |
|---|---|
| Apixaban | 21 |
| Warfarin | 16 |
Evaluate mortality rates for those participants randomized to warfarin and apixaban in patients with NVAF and ESRD on hemodialysis (NCT02942407)
Timeframe: Randomization up to Month 15/Final Visit
| Intervention | Participants (Count of Participants) |
|---|---|
| Apixaban | 21 |
| Warfarin | 13 |
"Adjudcated stroke defined as a new, non-traumatic episode of focal or global neurological dysfunction of sudden onset caused by central nervous system (CNS) vascular injury as a result of hemorrhage or infarction and not due to a readily identifiable non-vascular cause (i.e. brain tumor). CNS includes brain, spinal cord and retina. The required duration of the deficit is ≥ 24 hours.~Events with neurologic deficit lasting for < 24 hours and an imaging modality showing evidence of an acute stroke will be counted as stroke as well.~A retinal ischemic event (embolism, infarction) will be considered a stroke" (NCT02942407)
Timeframe: Randomization up to Month 15/Final Visit
| Intervention | Participants (Count of Participants) |
|---|---|
| Apixaban | 2 |
| Warfarin | 2 |
Number of participants experiencing adjudicated stroke or systemic embolism. (NCT02942407)
Timeframe: Randomization up to Month 15/Final Visit
| Intervention | Participants (Count of Participants) |
|---|---|
| Apixaban | 2 |
| Warfarin | 2 |
"Evaluate those experiencing stroke, systemic embolism, ISTH major bleeding, or all-cause mortality for those randomized to warfarin and apixaban in patients with NVAF and ESRD on hemodialysis~Definitions of stroke and systemic embolism are provided under the measurement description of the secondary outcomes for each individual event. Definition of major bleed is provided in outcome measurement description of the primary outcome measure." (NCT02942407)
Timeframe: Randomization up to Month 15/Final Visit
| Intervention | Participants (Count of Participants) |
|---|---|
| Apixaban | 27 |
| Warfarin | 29 |
"Adjudicated diagnosis of systemic arterial embolism (Non-pulmonary, non-cranial events) will require a positive clinical history consistent with an acute loss of blood flow to a peripheral artery (or arteries), which is supported by evidence of embolism/thrombosis from surgical specimens, autopsy, angiography, vascular imaging, or other objective testing.~Clinical presentation would include:~Abrupt development of pain, absent pulses, pallor, and/or paresis in an extremity (at least an entire digit) without previous severe claudication or findings of severe peripheral vascular disease.~Renal embolism will be diagnosed when sudden flank pain or a change in renal laboratory findings occurred.~Abdominal vascular/visceral embolism was considered definite if acute abdominal symptoms or referred symptoms developed along with a change in abdominal examination or appropriate laboratory values." (NCT02942407)
Timeframe: Randomization up to Month 15/Final Visit
| Intervention | Participants (Count of Participants) |
|---|---|
| Apixaban | 0 |
| Warfarin | 0 |
Evaluate days between time from initiation to discontinuation of randomized therapy. (NCT02942407)
Timeframe: Randomization up to Month 15/Final Visit
| Intervention | Days (Mean) |
|---|---|
| Apixaban | 304.4 |
| Warfarin | 279.6 |
165 reviews available for beta-alanine and Atrial Fibrillation
| Article | Year |
|---|---|
New anticoagulants in atrial fibrillation management.
Topics: Administration, Oral; Age Factors; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-A | 2013 |
Novel oral anticoagulants for stroke prevention in patients with atrial fibrillation.
Topics: Administration, Oral; Aging; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; bet | 2013 |
A new era of oral anticoagulation in atrial fibrillation: implications in clinical practice.
Topics: Administration, Oral; Adult; Age Distribution; Aged; Aged, 80 and over; Anticoagulants; Antithrombin | 2013 |
[The role of internal medicine in preventing stroke in atrial fibrillation].
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatr | 2012 |
[Advances in the secondary prevention of cardioembolic stroke].
Topics: Anticoagulants; Atrial Appendage; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Contraindicatio | 2012 |
Risk versus benefit of non-vitamin K dependent anticoagulants compared to warfarin for the management of atrial fibrillation in the elderly.
Topics: Aged; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Interactions; Fibrinolytic | 2013 |
[Improvements in oral anticoagulant therapy for atrial fibrillation].
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Azetidines; Benzimidazoles; Benzylamines; | 2013 |
Dabigatran for the prevention of stroke and systemic embolism in atrial fibrillation: A NICE single technology appraisal.
Topics: Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost-Benefit Analysis; Dabigatran; | 2013 |
Potential impact of new oral anticoagulants on the management of atrial fibrillation-related stroke in primary care.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clini | 2013 |
Is dabigatran considered a cost-effective alternative to warfarin treatment: a review of current economic evaluations worldwide.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost-Benefit Analysis; Dabigatran | 2013 |
[Direct oral thrombin inhibitor, "dabigatran"].
Topics: Administration, Oral; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; | 2013 |
Preventing stroke and systemic embolism in renal patients with atrial fibrillation: focus on anticoagulation.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; C | 2013 |
Traumatic intracranial hemorrhage in patients taking dabigatran: report of 3 cases and review of the literature.
Topics: Accidental Falls; Aged; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Craniocere | 2013 |
Gastrointestinal bleeding with the new oral anticoagulants--defining the issues and the management strategies.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; | 2013 |
Dabigatran, ROCKET atrial fibrillation, and beyond: basic science, mechanisms of agents, monitoring, and reversal.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Coagulation | 2013 |
[Electrical cardioversion for non-valvular atrial fibrillation--underestimated risk for thromboembolic complications?].
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Administration S | 2013 |
Importance of pharmacokinetic profile and variability as determinants of dose and response to dabigatran, rivaroxaban, and apixaban.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Biological | 2013 |
Stroke prevention in atrial fibrillation patients with chronic kidney disease.
Topics: Administration, Oral; Age Factors; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine | 2013 |
Cost-effectiveness of new oral anticoagulants compared with warfarin in preventing stroke and other cardiovascular events in patients with atrial fibrillation.
Topics: Administration, Oral; Age Factors; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Ben | 2013 |
Novel oral anticoagulants and stroke prevention in atrial fibrillation and chronic heart failure.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Chronic Disease; Dabigatran; Drug | 2014 |
Alternatives to warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a look back at the state of the field in 2012.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; | 2013 |
New alternative anticoagulants in atrial fibrillation: the move beyond warfarin.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; | 2013 |
What are the new therapeutic alternatives to warfarin in atrial fibrillation?
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; | 2013 |
Mixed treatment comparison meta-analysis of aspirin, warfarin, and new anticoagulants for stroke prevention in patients with nonvalvular atrial fibrillation.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Data Interpr | 2013 |
Safety and efficacy of dabigatran versus warfarin in patients undergoing catheter ablation of atrial fibrillation: a systematic review and meta-analysis.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation; | 2014 |
Dabigatran for periprocedural anticoagulation following radiofrequency ablation for atrial fibrillation: a meta-analysis of observational studies.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation; | 2013 |
New anticoagulants (dabigatran, apixaban, rivaroxaban) for stroke prevention in atrial fibrillation.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabig | 2013 |
[Effective, safe stroke prevention with novel oral anticoagulants in patients with atrial fibrillation. Focus on dabigatran].
Topics: Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alani | 2013 |
Novel oral anticoagulants: a review of new agents.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Administration S | 2013 |
Novel oral anticoagulants in non-valvular atrial fibrillation.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clini | 2013 |
Novel oral anticoagulants in secondary prevention of stroke.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabig | 2013 |
Safety and efficacy of dabigatran compared with warfarin for patients undergoing radiofrequency catheter ablation of atrial fibrillation: a meta-analysis.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation; | 2013 |
Cost-effectiveness of pharmacogenetics-guided warfarin therapy vs. alternative anticoagulation in atrial fibrillation.
Topics: Algorithms; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost-Benefit Analysis | 2014 |
Meta-analysis of randomized controlled trials on risk of myocardial infarction from the use of oral direct thrombin inhibitors.
Topics: Amidines; Anticoagulants; Antithrombins; Atrial Fibrillation; Azetidines; Benzimidazoles; Benzylamin | 2013 |
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al | 2013 |
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al | 2013 |
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al | 2013 |
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al | 2013 |
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al | 2013 |
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al | 2013 |
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al | 2013 |
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al | 2013 |
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al | 2013 |
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al | 2013 |
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al | 2013 |
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al | 2013 |
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al | 2013 |
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al | 2013 |
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al | 2013 |
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al | 2013 |
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al | 2013 |
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al | 2013 |
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al | 2013 |
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al | 2013 |
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al | 2013 |
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al | 2013 |
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al | 2013 |
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al | 2013 |
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al | 2013 |
New oral anticoagulants--a review.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; | 2013 |
Anticoagulation management in nonvalvular atrial fibrillation: current and future directions.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ab | 2013 |
An updated review of target-specific oral anticoagulants used in stroke prevention in atrial fibrillation, venous thromboembolic disease, and acute coronary syndromes.
Topics: Acute Coronary Syndrome; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatr | 2013 |
Outpatient management of oral anticoagulation in atrial fibrillation.
Topics: Ambulatory Care; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Fact | 2013 |
[Evidence of novel oral anticoagulants (NOAC)].
Topics: Administration, Ophthalmic; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta | 2013 |
Non-vitamin K antagonist oral anticoagulants in cardiovascular disease management: evidence and unanswered questions.
Topics: Administration, Oral; Animals; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Ca | 2014 |
{blacktriangledown} Apixaban and {blacktriangledown} rivaroxaban for stroke prevention in AF.
Topics: Adult; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Embolism; Fact | 2014 |
[New anticoagulants in patients with atrial fibrillation].
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Brain Infarction; Dabigatran; Hum | 2013 |
Meta-analysis of randomized controlled trials on the risk of bleeding with dabigatran.
Topics: Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Global Health; Hemorrh | 2014 |
New oral anticoagulants in practice: pharmacological and practical considerations.
Topics: Administration, Oral; Aging; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Comp | 2014 |
[Novel oral anticoagulants and atrial fibrillation in the elderly].
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; | 2013 |
Is there a role for novel oral anticoagulants in patients with an acute coronary syndrome? A review of the clinical trials.
Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; | 2013 |
Increased risk of myocardial infarction with dabigatran: fact or fiction?
Topics: Acute Coronary Syndrome; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatra | 2014 |
Meta-analysis of risk of stroke or transient ischemic attack with dabigatran for atrial fibrillation ablation.
Topics: Administration, Oral; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation; Dabigatr | 2014 |
Management of antiplatelet and anticoagulant therapy in patients with atrial fibrillation in the setting of acute coronary syndromes or percutaneous coronary interventions.
Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzi | 2014 |
New oral anticoagulants for stroke prevention in atrial fibrillation: impact of study design, double counting and unexpected findings on interpretation of study results and conclusions.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Tr | 2014 |
Practical aspects of new oral anticoagulant use in atrial fibrillation.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; | 2014 |
Dabigatran for stroke prevention in nonvalvular atrial fibrillation: focus in the geriatric population.
Topics: Aged; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Interaction | 2014 |
Risk of major bleeding and the standard doses of dabigatran.
Topics: Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; Ra | 2014 |
Direct thrombin inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in people with non-valvular atrial fibrillation.
Topics: Amidines; Antithrombins; Atrial Fibrillation; Azetidines; Benzimidazoles; Benzylamines; beta-Alanine | 2014 |
Benefit-risk assessment of dabigatran in the treatment of stroke prevention in non-valvular atrial fibrillation.
Topics: Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Risk Assessmen | 2014 |
[Successful thrombolysis without hemorrhage in a patient with cardioembolic stroke under dabigatran treatment-a case report and review of literature].
Topics: Aged; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Diffusion Magnet | 2014 |
The newer direct oral anticoagulants: a practical guide.
Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; | 2014 |
Anticoagulation in atrial fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; M | 2014 |
Anticoagulation in atrial fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; M | 2014 |
Anticoagulation in atrial fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; M | 2014 |
Anticoagulation in atrial fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; M | 2014 |
Anticoagulation: a GP primer on the new oral anticoagulants.
Topics: Anticoagulants; Antithrombins; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Atri | 2014 |
Management of anticoagulation around pacemaker and defibrillator surgery.
Topics: Aged; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; | 2014 |
Primary prevention of ischaemic stroke in atrial fibrillation: new oral anticoagulant drugs for all?
Topics: Administration, Oral; Age Factors; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine | 2014 |
[Dabigatran in the prevention of stroke in nonvalvular atrial fibrillation: complex clinical situations and real clinical practice].
Topics: Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Coagulation; Dabigatran; Hum | 2014 |
Stroke prevention in atrial fibrillation: established oral anticoagulants versus novel anticoagulants-translating clinical trial data into practice.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alani | 2014 |
[Dabigatran in prevention of stroke in atrial fibrillation: three years of clinical application].
Topics: Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Stroke | 2014 |
[Gastrointestinal bleeding under treatment with new oral anticoagulants].
Topics: Administration, Oral; Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacemen | 2014 |
Meta-analysis of efficacy and safety of rivaroxaban compared with warfarin or dabigatran in patients undergoing catheter ablation for atrial fibrillation.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation; | 2014 |
NOAC and intracerebral bleeding--presentation of four cases and review of the literature.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cerebral Hemorrhage; Dabiga | 2014 |
[Update on current care guideline: atrial fibrillation].
Topics: Administration, Oral; Anti-Arrhythmia Agents; Anticoagulants; Antithrombins; Atrial Fibrillation; Be | 2014 |
[Treatment of very old patients with non valvular atrial fibrillation. The valuable opportunity offered by new oral anticoagulants, to be cautiously used].
Topics: Administration, Oral; Age Factors; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Ben | 2013 |
Novel anticoagulants vs warfarin for stroke prevention in atrial fibrillation.
Topics: Animals; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Discove | 2014 |
Oral anticoagulants for stroke prevention in atrial fibrillation.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; | 2014 |
Target-specific oral anticoagulants: practice issues for the clinician.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; | 2014 |
Switching between oral anticoagulants.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; | 2014 |
Testing the therapeutic equivalence of novel oral anticoagulants for thromboprophylaxis in orthopedic surgery and for prevention of stroke in atrial fibrillation.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Coagu | 2015 |
[Stroke prevention after stroke in patients with atrial fibrillation: a case-based review].
Topics: Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alani | 2014 |
Balancing ischaemia and bleeding risks with novel oral anticoagulants.
Topics: Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa Inhibitors; | 2014 |
Approach to the new oral anticoagulants in family practice: part 1: comparing the options.
Topics: Acute Disease; Administration, Oral; Anticoagulants; Antidotes; Atrial Fibrillation; Benzimidazoles; | 2014 |
Novel oral anticoagulants in non-valvular atrial fibrillation.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Chemistry, | 2014 |
Non-vitamin K antagonist oral anticoagulants in atrial fibrillation and venous thromboembolism: where are we now?
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Biomedical Research; Dabigatran; | 2014 |
[More with atrial fibrillation, anticoagulants since the coming of NOAK ].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Aspirin; Atrial Fibrillat | 2015 |
Changing practice of anticoagulation: will target-specific anticoagulants replace warfarin?
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Factor | 2015 |
[The use of dabigatran for prevention of ischemic stroke in patiets with atrial fibrillation: special features of treatment in different clinical situations].
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Secondary Pre | 2014 |
The periprocedural management of novel oral anticoagulants in patients with nonvalvular atrial fibrillation: rationale and a summary of the available evidence from phase 3 clinical trials.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alani | 2015 |
Overview of the new oral anticoagulants: opportunities and challenges.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alani | 2015 |
[Prophylaxis of thromboembolism in atrial fibrillation: new oral anticoagulants and left atrial appendage closure].
Topics: Anticoagulants; Atrial Appendage; Atrial Fibrillation; Atrial Flutter; Benzimidazoles; beta-Alanine; | 2015 |
How to choose appropriate direct oral anticoagulant for patient with nonvalvular atrial fibrillation.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; beta-Alanine; Clinical Decision-Making; D | 2016 |
Atrial fibrillation and dabigatran: has the time come to use new anticoagulants?
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Coagulation; Dabigatran; He | 2010 |
Stroke in atrial fibrillation--hope on the horizon?
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigat | 2010 |
Stroke prevention in the high-risk atrial fibrillation patient: Medical management.
Topics: Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatra | 2011 |
What's new in treating older adults?
Topics: Age Factors; Aged; Aged, 80 and over; Aging; Antibodies, Monoclonal; Antibodies, Monoclonal, Humaniz | 2010 |
Advances in the treatment of atrial fibrillation.
Topics: Amiodarone; Anisoles; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Benzimidazoles; b | 2010 |
Changing anticoagulant paradigms for atrial fibrillation: dabigatran, apixaban and rivaroxaban.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Design; Humans; | 2011 |
Atrial fibrillation in 2010: advances in treatment and management.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Randomized Co | 2011 |
New anticoagulants: pharmacology and clinical studies.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Atrial Fibrillation | 2011 |
Dabigatran as anticoagulant therapy for atrial fibrillation. Which patients should receive it, which patients may not need it, and other practical aspects of patient management.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Randomized Co | 2011 |
[Dabigatran, a new oral anticoagulant].
Topics: Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alani | 2011 |
Frontiers of anticoagulation therapy for atrial fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Stroke | 2011 |
New options for stroke prevention in atrial fibrillation.
Topics: Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Interactions; Factor Xa Inhibito | 2010 |
Dabigatran: an oral direct thrombin inhibitor for use in atrial fibrillation.
Topics: Age Factors; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Inte | 2011 |
Atrial fibrillation: epidemiology, prognosis and therapy.
Topics: Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Appendage; Atrial Fibrillation; Benzimida | 2011 |
[New oral anticoagulant drugs: dabigatran, rivaroxaban and apixaban. Present and future].
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Tr | 2011 |
Is it time to abandon warfarin and embrace oral direct thrombin inhibitors to prevent stroke in patients with atrial fibrillation?
Topics: Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alani | 2011 |
Antithrombotic therapy in atrial fibrillation: evaluation and positioning of new oral anticoagulant agents.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; | 2011 |
New anticoagulants for prevention of stroke in patients with atrial fibrillation.
Topics: Animals; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Pyra | 2011 |
[New concepts in the therapy of atrial fibrillation].
Topics: Anisoles; Anti-Arrhythmia Agents; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablati | 2011 |
[The new Anticoagulants - Relevant Facts for the GP].
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Biological Availab | 2011 |
Stroke prevention in nonvalvular atrial fibrillation.
Topics: Anticoagulants; Atrial Appendage; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cardiac Cathete | 2011 |
[Atrial fibrillation: novel possibilities of anticoagulant therapy in patients subjected to cardioversion].
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Monitoring; Echo | 2011 |
[Thromboembolic prophylaxis 2011: is warfarin on the wane?].
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzamides; Benzimidazoles; beta-Alanine; | 2011 |
Questions and answers on the use of dabigatran and perspectives on the use of other new oral anticoagulants in patients with atrial fibrillation. A consensus document of the Italian Federation of Thrombosis Centers (FCSA).
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; | 2011 |
Preventing cardioembolic stroke in atrial fibrillation with dabigatran.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as | 2012 |
[Atrial fibrillation: what the GP needs to know].
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; | 2011 |
Advances in anticoagulation: focus on dabigatran, an oral direct thrombin inhibitor.
Topics: Anesthesia, Conduction; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Chemistry | 2011 |
Dabigatran: a new option for anticoagulation in atrial fibrillation and venous thromboembolism.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Biopharmace | 2011 |
A new landscape for stroke prevention in atrial fibrillation: focus on new anticoagulants, antiarrhythmic drugs, and devices.
Topics: Animals; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; | 2011 |
Apixaban for stroke prevention in atrial fibrillation: a review of the clinical trial evidence.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Top | 2011 |
Promise of factor Xa inhibition in atrial fibrillation.
Topics: Age Factors; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Fa | 2012 |
[Dabigatran eteksilat new anticoagulant for the prevention of stroke in patients with atrial fibrillation without valvular lesions].
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Coagu | 2011 |
Striking a balance between the risks and benefits of anticoagulation bridge therapy in patients with atrial fibrillation: clinical updates and remaining controversies.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; International | 2011 |
Stroke prevention in atrial fibrillation: do we still need warfarin?
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigat | 2012 |
Pharmacological basis and clinical evidence of dabigatran therapy.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Kidney Failur | 2011 |
A new era of antithrombotic therapy in patients with atrial fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Fibrinolytic Agents; | 2012 |
Direct thrombin inhibitors and factor Xa inhibitors in patients with cerebrovascular disease.
Topics: Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa Inhibitors; | 2012 |
ARISTOTLE RE-LYs on the ROCKET. What's new in stroke prevention in patients with atrial fibrillation?
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigat | 2012 |
A new generation of oral direct anticoagulants.
Topics: Acute Coronary Syndrome; Administration, Oral; Animals; Anticoagulants; Atrial Fibrillation; Benzimi | 2012 |
Is dabigatran cost effective compared with warfarin for stroke prevention in atrial fibrillation? A critically appraised topic.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost-Benefit Analysis; Dabi | 2012 |
Novel oral anticoagulation in management of venous thromboembolism, atrial fibrillation, and acute coronary syndrome.
Topics: Acute Coronary Syndrome; Administration, Oral; Antithrombins; Atrial Fibrillation; Benzimidazoles; b | 2012 |
Dabigatran and atrial fibrillation: the alternative to warfarin for selected patients.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; I | 2012 |
Dabigatran or warfarin for the prevention of stroke in atrial fibrillation? A closer look at the RE-LY trial.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Interactions; Hu | 2012 |
Dabigatran and factor Xa inhibitors for stroke prevention in patients with nonvalvular atrial fibrillation.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Factor | 2012 |
New anticoagulant drugs for treatment of venous thromboembolism and stroke prevention in atrial fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Clinica | 2012 |
Progress for stroke prevention with atrial fibrillation: emergence of alternative oral anticoagulants.
Topics: Administration, Oral; Animals; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Da | 2012 |
Dabigatran: a new chapter in anticoagulation.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigat | 2012 |
[Clinical studies, the interests and limits of using dabigatran in atrial fibrillation].
Topics: Aged; Anti-Arrhythmia Agents; Anticoagulants; Antidotes; Atrial Fibrillation; Benzimidazoles; beta-A | 2012 |
[Pharmacological sheet. Dabigatran, oral administration (Pradaxa)].
Topics: Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Interactions; Fibrinolytic Agent | 2012 |
Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; | 2012 |
Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; | 2012 |
Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; | 2012 |
Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; | 2012 |
Prevention of stroke in patients with atrial fibrillation: anticoagulant and antiplatelet options.
Topics: Anticoagulants; Antithrombins; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clopidogr | 2012 |
[Prophylaxis of stroke and embolisms in atrial fibrillation--what is new in the guidelines?].
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Eviden | 2012 |
[Prevention of cardioembolic stroke].
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Brain Ischemia; Dabigatran; Doubl | 2012 |
Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; | 2012 |
An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation.
Topics: Aged; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Tri | 2012 |
Adjusted indirect comparison of new oral anticoagulants for stroke prevention in atrial fibrillation.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Biologic | 2012 |
Comparison of efficacy and safety of dabigatran, rivaroxaban and apixaban in patients with atrial fibrillation using network meta-analysis.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cereb | 2012 |
Phase III studies on novel oral anticoagulants for stroke prevention in atrial fibrillation: a look beyond the excellent results.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; | 2012 |
Clinical considerations of anticoagulation therapy for patients with atrial fibrillation.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; C | 2012 |
Emerging oral anticoagulants for stroke prevention in patients with non-valvular atrial fibrillation.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alani | 2012 |
Oral anticoagulation in atrial fibrillation: balancing the risk of stroke with the risk of bleed.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Decision Support Tech | 2012 |
Challenges in atrial fibrillation.
Topics: Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clopidogrel; Dabigatran; Drug Therapy, C | 2012 |
Home-monitoring of oral anticoagulation vs. dabigatran. An indirect comparison.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; | 2012 |
Stroke prevention in atrial fibrillation: concepts and controversies.
Topics: Administration, Oral; Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Benzi | 2012 |
[The new anticoagulants - their role in secondary prevention of thromboembolism after stroke].
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; | 2012 |
Management consensus guidance for the use of rivaroxaban--an oral, direct factor Xa inhibitor.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Atrial Fibrillation | 2012 |
Management consensus guidance for the use of rivaroxaban--an oral, direct factor Xa inhibitor.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Atrial Fibrillation | 2012 |
Management consensus guidance for the use of rivaroxaban--an oral, direct factor Xa inhibitor.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Atrial Fibrillation | 2012 |
Management consensus guidance for the use of rivaroxaban--an oral, direct factor Xa inhibitor.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Atrial Fibrillation | 2012 |
What did we learn from new oral anticoagulant treatment?
Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; B | 2012 |
Antithrombotic treatment of atrial fibrillation: new insights.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; | 2012 |
[New oral anticoagulants - sunset for warfarin in therapy of atrial fibrillation].
Topics: Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alani | 2012 |
[Anticoagulant therapy in connection with cardioversion in patients with atrial fibrillation].
Topics: Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Biological Availability; Blood Coa | 2012 |
New evidences for old concerns with oral anticoagulation in atrial fibrillation: focus on dabigatran.
Topics: Administration, Oral; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; | 2012 |
[Stroke risk--atrial fibrillation].
Topics: Aged; Anticoagulants; Atrial Appendage; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cross-Sec | 2012 |
The novel anticoagulants: the surgeons' prospective.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Loss, Surgical; Clinical Tr | 2013 |
New oral anticoagulants in atrial fibrillation: a reappraisal of trial results looking at absolute figures.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Tr | 2013 |
A review of oral anticoagulants in patients with atrial fibrillation.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morphol | 2012 |
[Anticoagulant therapy in stroke patients].
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Brain Ischemia; Cerebral He | 2013 |
Review of recently approved alternatives to anticoagulation with warfarin for emergency clinicians.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Approval; Emerge | 2013 |
Novel oral anticoagulants for stroke prevention in patients with atrial fibrillation: dawn of a new era.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; | 2013 |
28 trials available for beta-alanine and Atrial Fibrillation
| Article | Year |
|---|---|
Assessing the impact of dabigatran and warfarin on health-related quality of life: results from an RE-LY sub-study.
Topics: Aged; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; | 2013 |
Dabigatran versus warfarin anticoagulation before and after catheter ablation for the treatment of atrial fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Canada; Catheter Ablation; Comorb | 2013 |
Balancing the benefits and risks of 2 doses of dabigatran compared with warfarin in atrial fibrillation.
Topics: Aged; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; | 2013 |
The Long-Term Multicenter Observational Study of Dabigatran Treatment in Patients With Atrial Fibrillation (RELY-ABLE) Study.
Topics: Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatra | 2013 |
The Long-Term Multicenter Observational Study of Dabigatran Treatment in Patients With Atrial Fibrillation (RELY-ABLE) Study.
Topics: Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatra | 2013 |
The Long-Term Multicenter Observational Study of Dabigatran Treatment in Patients With Atrial Fibrillation (RELY-ABLE) Study.
Topics: Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatra | 2013 |
The Long-Term Multicenter Observational Study of Dabigatran Treatment in Patients With Atrial Fibrillation (RELY-ABLE) Study.
Topics: Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatra | 2013 |
Dabigatran compared with warfarin in patients with atrial fibrillation and symptomatic heart failure: a subgroup analysis of the RE-LY trial.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Dose-Response R | 2013 |
Mixed treatment comparison meta-analysis of aspirin, warfarin, and new anticoagulants for stroke prevention in patients with nonvalvular atrial fibrillation.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Data Interpr | 2013 |
Dabigatran versus warfarin in patients with mechanical heart valves.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Heart V | 2013 |
Dabigatran versus warfarin in patients with mechanical heart valves.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Heart V | 2013 |
Dabigatran versus warfarin in patients with mechanical heart valves.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Heart V | 2013 |
Dabigatran versus warfarin in patients with mechanical heart valves.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Heart V | 2013 |
Dabigatran versus warfarin in patients with mechanical heart valves.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Heart V | 2013 |
Dabigatran versus warfarin in patients with mechanical heart valves.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Heart V | 2013 |
Dabigatran versus warfarin in patients with mechanical heart valves.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Heart V | 2013 |
Dabigatran versus warfarin in patients with mechanical heart valves.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Heart V | 2013 |
Dabigatran versus warfarin in patients with mechanical heart valves.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Heart V | 2013 |
Dabigatran versus warfarin in patients with mechanical heart valves.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Heart V | 2013 |
Dabigatran versus warfarin in patients with mechanical heart valves.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Heart V | 2013 |
Dabigatran versus warfarin in patients with mechanical heart valves.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Heart V | 2013 |
Dabigatran versus warfarin in patients with mechanical heart valves.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Heart V | 2013 |
Dabigatran versus warfarin in patients with mechanical heart valves.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Heart V | 2013 |
Dabigatran versus warfarin in patients with mechanical heart valves.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Heart V | 2013 |
Dabigatran versus warfarin in patients with mechanical heart valves.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Heart V | 2013 |
Dabigatran versus warfarin in patients with mechanical heart valves.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Heart V | 2013 |
Dabigatran versus warfarin in patients with mechanical heart valves.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Heart V | 2013 |
Dabigatran versus warfarin in patients with mechanical heart valves.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Heart V | 2013 |
Dabigatran versus warfarin in patients with mechanical heart valves.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Heart V | 2013 |
Dabigatran versus warfarin in patients with mechanical heart valves.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Heart V | 2013 |
Dabigatran versus warfarin in patients with mechanical heart valves.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Heart V | 2013 |
Dabigatran versus warfarin in patients with mechanical heart valves.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Heart V | 2013 |
Dabigatran versus warfarin in patients with mechanical heart valves.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Heart V | 2013 |
Dabigatran versus warfarin in patients with mechanical heart valves.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Heart V | 2013 |
Causes of death and influencing factors in patients with atrial fibrillation: a competing-risk analysis from the randomized evaluation of long-term anticoagulant therapy study.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al | 2013 |
A head-to-head comparison of periprocedural coagulability under anticoagulation with rivaroxaban versus dabigatran in patients undergoing ablation of atrial fibrillation.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Fibrin | 2013 |
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al | 2013 |
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al | 2013 |
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al | 2013 |
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al | 2013 |
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al | 2013 |
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al | 2013 |
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al | 2013 |
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al | 2013 |
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al | 2013 |
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al | 2013 |
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al | 2013 |
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al | 2013 |
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al | 2013 |
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al | 2013 |
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al | 2013 |
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al | 2013 |
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al | 2013 |
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al | 2013 |
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al | 2013 |
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al | 2013 |
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al | 2013 |
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al | 2013 |
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al | 2013 |
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al | 2013 |
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al | 2013 |
Validation of a patient decision aid for choosing between dabigatran and warfarin for atrial fibrillation.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; | 2013 |
Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation: a RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) trial analysis.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatr | 2014 |
Warfarin or dabigatran for treatment of atrial fibrillation.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Europe; Hemorrh | 2014 |
Major bleeding with dabigatran and rivaroxaban in patients with atrial fibrillation: a real-world setting.
Topics: Aged; Aged, 80 and over; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Databases, F | 2014 |
Comparison of dabigatran and uninterrupted warfarin in patients with atrial fibrillation undergoing cardiac rhythm device implantations. Case-control study.
Topics: Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Case-Cont | 2014 |
[Comparison of the safety of rivaroxaban versus dabigatran therapy in patients with persistent atrial fibrillation].
Topics: Aged; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa Inhibi | 2014 |
Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Echocardiography, Tra | 2011 |
Efficacy and safety of dabigatran vs. warfarin in patients with atrial fibrillation--sub-analysis in Japanese population in RE-LY trial.
Topics: Aged; Aged, 80 and over; Anticoagulants; Asian People; Atrial Fibrillation; Benzimidazoles; beta-Ala | 2011 |
Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial.
Topics: Age Factors; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alan | 2011 |
Risks for stroke, bleeding, and death in patients with atrial fibrillation receiving dabigatran or warfarin in relation to the CHADS2 score: a subgroup analysis of the RE-LY trial.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al | 2011 |
Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial.
Topics: Aged; Aged, 80 and over; Angina, Unstable; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzi | 2012 |
[Expectation to and problems of thrombin inhibitor].
Topics: Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Stroke; Warfar | 2011 |
Dabigatran in clinical practice for atrial fibrillation with special reference to activated partial thromboplastin time.
Topics: Aged; Aged, 80 and over; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Dose-Respons | 2012 |
Intracranial hemorrhage in atrial fibrillation patients during anticoagulation with warfarin or dabigatran: the RE-LY trial.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Humans; | 2012 |
Cost-effectiveness of dabigatran compared with warfarin for patients with atrial fibrillation in Sweden.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost-Ben | 2013 |
Efficacy and safety of periprocedural dabigatran in patients undergoing catheter ablation of atrial fibrillation.
Topics: Aged; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Abl | 2012 |
Analysis of upper gastrointestinal adverse events among patients given dabigatran in the RE-LY trial.
Topics: Adult; Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Da | 2013 |
A randomized controlled trial of dabigatran versus warfarin for periablation anticoagulation in patients undergoing ablation of atrial fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Humans; Male; | 2013 |
352 other studies available for beta-alanine and Atrial Fibrillation
| Article | Year |
|---|---|
Cost-Utility Analysis of Dabigatran and Warfarin for Stroke Prevention Among Patients With Nonvalvular Atrial Fibrillation in India.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost-Benefit Analysis; Dabigatran | 2022 |
Questions in the comparative effectiveness of dabigatran and warfarin in atrial fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; beta-Alanine; Dabigatran; Humans; Warfarin | 2017 |
Dabigatran: Important Considerations in the Elderly.
Topics: Aged; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; | 2017 |
Anticoagulation therapy: Uninterrupted dabigatran during ablation for AF.
Topics: Anticoagulants; Atrial Fibrillation; beta-Alanine; Dabigatran; Humans; Warfarin | 2017 |
Osteoporotic Fractures Associated With Dabigatran vs Warfarin.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Osteoporotic | 2017 |
Osteoporotic Fractures Associated With Dabigatran vs Warfarin-Reply.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Osteoporotic | 2017 |
Uninterrupted Dabigatran versus Warfarin for Ablation in Atrial Fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation; Dabigatran; Hu | 2017 |
Uninterrupted Dabigatran versus Warfarin for Ablation in Atrial Fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation; Dabigatran; Hu | 2017 |
Uninterrupted Dabigatran versus Warfarin for Ablation in Atrial Fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation; Dabigatran; Hu | 2017 |
Switching off the jitters: Dabigatran as a candidate approach to halt atrial fibrillation?
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; beta-Alanine; Dabigatran; Humans; Stroke; Warfar | 2018 |
[Dabigatran as cause of severe gastrointestinal bleeding in a Jehovah's Witness patient].
Topics: Aged; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Transfusion; Critical | 2013 |
Recent advances in antithrombotic therapy for stroke prevention in patients with atrial fibrillation.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as | 2013 |
Dabigatran overdose secondary to acute kidney injury and amiodarone use.
Topics: Acute Kidney Injury; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Antithrombins; Atrial Fi | 2013 |
Reversing dabigatran in life-threatening bleeding occurring during cardiac ablation with factor eight inhibitor bypassing activity.
Topics: Aged; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Coagulation Factors; C | 2013 |
Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in patients with atrial fibrillation--a real patient data analysis in a Hong Kong teaching hospital.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost-Ben | 2013 |
Dabigatran: a nephrological way out.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Drug Approval; Humans; Stroke; Th | 2013 |
The reply.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Drug Approval; Humans; Stroke; Th | 2013 |
Hemorrhagic complications in emergency department patients who are receiving dabigatran compared with warfarin.
Topics: Acute Kidney Injury; Age Factors; Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Benzi | 2013 |
Acute pulmonary emboli in a patient on long-term dabigatran therapy.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Humans; | 2013 |
Economic appraisal of dabigatran as first-line therapy for stroke prevention in atrial fibrillation.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al | 2013 |
[Bleeding in the appointment of dabigatran in the patients with renal insufficiency caused by coadministration of spironolactone and ACE inhibitors].
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Atrial Fibrillation; Benzimidazoles; beta-Alanine; C | 2013 |
Cost-effectiveness of apixaban, dabigatran, rivaroxaban, and warfarin for stroke prevention in atrial fibrillation.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cohor | 2013 |
Use of dabigatran for periprocedural anticoagulation in patients undergoing catheter ablation for atrial fibrillation.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Confidence Intervals; Dabig | 2013 |
[Your patient needs antithrombotics, 2. What do the new substances offer? (interview by Dr. med. Peter Stiefelhagen)].
Topics: Adenosine; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cardiovascular Diseases; Clopidogrel; | 2013 |
Dabigatran versus warfarin therapy for uninterrupted oral anticoagulation during atrial fibrillation ablation.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alani | 2013 |
Dabigatran in the peri-procedural period for radiofrequency ablation of atrial fibrillation: efficacy, safety, and impact on duration of hospital stay.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation; | 2013 |
Modeling of the impact on health outcomes of the use of dabigatran in patients with atrial fibrillation.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Benzimidazoles; b | 2013 |
A comparative analysis of models used to evaluate the cost-effectiveness of dabigatran versus warfarin for the prevention of stroke in atrial fibrillation.
Topics: Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost-Benefit Analysis; Dabigatran; Drug Costs; He | 2013 |
Comparative effectiveness of dabigatran, rivaroxaban, apixaban, and warfarin in the management of patients with nonvalvular atrial fibrillation.
Topics: Age Factors; Aged; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cardiovascular | 2013 |
Continuous warfarin versus periprocedural dabigatran to reduce stroke and systemic embolism in patients undergoing catheter ablation for atrial fibrillation or left atrial flutter.
Topics: Adult; Anticoagulants; Atrial Fibrillation; Atrial Flutter; Benzimidazoles; beta-Alanine; Catheter A | 2013 |
[Stroke prevention in atrial fibrillation : old and new anticoagulants].
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; | 2013 |
Effect of dabigatran on referrals to and switching from warfarin in two academic anticoagulation management services.
Topics: Academic Medical Centers; Aged; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; | 2013 |
Periprocedural dabigatran in atrial fibrillation ablation: a new kid on the block.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation; | 2013 |
Dabigatran in clinical practice--one-year experience at Skåne University Hospital.
Topics: Aged; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Humans; | 2013 |
Can dabigatran improve blood pressure control?
Topics: Acenocoumarol; Aged, 80 and over; Anticoagulants; Antihypertensive Agents; Antithrombins; Atrial Fib | 2013 |
Conventional and new oral anticoagulants in the treatment of chest disease and its complications.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost-Benefit Analy | 2013 |
Bleeding events and activated partial thromboplastin time with dabigatran in clinical practice.
Topics: Age Factors; Aged; Antithrombins; ATP Binding Cassette Transporter, Subfamily B, Member 1; Atrial Fi | 2013 |
Massive left atrial thrombus in a patient with rheumatic mitral stenosis and atrial fibrillation while anticoagulated with dabigatran.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Substitution; Ec | 2013 |
Economic evaluation of percutaneous left atrial appendage occlusion, dabigatran, and warfarin for stroke prevention in patients with nonvalvular atrial fibrillation.
Topics: Aged; Atrial Appendage; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Computer Simulation; Coro | 2013 |
Placing a value on new technologies.
Topics: Atrial Appendage; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Coronary Occlusion; Dabigatran; | 2013 |
Extracorporeal therapy for dabigatran removal in the treatment of acute bleeding: a single center experience.
Topics: Accidental Falls; Acute Disease; Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Benzim | 2013 |
Dilemma of indication for thrombolysis in a patient with acute ischemic stroke treated with a novel oral anticoagulant.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Coagu | 2014 |
New oral anticoagulants in atrial fibrillation forever?
Topics: Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Embolism; Female; Huma | 2013 |
Evaluation of coagulation assays versus LC-MS/MS for determinations of dabigatran concentrations in plasma.
Topics: Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Coagulation Tests; Chromatog | 2013 |
Adherence and outcomes of patients treated with dabigatran: pharmacist-managed anticoagulation clinic versus usual care.
Topics: Adult; Aged; Antithrombins; Atrial Fibrillation; Atrial Flutter; Benzimidazoles; beta-Alanine; Calif | 2013 |
Plasma dabigatran activity one week after discontinuation despite normal renal function.
Topics: Aged; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Gastroin | 2013 |
Contra: "New oral anticoagulants should not be used as 1st choice for secondary stroke prevention in atrial fibrillation".
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; | 2013 |
Pro: "The novel oral anticoagulants should be used as 1st choice for secondary prevention in patients with atrial fibrillation.".
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Diabet | 2013 |
Anticoagulation therapy: Dabigatran--a RELY-ABLE therapy?
Topics: Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Embolism; Female; Humans; Male; St | 2013 |
"Blue letter effects": Changes in physicians' attitudes toward dabigatran after a safety advisory in a specialized hospital for cardiovascular care in Japan.
Topics: Aged; Atrial Fibrillation; Attitude of Health Personnel; Benzimidazoles; beta-Alanine; Contraindicat | 2013 |
Dental management considerations for a patient taking dabigatran etexilate: a case report.
Topics: Aged; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Male; Or | 2013 |
Adherence to anticoagulant treatment with dabigatran in a real-world setting.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Benzimidazoles; b | 2013 |
Use and associated risks of concomitant aspirin therapy with oral anticoagulation in patients with atrial fibrillation: insights from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Registry.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; | 2013 |
Reversal of dabigatran with haemodialysis in a patient requiring decompression for cord compression from an epidural abscess.
Topics: Aged; Anti-Bacterial Agents; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood | 2013 |
Medical costs in the US of clinical events associated with oral anticoagulant (OAC) use compared to warfarin among non-valvular atrial fibrillation patients ≥75 and <75 years of age, based on the ARISTOTLE, RE-LY, and ROCKET-AF trials.
Topics: Administration, Oral; Age Factors; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Ben | 2013 |
RE-LYing on dabigatran for periprocedural anticoagulation: is it safe?
Topics: Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Humans; Intracranial Embolism | 2013 |
Fatal association of mechanical valve thrombosis with dabigatran: a report of two cases.
Topics: Aged; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Fatal Outcome; F | 2013 |
Periprocedural dabigatran anticoagulation for atrial fibrillation ablation: do we have enough information to make a rational decision.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation; | 2013 |
Letter by May et al regarding article, "Use of dabigatran for periprocedural anticoagulation in patients undergoing catheter ablation for atrial fibrillation" by Bassiouny et al.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Humans; Male; Thromboembo | 2013 |
[New oral anticoagulants in nonvalvular atrial fibrillation].
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cardiovascu | 2013 |
Should the newer oral anticoagulants be withheld from patients with valvular AF?
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Heart Valve Diseases; | 2013 |
Atrial fibrillation and anticoagulation management: a wake-up call to practitioners, patients, and policymakers.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost-Benefit Analy | 2013 |
Endovascular thrombectomy for acute ischemic stroke patients anticoagulated with dabigatran.
Topics: Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Brain Ischemia | 2013 |
Higher persistence in newly diagnosed nonvalvular atrial fibrillation patients treated with dabigatran versus warfarin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al | 2013 |
The promise of pharmacoepidemiology in helping clinicians assess drug risk.
Topics: Administration, Oral; Advertising; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine | 2013 |
[Differential therapy with the new anticoagulants, 5].
Topics: Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alani | 2013 |
New oral anticoagulants for non-valvular atrial fibrillation--safety issues.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Tr | 2013 |
The incidence of asymptomatic cerebral microthromboembolism after atrial fibrillation ablation: comparison of warfarin and dabigatran.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Comorbidity; Dabig | 2013 |
New oral anticoagulants in heart failure.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Heart Failure | 2013 |
Response to Letter by May et al regarding article, "Use of dabigatran for periprocedural anticoagulation in patients undergoing catheter ablation for atrial fibrillation" by Bassiouny et al.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Humans; Male; Thromboembo | 2013 |
Dabigatran and mechanical heart valves--not as easy as we hoped.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Heart Valve P | 2013 |
Anticoagulation therapy: Results of RE-ALIGN disappoint.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Heart Valve Prosthesis; H | 2013 |
A comparison of methods for estimating glomerular filtration rate for a population in Hawai'i with non-valvular atrial fibrillation.
Topics: Aged, 80 and over; Anticoagulants; Arginine; Asian People; Atrial Fibrillation; Benzimidazoles; beta | 2013 |
Dabigatran-related intracerebral hemorrhage resulting in hematoma expansion.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cereb | 2014 |
Dabigatran in the setting of catheter ablation of atrial fibrillation: the road ahead.
Topics: Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation; Dabigatran; Humans; Preoperati | 2014 |
Dabigatran and rivaroxaban prescription for atrial fibrillation in Catalonia, Spain: the need to manage the introduction of new drugs.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; D | 2014 |
Apixaban, dabigatran, and rivaroxaban versus warfarin for stroke prevention in non-valvular atrial fibrillation: a cost-effectiveness analysis.
Topics: Aged; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost-Benefit | 2014 |
A single centre experience of the efficacy and safety of dabigatran etexilate used for stroke prevention in atrial fibrillation.
Topics: Adult; Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Da | 2014 |
Cost-effectiveness of oral anticoagulants for treatment of atrial fibrillation.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost- | 2013 |
New oral anticoagulants: an emergency department overview.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Australia; Benzimidazoles; beta-Alanine; | 2013 |
Life-threatening epistaxis and red blood cell polyagglutination under dabigatran.
Topics: Aged, 80 and over; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cardiovascular | 2014 |
Dabigatran-induced upper intestinal bleeding in a patient with chronic kidney disease.
Topics: Aged, 80 and over; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Diabetes Mellitus, | 2013 |
Evaluation of dabigatran utilization and risk among hospitalized patients.
Topics: Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical | 2014 |
Early adoption of dabigatran and its dosing in US patients with atrial fibrillation: results from the outcomes registry for better informed treatment of atrial fibrillation.
Topics: Administration, Oral; Age Factors; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Ben | 2013 |
Ischemic stroke and intestinal bleeding under dabigatran in metabolic myopathy.
Topics: Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Brain Isc | 2013 |
New oral anticoagulants: their role and future.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; | 2013 |
Patient outcomes using the European label for dabigatran. A post-hoc analysis from the RE-LY database.
Topics: Aged; Aged, 80 and over; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost-Benefit Analysis; D | 2014 |
Dabigatran in the setting of catheter ablation of atrial fibrillation: the road ahead. The authors' reply.
Topics: Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation; Dabigatran; Humans; Preoperati | 2014 |
ACP Journal Club. Dabigatran increased bleeding and stroke compared with warfarin after mechanical heart valve implantation.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Heart Valve Prosthesis; H | 2013 |
Dabigatran use in mechanical heart valve patients.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Heart Valve Prosthesis; H | 2014 |
Thrombin generation using the calibrated automated thrombinoscope to assess reversibility of dabigatran and rivaroxaban.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Atrial Fibrillation | 2014 |
Myocardial ischemic events in 'real world' patients with atrial fibrillation treated with dabigatran or warfarin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al | 2014 |
Dabigatran versus warfarin in patients with mechanical heart valves: comment.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Heart Valve Prosthesis; H | 2014 |
[Patient with acute renal injury presenting dabigatran overdose: Hemodialysis for surgery].
Topics: Acute Kidney Injury; Aged, 80 and over; Alzheimer Disease; Antithrombins; Atrial Fibrillation; Benzi | 2014 |
Dabigatran versus warfarin in patients with mechanical heart valves: reply.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Heart Valve Prosthesis; H | 2014 |
Proposed approach to thrombolysis in dabigatran-treated patients presenting with ischemic stroke.
Topics: Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Coa | 2014 |
Dabigatran in patients with mechanical heart valves.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Heart Valve Prosthesis; H | 2014 |
Dabigatran in patients with mechanical heart valves.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Heart Valve Prosthesis; H | 2014 |
Dabigatran in patients with mechanical heart valves.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Heart Valve Prosthesis; H | 2014 |
Dabigatran in patients with mechanical heart valves.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Heart Valve Prosthesis; H | 2014 |
Dabigatran in patients with mechanical heart valves.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Heart Valve Prosthesis; H | 2014 |
Dabigatran in patients with mechanical heart valves.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Heart Valve Prosthesis; H | 2014 |
Novel anticoagulants in patients with mechanical heart valves.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Heart Valve Prosthesis; H | 2014 |
Assessment of dabigatran utilization and prescribing patterns for atrial fibrillation in a physician group practice setting.
Topics: Adult; Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Da | 2014 |
Treatment with novel oral anticoagulants in a real-world cohort of patients undergoing cardiac rhythm device implantations.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; | 2014 |
Comparison of the phase III clinical trial designs of novel oral anticoagulants versus warfarin for the treatment of nonvalvular atrial fibrillation: implications for clinical practice.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Tr | 2014 |
Cost-effectiveness of apixaban versus other new oral anticoagulants for stroke prevention in atrial fibrillation.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost-Benefi | 2014 |
Impaired renal function and bleeding in elderly treated with dabigatran.
Topics: Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatra | 2014 |
Bleeding events among new starters and switchers to dabigatran compared with warfarin in atrial fibrillation.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al | 2014 |
Rivaroxaban and dabigatran in patients undergoing catheter ablation of atrial fibrillation.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cathe | 2014 |
Massive haemoptysis following dabigatran administration in a patient with bronchiectasis.
Topics: Aged; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Bronchial Arteries; Bronchie | 2014 |
Dabigatran-induced lupus temporarily preventing blood group determination.
Topics: Aged, 80 and over; Anemia; Antibodies, Antinuclear; Antithrombins; Atrial Fibrillation; Benzimidazol | 2014 |
Design and rationale of Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation: a global registry program on long-term oral antithrombotic treatment in patients with atrial fibrillation.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cohort Studies; Cr | 2014 |
Design and rationale of Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation: a global registry program on long-term oral antithrombotic treatment in patients with atrial fibrillation.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cohort Studies; Cr | 2014 |
Design and rationale of Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation: a global registry program on long-term oral antithrombotic treatment in patients with atrial fibrillation.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cohort Studies; Cr | 2014 |
Design and rationale of Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation: a global registry program on long-term oral antithrombotic treatment in patients with atrial fibrillation.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cohort Studies; Cr | 2014 |
Design and rationale of Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation: a global registry program on long-term oral antithrombotic treatment in patients with atrial fibrillation.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cohort Studies; Cr | 2014 |
Design and rationale of Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation: a global registry program on long-term oral antithrombotic treatment in patients with atrial fibrillation.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cohort Studies; Cr | 2014 |
Design and rationale of Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation: a global registry program on long-term oral antithrombotic treatment in patients with atrial fibrillation.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cohort Studies; Cr | 2014 |
Design and rationale of Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation: a global registry program on long-term oral antithrombotic treatment in patients with atrial fibrillation.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cohort Studies; Cr | 2014 |
Design and rationale of Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation: a global registry program on long-term oral antithrombotic treatment in patients with atrial fibrillation.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cohort Studies; Cr | 2014 |
Safety of short-term use of dabigatran or rivaroxaban for direct-current cardioversion in patients with atrial fibrillation and atrial flutter.
Topics: Administration, Oral; Aged; Anticoagulants; Antithrombins; Atrial Fibrillation; Atrial Flutter; Benz | 2014 |
Efficacy and safety of edoxaban in comparison with dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation. An indirect comparison analysis.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clini | 2014 |
Safety of new oral anticoagulants for patients undergoing atrial fibrillation ablation.
Topics: Aged; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Abl | 2014 |
Intracranial hemorrhage during dabigatran treatment.
Topics: Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatra | 2014 |
Economic evaluation of warfarin, dabigatran, rivaroxaban, and apixaban for stroke prevention in atrial fibrillation.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost-Ben | 2014 |
A case of dabigatran-associated acute renal failure.
Topics: Acute Kidney Injury; Aged; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Biopsy; | 2013 |
[Hemodialysis to remove anticoagulant dabigatran during emergencies].
Topics: Aged, 80 and over; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Coagulati | 2014 |
Self-management of vitamin K antagonists is more cost-effective than dabigatran for stroke prevention in non-valvular atrial fibrillation in Spain.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Humans; Male; Stroke; Vit | 2013 |
Self-management of vitamin K antagonists is more cost-effective than dabigatran for stroke prevention in non-valvular atrial fibrillation in Spain. Response.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Humans; Male; Stroke; Vit | 2013 |
On the cost-effectiveness of dabigatran.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Humans; Male; Stroke; Vit | 2013 |
On the cost-effectiveness of dabigatran. Response.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Humans; Male; Stroke; Vit | 2013 |
Perioperative management of patients on new oral anticoagulants.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Biological | 2014 |
A new class of powerful and informative simultaneous confidence intervals.
Topics: Algorithms; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Biosta | 2014 |
New era of oral anticoagulation for Japanese non-valvular atrial fibrillation patients.
Topics: Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Humans; Intrac | 2014 |
Stroke prevention in patients with atrial fibrillation in France: comparative cost-effectiveness of new oral anticoagulants (apixaban, dabigatran, and rivaroxaban), warfarin, and aspirin.
Topics: Anticoagulants; Antithrombins; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Comparati | 2014 |
New oral anticoagulants vs vitamin K antagonists: benefits for health-related quality of life in patients with atrial fibrillation.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabig | 2014 |
Patterns of initiation of oral anticoagulants in patients with atrial fibrillation- quality and cost implications.
Topics: Administration, Oral; Adolescent; Adult; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; | 2014 |
Direct oral anticoagulants in atrial fibrillation.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; | 2014 |
Dabigatran in catheter ablation of atrial fibrillation: a call for a randomized control trial.
Topics: Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation; Humans; Ischemic Attack, Trans | 2014 |
Good outcome after intravenous thrombolysis for acute stroke in a patient under treatment with dabigatran.
Topics: Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Fibrinolytic Agents; H | 2014 |
The peri-procedural use of dabigatran in patients undergoing left atrial ablation for atrial fibrillation.
Topics: Aged; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation; Dabigatra | 2014 |
Adherence to dabigatran therapy and longitudinal patient outcomes: insights from the veterans health administration.
Topics: Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cohort St | 2014 |
Adherence to dabigatran therapy and longitudinal patient outcomes: insights from the veterans health administration.
Topics: Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cohort St | 2014 |
Adherence to dabigatran therapy and longitudinal patient outcomes: insights from the veterans health administration.
Topics: Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cohort St | 2014 |
Adherence to dabigatran therapy and longitudinal patient outcomes: insights from the veterans health administration.
Topics: Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cohort St | 2014 |
[Dabigatran versus warfarin in patients with mechanical heart valves].
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Heart Valve Prosthesis; H | 2014 |
New oral anticoagulants vs. warfarin treatment: no need for pharmacogenomics?
Topics: Administration, Oral; Anticoagulants; Antithrombins; Aryl Hydrocarbon Hydroxylases; Atrial Fibrillat | 2014 |
New oral anticoagulants: a practical guide on prescription, laboratory testing and peri-procedural/bleeding management. Australasian Society of Thrombosis and Haemostasis.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Coagu | 2014 |
Intracranial hemorrhage mortality in atrial fibrillation patients treated with dabigatran or warfarin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatr | 2014 |
Atrial fibrillation choices. Picking an anti-clotting drug.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Food-Drug Interaction | 2014 |
Characteristics affecting oral anticoagulant therapy choice among patients with non-valvular atrial fibrillation: a retrospective claims analysis.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillatio | 2014 |
Treatment of atrial fibrillation.
Topics: Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatra | 2014 |
Continuation of dabigatran therapy in "real-world" practice in Hong Kong.
Topics: Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatra | 2014 |
Monitoring of dabigatran therapy using Hemoclot(®) Thrombin Inhibitor assay in patients with atrial fibrillation.
Topics: Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatra | 2015 |
Efficacy and cost-effectiveness of dabigatran etexilate versus warfarin in atrial fibrillation in different age subgroups.
Topics: Aged; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost-Benefit Analysis; Dabig | 2014 |
Bleeding rates in Veterans Affairs patients with atrial fibrillation who switch from warfarin to dabigatran.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al | 2014 |
Evaluation of Trends of Inpatient Hospitalisation for Significant Haemorrhage in Patients Anticoagulated for Atrial Fibrillation before and after the Release of Novel Anticoagulants.
Topics: Age Factors; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cohort Studies | 2015 |
Anticlotting therapy for atrial fibrillation: should you stay with the devil you know? Preventing stroke with warfarin (Coumadin) can be tricky. New anticlotting drugs can help if you accept certain trade-offs--and take them exactly as directed.
Topics: Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Approval; Female; Fibrinolytic A | 2014 |
Peri-procedural interrupted oral anticoagulation for atrial fibrillation ablation: comparison of aspirin, warfarin, dabigatran, and rivaroxaban.
Topics: Administration, Oral; Aged; Algorithms; Anticoagulants; Aspirin; Atrial Fibrillation; Benzimidazoles | 2014 |
ACP Journal Club. In atrial fibrillation, dabigatran had similar efficacy to warfarin but caused less bleeding in higher GFR.
Topics: Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Humans; Kidney; Male; Warfarin | 2014 |
Estimated medical cost reductions associated with use of novel oral anticoagulants vs warfarin in a real-world non-valvular atrial fibrillation patient population.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Health | 2014 |
Eligibility and preference of new oral anticoagulants in patients with atrial fibrillation: comparison between patients with versus without stroke.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Humans; | 2014 |
Letter by Seitz and Beurtheret regarding article, "Causes of death and influencing factors in patients with atrial fibrillation: a competing risk analysis from the randomized evaluation of long-term anticoagulant therapy study".
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Humans; Ma | 2014 |
Response to letter regarding article, "Causes of death and influencing factors in patients with atrial fibrillation: a competing-risk analysis from the randomized evaluation of long-term anticoagulant therapy study".
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Humans; Ma | 2014 |
On the monitoring of dabigatran treatment in "real life" patients with atrial fibrillation.
Topics: Aged; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Coagulation Tests; Chr | 2014 |
Anticoagulant-related gastrointestinal bleeding--could this facilitate early detection of benign or malignant gastrointestinal lesions?
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Top | 2014 |
[Cost-effectiveness of apixaban compared to other new oral anticoagulants in patients with non-valvular atrial fibrillation].
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Coagu | 2014 |
Dabigatran and warfarin for secondary prevention of stroke in atrial fibrillation patients: a nationwide cohort study.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al | 2014 |
Monitoring of anticoagulant effects of dabigatran in everyday practice: first experience in 32 Polish patients.
Topics: Aged; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Monitoring; | 2014 |
Letter by Hifumi et al regarding article, "Management and outcomes of major bleeding during treatment with dabigatran or warfarin".
Topics: Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Hemorrhage; Humans; Male; Venous Thromboe | 2014 |
Response to letter regarding article, "Management and outcomes of major bleeding during treatment with dabigatran or warfarin".
Topics: Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Hemorrhage; Humans; Male; Venous Thromboe | 2014 |
Identifying future research priorities using value of information analyses: left atrial appendage occlusion devices in atrial fibrillation.
Topics: Aged; Anticoagulants; Atrial Appendage; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cardiac S | 2014 |
[Eligibility for dabigatran therapy: the real-life experience of a Tuscany general hospital].
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; | 2014 |
Non-vitamin K antagonist oral anticoagulation agents in anticoagulant naïve atrial fibrillation patients: Danish nationwide descriptive data 2011-2013.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; be | 2015 |
Dabigatran-related coagulopathy: when can we assume the effect has "worn off"?
Topics: Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Fibrinolytic Agents; H | 2014 |
2014 focused update of the Canadian Cardiovascular Society Guidelines for the management of atrial fibrillation.
Topics: Algorithms; Anticoagulants; Antithrombins; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanin | 2014 |
2014 focused update of the Canadian Cardiovascular Society Guidelines for the management of atrial fibrillation.
Topics: Algorithms; Anticoagulants; Antithrombins; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanin | 2014 |
2014 focused update of the Canadian Cardiovascular Society Guidelines for the management of atrial fibrillation.
Topics: Algorithms; Anticoagulants; Antithrombins; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanin | 2014 |
2014 focused update of the Canadian Cardiovascular Society Guidelines for the management of atrial fibrillation.
Topics: Algorithms; Anticoagulants; Antithrombins; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanin | 2014 |
Influence of cell-associated tissue factor concentration on the anticoagulant activity of dabigatran. A possible explanation for the reduced incidence of intracranial bleeding.
Topics: Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Coagulation; Case-Control St | 2015 |
Myocardial ischemic events in 'real world' patients treated with dabigatran.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Humans; Ma | 2014 |
The reply.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Humans; Ma | 2014 |
Cost-effectiveness of dabigatran and rivaroxaban compared with warfarin for stroke prevention in patients with atrial fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Coagulation; Cost-Benefit A | 2014 |
Cost effectiveness of new oral anticoagulants for stroke prevention in patients with atrial fibrillation in two different European healthcare settings.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; | 2014 |
Novel anticoagulants eliminate the need for left atrial appendage exclusion devices.
Topics: Anticoagulants; Atrial Appendage; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials | 2014 |
Anticoagulant treatment in German family practices - screening results from a cluster randomized controlled trial.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; | 2014 |
Help prevent Afib-related stroke. New anticoagulants for atrial fibrillation prove as effective, or even better than, warfarin--and easier to use.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug E | 2014 |
Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation.
Topics: Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Benzimidazoles | 2015 |
Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation.
Topics: Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Benzimidazoles | 2015 |
Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation.
Topics: Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Benzimidazoles | 2015 |
Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation.
Topics: Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Benzimidazoles | 2015 |
The importance of postapproval data for dabigatran.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female | 2015 |
Risk of bleeding with dabigatran in atrial fibrillation.
Topics: Age Factors; Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidaz | 2015 |
A comparison of bleeding complications between warfarin, dabigatran, and rivaroxaban in patients undergoing cryoballoon ablation.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation; Comorbid | 2014 |
Approach to the new oral anticoagulants in family practice: part 2: addressing frequently asked questions.
Topics: Acute Disease; Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alani | 2014 |
Intensity and quality of warfarin anticoagulation in Chinese patients: setting the record straight.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Huma | 2015 |
Ischemic stroke and intracranial hemorrhage with aspirin, dabigatran, and warfarin: impact of quality of anticoagulation control.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; | 2015 |
Letter by Chin et al regarding article, "Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation: a RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial analy
Topics: Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Humans; Kidney; Male; Warfarin | 2014 |
Response to letter regarding article, "Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation: a RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial analysi
Topics: Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Humans; Kidney; Male; Warfarin | 2014 |
Atrial fibrillation: Risk of bleeding with dabigatran versus warfarin particularly high in CKD.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Hemorrhage | 2015 |
RE-CIRCUIT study-randomized evaluation of Dabigatran etexilate compared to warfarin in pulmonary vein ablation: assessment of an uninterrupted periprocedural anticoagulation strategy.
Topics: Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation; Humans; Ischemic Attack, Trans | 2015 |
CHA2DS2-VASc and HAS-BLED scores and activated partial thromboplastin time for prediction of high plasma concentration of dabigatran at trough.
Topics: Adolescent; Adult; Aged; Algorithms; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazo | 2015 |
[Laboratory assessment of haemostatic parameters in patients taking a direct thrombin inhibitor].
Topics: Aged; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Coagulation; Blood Coa | 2014 |
Transition from apixaban to warfarin--addressing excess stroke, systemic embolism, and major bleeding.
Topics: Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa Inhibitors; | 2015 |
Safety of novel oral anticoagulants compared with uninterrupted warfarin for catheter ablation of atrial fibrillation.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cathe | 2015 |
Pitfalls of the interpretation of myocardial infarction data in patients on dabigatran treatment.
Topics: Acute Coronary Syndrome; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Humans; M | 2015 |
[Retrospective study about 73 consecutive patients treated by direct oral anticoagulant and admitted to an emergency room].
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatr | 2015 |
Dabigatran and rivaroxaban use in atrial fibrillation patients on hemodialysis.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatr | 2015 |
Gastrointestinal bleeding. Gastrointestinal bleeding risk is increased by novel anticoagulants.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Hemorrhage | 2015 |
[Fewer strokes, lower mortality. Large general practice studies confirm good safety profile of dabigatran].
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatr | 2014 |
[Dabigatran and risk of bleeding].
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Hemorrhage | 2015 |
Novel anticoagulants make life easier for patients with atrial fibrillation. The new drugs have many advantages over Coumadin--but they aren't perfect--and they have no antidotes in case of overdose.
Topics: Anticoagulants; Antidotes; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Mo | 2014 |
Letter by Feng et al regarding article, "Ischemic stroke and intracranial hemorrhage with aspirin, dabigatran, and warfarin: impact of quality of anticoagulation control".
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Humans; Intracra | 2015 |
Response to letter regarding article, "Ischemic stroke and intracranial hemorrhage with aspirin, dabigatran, and warfarin: impact of quality of anticoagulation control".
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Humans; Intracra | 2015 |
Defining non-valvular atrial fibrillation while selecting anticoagulation therapy.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Heart Valve Diseases; | 2015 |
Patterns of oral anticoagulants use in atrial fibrillation.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cross-Se | 2015 |
Risk stratification and stroke prevention therapy care gaps in Canadian atrial fibrillation patients (from the Co-ordinated National Network to Engage Physicians in the Care and Treatment of Patients With Atrial Fibrillation chart audit).
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Canada; | 2015 |
[Exfoliative esophagitis while taking dabigatran].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Anti-Ulcer Agents; Antithrombins; Atrial Fibrillation | 2015 |
Vitamin K antagonist-experienced patients with a history of stroke/transient ischaemic attack who switched from warfarin to dabigatran increased their rate of recurrent stroke/transient ischaemic attack compared with those on warfarin.
Topics: Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Humans; Ischemic Attack, T | 2015 |
Site-level variation in and practices associated with dabigatran adherence.
Topics: Aged; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cross-Sectional Studies; Dab | 2015 |
Contact with pharmacist can improve adherence to new anticoagulant, study finds.
Topics: Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Drug Monitoring; Female; Humans; M | 2015 |
Cardiology patient page. Patient guide for taking the non-vitamin K antagonist oral anticoagulants for atrial fibrillation.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Contraindic | 2015 |
Comparative risk of gastrointestinal bleeding with dabigatran, rivaroxaban, and warfarin: population based cohort study.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cohort S | 2015 |
Safety of new oral anticoagulants.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Gastrointestinal Hemorrha | 2015 |
Risk of gastrointestinal bleeding associated with oral anticoagulants: population based retrospective cohort study.
Topics: Administration, Oral; Adult; Age Factors; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; | 2015 |
Relation between dabigatran concentration, as assessed using the direct thrombin inhibitor assay, and activated clotting time/activated partial thromboplastin time in patients with atrial fibrillation.
Topics: Aged; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Coagulation; Dabigatra | 2015 |
[Periprocedural management of anticoagulation in patients undergoing atrial fibrillation ablation].
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation; Dabigatran; Hu | 2015 |
Anticoagulation therapy: Bleeding no worse with novel agents.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Gastrointestinal Hemorrha | 2015 |
Feasibility and safety of uninterrupted dabigatran therapy in patients undergoing ablation for atrial fibrillation.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation; Dabigatr | 2015 |
[Prevention and emergency measures].
Topics: Administration, Oral; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Emergencies; Hu | 2015 |
[Advantages of NOAKs validated in clinical routine].
Topics: Aged; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Approval; G | 2015 |
Effective antidotes for new anticoagulants.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Gastrointestinal Hemorrha | 2015 |
Efficacy of Dabigatran for Dissolving Deep Vein Thromboses in Outpatients With a Deteriorated General Condition.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabig | 2015 |
Meta-analysis should not be subject to selectivity and imbalance.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Gastrointestinal Hemorrha | 2015 |
One-Year Risk of Bleeding With Dabigatran in Patients With Atrial Fibrillation: Placing Real-World Results Into Perspective.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Hemorrhage | 2015 |
Bleeding in Patients of African Ancestry Using Dabigatran: A Potential Effect of Creatine Kinase.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Hemorrhage | 2015 |
The Role of Selection in the Risk of Bleeding With Dabigatran in Patients With Atrial Fibrillation.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Hemorrhage | 2015 |
A Methodological Appraisal of Recent Real-World Data Publications on Dabigatran.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Hemorrhage | 2015 |
Dosage of Dabigatran as a Risk Factor for Bleeding in Atrial Fibrillation.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Hemorrhage | 2015 |
Patient Characteristics and Risk of Bleeding With Dabigatran in Atrial Fibrillation.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Hemorrhage | 2015 |
Risk of Bleeding With Dabigatran in 2010-2011 Medicare Data.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Hemorrhage | 2015 |
Neither dabigatran nor rivaroxaban were linked to increased GI bleeding compared with warfarin.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Gastrointestinal Hemorrha | 2015 |
Letter by Lavine Regarding Article, "Cardiovascular, Bleeding, and Mortality Risks in Elderly Medicare Patients Treated With Dabigatran or Warfarin for Nonvalvular Atrial Fibrillation".
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Hemorrhage; Humans; Medicare; War | 2015 |
Dabigatran in 'real-world' clinical practice for stroke prevention in patients with non-valvular atrial fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Stroke; Warfa | 2015 |
Bleeding risk higher with rivaroxaban than dabigatran for stroke prevention, head-to-head trial shows.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; | 2016 |
[Advances in the prevention of cerebral ischaemia due to atrial fibrillation].
Topics: Amiodarone; Anticoagulants; Antifibrinolytic Agents; Atrial Fibrillation; Benzimidazoles; beta-Alani | 2010 |
Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost-Ben | 2011 |
What do the RE-LY, AVERROES and ROCKET-AF trials tell us for stroke prevention in atrial fibrillation?
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clini | 2011 |
2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (update on Dabigatran): a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines.
Topics: Advisory Committees; American Heart Association; Anticoagulants; Antithrombins; Atrial Fibrillation; | 2011 |
2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (update on dabigatran). A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.
Topics: Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Evidence-Based Medicine; Fibrinolytic | 2011 |
2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (update on dabigatran): a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines.
Topics: Advisory Committees; American Heart Association; Atrial Fibrillation; Benzimidazoles; beta-Alanine; | 2011 |
[Should dabigatran or vitamin K antagonists be used in prevention of stroke in patients with atrial fibrillation?].
Topics: Acenocoumarol; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles | 2011 |
Next generation anticoagulants may push warfarin to the wayside.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Approval; Drug E | 2011 |
New drug offers warfarin alternative for atrial fibrillation. An immediate switch is right for some people, but not necessary for all.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug and Narcotic Con | 2011 |
Place of dabigatran in contemporary pharmacotherapy.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigat | 2011 |
Anticoagulant options--why the FDA approved a higher but not a lower dose of dabigatran.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Approval; Emboli | 2011 |
Dabigatran compared with warfarin for stroke prevention in atrial fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost-Benefit Analysis; Dabigatran | 2011 |
Dabigatran compared with warfarin for stroke prevention in atrial fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost-Benefit Analysis; Dabigatran | 2011 |
Prevention of atrial fibrillation complications with antiarrhythmic drugs: still an unmet need in clinical practice.
Topics: Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanin | 2011 |
Incidence of chronic kidney disease in patients with atrial fibrillation and its relevance for prescribing new oral antithrombotic drugs.
Topics: Administration, Oral; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Biomarkers; Chronic Disease | 2011 |
Cost-effectiveness of dabigatran for stroke prophylaxis in atrial fibrillation.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cohort Studies; Cost-Benefi | 2011 |
Switching patients from warfarin to dabigatran therapy: to RE-LY or not to rely.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Coronary Thrombosis; Dabiga | 2012 |
Ask the doctor. For several years, I have been taking warfarin because of atrial fibrillation. I recently suffered several nosebleeds, which took two days to control. The trauma of those episodes makes me want to swear off warfarin, but I am not sure what
Topics: Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Fibrinolytic Agents; Health Knowledge | 2011 |
Potential inaccuracy of point-of-care INR in dabigatran-treated patients.
Topics: Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Monitoring; Femal | 2011 |
Dabigatran in atrial fibrillation: pharmacology and clinical trials.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigat | 2011 |
Atrial fibrillation: outpatient presentation and management.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-A | 2011 |
Dabigatran in patients with nonvalvular atrial fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Creatinine; Dabigatran; Dose-Resp | 2011 |
New options in anticoagulation for atrial fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Intention to | 2011 |
New anticoagulants: moving on from scientific results to clinical implementation.
Topics: Acute Coronary Syndrome; Anticoagulants; Arthroplasty, Replacement, Hip; Atrial Fibrillation; Benzim | 2011 |
A new era for anticoagulation in atrial fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; | 2011 |
Drug-induced exanthem following dabigatran.
Topics: Adult; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Hypersensi | 2011 |
[New anticoagulants: "efficacy and safety" or "efficacy or safety"].
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans | 2011 |
Dabigatran for stroke prevention in all patients with atrial fibrillation?
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatr | 2011 |
The use of dabigatran immediately after atrial fibrillation ablation.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation; | 2012 |
Dabigatran etexilate in atrial fibrillation patients with severe renal impairment: dose identification using pharmacokinetic modeling and simulation.
Topics: Antithrombins; Area Under Curve; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Computer Simulat | 2012 |
Update on dabigatran for stroke prevention in atrial fibrillation.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; | 2011 |
What's a mother to do?
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation; Dabigatran; Fe | 2012 |
Learning the respective roles of warfarin and dabigatran to prevent stroke in patients with nonvalvular atrial fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Monitoring; Fema | 2011 |
Concerns about studies investigating new anticoagulant drugs for stroke prevention in atrial fibrillation.
Topics: Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatra | 2012 |
[Anticoagulation in atrial fibrillation: a new era has begun].
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; | 2012 |
Fatal intracerebral hemorrhage associated with administration of recombinant tissue plasminogen activator in a stroke patient on treatment with dabigatran.
Topics: Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cerebral Hemorrhage; Cerebrovascular Circulation; | 2011 |
Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a 'real world' atrial fibrillation population: a modelling analysis based on a nationwide cohort study.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Cohort | 2012 |
Spontaneous splenic hemorrhage after initiation of dabigatran (Pradaxa) for atrial fibrillation.
Topics: Aged; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Emergency Service, Hospital; Fe | 2012 |
Dabigatran use in a postoperative coronary artery bypass surgery patient with nonvalvular atrial fibrillation and heparin-PF4 antibodies.
Topics: Aged; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Coronary Artery Bypass; Dabi | 2012 |
Twice daily dosing of dabigatran for stroke prevention in atrial fibrillation: a pharmacokinetic justification.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials, Phase II a | 2012 |
Application of the RELY study to lifetime risks of atrial fibrillation: implications for spontaneous intracranial hemorrhage.
Topics: Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Intracranial H | 2012 |
The king is dead (warfarin): direct thrombin and factor Xa inhibitors: the next Diadochian War?
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Brain Ischemia; Cerebral Hemorrha | 2012 |
Letter by Govindarajan and Salgado regarding article, "Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the Randomized Evaluation of Long-Term Anticoagulant Therapy (
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Hemorrhage; Humans; Male; | 2012 |
Letter by Reynolds et al regarding article, "Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) tri
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Hemorrhage; Humans; Male; | 2012 |
Letter by Reiffel regarding article, "Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) trial".
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Hemorrhage; Humans; Male; | 2012 |
Anticoagulation for atrial fibrillation ablation: what is the optimal strategy?
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Humans; Male; | 2012 |
Feasibility and safety of dabigatran versus warfarin for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation: results from a multicenter prospective registry.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation; Dabigatr | 2012 |
Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in patients with atrial fibrillation and prior stroke or transient ischemic attack.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cohort Studies; Cost-Benefi | 2012 |
Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Atrial Flutter; Benzimidazoles; | 2012 |
Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Atrial Flutter; Benzimidazoles; | 2012 |
Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Atrial Flutter; Benzimidazoles; | 2012 |
Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Atrial Flutter; Benzimidazoles; | 2012 |
Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Atrial Flutter; Benzimidazoles; | 2012 |
Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Atrial Flutter; Benzimidazoles; | 2012 |
Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Atrial Flutter; Benzimidazoles; | 2012 |
Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Atrial Flutter; Benzimidazoles; | 2012 |
Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Atrial Flutter; Benzimidazoles; | 2012 |
What's the "go to" anticoagulant for stroke prevention in atrial fibrillation?
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; | 2012 |
Monitoring of the effects of new-generation oral anticoagulants – what does it mean? – .
Topics: Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Humans; Male; Partial Thrombo | 2012 |
Dabigatran efficacy-safety assessment for stroke prevention in patients with atrial fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Coagulation; Dabigatran; Ev | 2012 |
Efficacy and safety of dabigatran compared to warfarin in patients with paroxysmal, persistent, and permanent atrial fibrillation: results from the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) study.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Dose-Response Relatio | 2012 |
Stroke prophylaxis with warfarin or dabigatran for patients with non-valvular atrial fibrillation-cost analysis.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; | 2012 |
Neurosurgical complications of direct thrombin inhibitors--catastrophic hemorrhage after mild traumatic brain injury in a patient receiving dabigatran.
Topics: Aged, 80 and over; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Brain Hemorrhage, Traumatic; B | 2012 |
Exfoliative esophagitis and esophageal ulcer induced by dabigatran.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Esophagitis; Es | 2012 |
[Update on current care guidelines: atrial fibrillation].
Topics: Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanin | 2012 |
Medical cost reductions associated with the usage of novel oral anticoagulants vs warfarin among atrial fibrillation patients, based on the RE-LY, ROCKET-AF, and ARISTOTLE trials.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost Contro | 2012 |
Dabigatran-induced gastrointestinal bleeding in an elderly patient with moderate renal impairment.
Topics: Acute Kidney Injury; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Creati | 2012 |
Fatal basilar artery occlusion under dabigatran occurring 13 days after femoral embolectomy.
Topics: Aged; Anticoagulants; Antithrombins; Arterial Occlusive Diseases; Atrial Fibrillation; Benzimidazole | 2012 |
Avoiding adverse events with dabigatran by careful selection of eligible patients.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Contr | 2012 |
Endovascular therapy after stroke in a patient treated with dabigatran.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheterization; Cerebral A | 2012 |
Dabigatran for the prevention of stroke in atrial fibrillation: is RE-LY reliable?
Topics: Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Stroke | 2012 |
Dabigatran in patients with atrial fibrillation: perioperative and periinterventional management.
Topics: Atrial Fibrillation; Austria; Benzimidazoles; beta-Alanine; Dabigatran; Female; Humans; Male; Periop | 2012 |
Intravenous thrombolysis in a stroke patient taking dabigatran.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Coagulation; Cerebral Angio | 2012 |
The Food and Drug Administration decision not to approve the 110 mg dose of dabigatran: give us a way out.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cerebral Hemorrhage; Dabigatran; | 2012 |
Letter by Freeman et al regarding article, "Intracranial hemorrhage in atrial fibrillation patients during anticoagulation with warfarin or dabigatran: the RE-LY Trial".
Topics: Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Humans; Intracranial Hemorrhages; Male; W | 2012 |
[Expanded arsenal in atrial fibrillation: bye-bye marcumar?].
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug A | 2012 |
An anticoagulation option for nonvalvular atrial fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Decision Support Tech | 2012 |
[Prevention of stroke in atrial fibrillation].
Topics: Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatra | 2012 |
Acute ischemic stroke treated with intravenous tissue plasminogen activator in a patient taking dabigatran with radiographic evidence of recanalization.
Topics: Angiography, Digital Subtraction; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; | 2012 |
Spontaneous gross haematuria during dabigatran therapy for secondary stroke prevention.
Topics: Adenocarcinoma; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antithrombins; Atrial Fibrillati | 2012 |
Dabigatran for stroke prevention in atrial fibrillation.
Topics: Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Evidence-Based Medicin | 2012 |
Cost-effectiveness of dabigatran versus genotype-guided management of warfarin therapy for stroke prevention in patients with atrial fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost-Benefit Analysis; Dabigatran | 2012 |
A clinical decision aid for the selection of antithrombotic therapy for the prevention of stroke due to atrial fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Decision Support Tech | 2012 |
Letter by Stollberger and Finsterer regarding article, "intracranial hemorrhage in patients with atrial fibrillation during anticoagulation with Warfarin or Dabigatran: the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial".
Topics: Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Humans; Intracranial Hemorrhages; Male; W | 2012 |
Indirect comparison studies--are they useful? Insights from the novel oral anticoagulants for stroke prevention in atrial fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Top | 2012 |
Life-threatening bleeding in four patients with an unusual excessive response to dabigatran: implications for emergency surgery and resuscitation.
Topics: Aged; Aged, 80 and over; Antithrombins; Arthroplasty, Replacement; Atrial Fibrillation; Benzimidazol | 2012 |
Comparative efficacy and safety of new oral anticoagulants in patients with atrial fibrillation.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clini | 2012 |
New anticoagulant fights for credibility.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Formularies as Topic; | 2012 |
New oral anticoagulant in atrial fibrillation: are they comparable?
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Embolism; Female; Hum | 2012 |
How country-specific should a country-specific cost-effectiveness analysis be?
Topics: Acute Coronary Syndrome; Adenosine; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanin | 2013 |
Factors influencing doctors' selection of dabigatran in non-valvular atrial fibrillation.
Topics: Adult; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Eligibility De | 2013 |
Head-to-head or indirect comparisons of the novel oral anticoagulants in atrial fibrillation: what's next?
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Top | 2012 |
[Comparison of three methods of antithrombotic therapy in elderly patients with nonvalvular atrial fibrillation].
Topics: Administration, Oral; Aged; Anticoagulants; Antithrombins; Aspirin; Atrial Fibrillation; Benzimidazo | 2012 |
The untold story of Dabigatran etexilate: alveolar hemorrhage in an elderly patient with interstitial pulmonary fibrosis.
Topics: Aged, 80 and over; Anemia; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigat | 2013 |
Agranulocytosis immediately after oral administration of cibenzoline and dabigatran in a patient with paroxysmal atrial fibrillation.
Topics: Administration, Oral; Aged; Agranulocytosis; Anti-Arrhythmia Agents; Antithrombins; Atrial Fibrillat | 2012 |
Intravenous thrombolysis in a stroke patient taking dabigatran.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Fibrinolytic Agents; Humans; Infa | 2013 |
A comparison of bleeding complications post-ablation between warfarin and dabigatran.
Topics: Aged; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Abl | 2012 |
Novel oral anticoagulants for stroke prevention in atrial fibrillation.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; | 2012 |
Dabigatran versus rivaroxaban for the prevention of stroke and systemic embolism in atrial fibrillation in Canada. Comparative efficacy and cost-effectiveness.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Canada; Clinical Trials as Topic; | 2012 |
Response to the letter by Lee et al.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Fibrinolytic Agents; Humans; Infa | 2013 |
National trends in oral anticoagulant use in the United States, 2007 to 2011.
Topics: Administration, Oral; Aged; Aged, 80 and over; Ambulatory Care; Anticoagulants; Antithrombins; Atria | 2012 |
National trends in oral anticoagulant use in the United States, 2007 to 2011.
Topics: Administration, Oral; Aged; Aged, 80 and over; Ambulatory Care; Anticoagulants; Antithrombins; Atria | 2012 |
National trends in oral anticoagulant use in the United States, 2007 to 2011.
Topics: Administration, Oral; Aged; Aged, 80 and over; Ambulatory Care; Anticoagulants; Antithrombins; Atria | 2012 |
National trends in oral anticoagulant use in the United States, 2007 to 2011.
Topics: Administration, Oral; Aged; Aged, 80 and over; Ambulatory Care; Anticoagulants; Antithrombins; Atria | 2012 |
National trends in oral anticoagulant use in the United States, 2007 to 2011.
Topics: Administration, Oral; Aged; Aged, 80 and over; Ambulatory Care; Anticoagulants; Antithrombins; Atria | 2012 |
National trends in oral anticoagulant use in the United States, 2007 to 2011.
Topics: Administration, Oral; Aged; Aged, 80 and over; Ambulatory Care; Anticoagulants; Antithrombins; Atria | 2012 |
National trends in oral anticoagulant use in the United States, 2007 to 2011.
Topics: Administration, Oral; Aged; Aged, 80 and over; Ambulatory Care; Anticoagulants; Antithrombins; Atria | 2012 |
National trends in oral anticoagulant use in the United States, 2007 to 2011.
Topics: Administration, Oral; Aged; Aged, 80 and over; Ambulatory Care; Anticoagulants; Antithrombins; Atria | 2012 |
National trends in oral anticoagulant use in the United States, 2007 to 2011.
Topics: Administration, Oral; Aged; Aged, 80 and over; Ambulatory Care; Anticoagulants; Antithrombins; Atria | 2012 |
National trends in oral anticoagulant use in the United States, 2007 to 2011.
Topics: Administration, Oral; Aged; Aged, 80 and over; Ambulatory Care; Anticoagulants; Antithrombins; Atria | 2012 |
National trends in oral anticoagulant use in the United States, 2007 to 2011.
Topics: Administration, Oral; Aged; Aged, 80 and over; Ambulatory Care; Anticoagulants; Antithrombins; Atria | 2012 |
National trends in oral anticoagulant use in the United States, 2007 to 2011.
Topics: Administration, Oral; Aged; Aged, 80 and over; Ambulatory Care; Anticoagulants; Antithrombins; Atria | 2012 |
National trends in oral anticoagulant use in the United States, 2007 to 2011.
Topics: Administration, Oral; Aged; Aged, 80 and over; Ambulatory Care; Anticoagulants; Antithrombins; Atria | 2012 |
National trends in oral anticoagulant use in the United States, 2007 to 2011.
Topics: Administration, Oral; Aged; Aged, 80 and over; Ambulatory Care; Anticoagulants; Antithrombins; Atria | 2012 |
National trends in oral anticoagulant use in the United States, 2007 to 2011.
Topics: Administration, Oral; Aged; Aged, 80 and over; Ambulatory Care; Anticoagulants; Antithrombins; Atria | 2012 |
National trends in oral anticoagulant use in the United States, 2007 to 2011.
Topics: Administration, Oral; Aged; Aged, 80 and over; Ambulatory Care; Anticoagulants; Antithrombins; Atria | 2012 |
Cost-effectiveness of dabigatran for stroke prevention in non-valvular atrial fibrillation in Spain.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost-Benefit Analysis; Dabi | 2012 |
Dabigatran-induced acute hepatitis.
Topics: Aged; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Chemical and Drug Induced Li | 2012 |
Dabigatran emerges as safe and effective warfarin alternative. The recently approved drug is more expensive, but appears to be more predictable.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Approval; Drug I | 2011 |
Safety of dabigatran versus warfarin for periprocedural anticoagulation in patients undergoing ablation for atrial fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Humans; Male; Registries; | 2012 |
Diffuse alveolar hemorrhage associated with dabigatran.
Topics: Aged; Antithrombins; Atrial Fibrillation; Atrial Flutter; Benzimidazoles; beta-Alanine; Dabigatran; | 2012 |
Differences in intraprocedural ACTs with standardized heparin dosing during catheter ablation for atrial fibrillation in patients treated with dabigatran vs. patients on uninterrupted warfarin.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation; | 2012 |
Eligibility of patients with atrial fibrillation for new oral anticoagulants.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; | 2013 |
Dabigatran in atrial fibrillation: incremental benefit over a time horizon of 5 or 10 years.
Topics: Aged; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost-Benefit | 2013 |
Catheter ablation of atrial fibrillation: the need for studies to assess the efficacy and safety of novel anticoagulants.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation; | 2013 |
Dabigatran for anticoagulation in atrial fibrillation - early clinical experience in a hospital population and comparison to trial data.
Topics: Aged; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Da | 2013 |
Faculty of Consulting Physicians of South Africa (FCPSA): saving brain with dabigatran.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; I | 2012 |
[Antithrombotic prevention in atrial fibrillation: the new anticoagulant drugs].
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans | 2012 |
New ESC guidelines on atrial fibrillation accept reality of next generation of anti-coagulants.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigat | 2012 |
Dabigatran compared with warfarin for stroke prevention with atrial fibrillation: experience in Hong Kong.
Topics: Aged; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Hong Kon | 2012 |
[New advances in anticoagulation: is it time to forget about heparin and vitamin K antagonists? Yes].
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alani | 2012 |
Periprocedural management and approach to bleeding in patients taking dabigatran.
Topics: Aged; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Contraindications; Dabigatra | 2012 |
Direct thrombin inhibitors: a case indicating benefit from 'plasmapheresis' in toxicity: a call for establishing "guidelines" in overdose and to find an "antidote"!
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antidotes; Antithrombins; Aspirin; Atrial Fibrillation; Ben | 2012 |
Public health. Change of heart.
Topics: Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost Savings; Dabigatran; Humans; | 2012 |
Case study. Risk and reward.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; England; Hospitals, P | 2012 |
Potential net clinical benefit of population-wide implementation of apixaban and dabigatran among European patients with atrial fibrillation. A modelling analysis from the Euro Heart Survey.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; | 2013 |
[New anticoagulants: better knowledge, better prescriptions].
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Eviden | 2012 |
Benefits of dabigatran maintained for more than two years.
Topics: American Heart Association; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Brain; | 2012 |
Rivaroxaban and atrial fibrillation: continue to use warfarin or in some cases, dabigatran.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Interactions; Fa | 2012 |
Dabigatran vs warfarin for radiofrequency catheter ablation of atrial fibrillation.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Case-Control Studies; Cathe | 2013 |
[Safety and efficacy of various modalities of antiplatelet prophylaxis of ischemic stroke in elderly patients with non-valvular atrial fibrillation].
Topics: Age Factors; Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidaz | 2012 |
Transitions of care in anticoagulation management for patients with atrial fibrillation.
Topics: Administration, Oral; Aftercare; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Ala | 2012 |
Cost-effectiveness of dabigatran for stroke prevention in atrial fibrillation in Switzerland.
Topics: Aged; Antifibrinolytic Agents; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cos | 2013 |
Australian MPs demand more data on dabigatran for atrial fibrillation.
Topics: Antithrombins; Atrial Fibrillation; Australia; Benzimidazoles; beta-Alanine; Cost-Benefit Analysis; | 2013 |
[Wünderlich syndrome in patient anticoagulated with dabigatran].
Topics: Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Brain Ischemia | 2013 |
[Percutaneous left atrial appendage closure after resolution of left atrial appendage thrombi with dabigatran].
Topics: Anticoagulants; Antithrombins; Atherectomy; Atrial Appendage; Atrial Fibrillation; Benzimidazoles; b | 2013 |